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The prevailing view of outcome of major depressive disorder (MDD) is based 
on mostly inpatient tertiary centre cohorts, and emphasizes chronicity and 
frequent recurrences. This study investigated the 5-year outcome of MDD 
among psychiatric out- and inpatients as a part of the Vantaa Depression Study 
(VDS), a regionally representative, prospective and naturalistic follow-up study. 
The long-term outcome of MDD was in these settings more variable than in 
earlier, mostly inpatient studies, while MDD was still highly recurrent, but the 
recurrent episodes seemed shorter, and the outcome was less chronic. Higher 
severity of MDD, episode duration and preceding dysthymia, comorbid cluster C 
personality disorders and social phobia predicted a worse outcome. Time spent 
depressed was the central factor determining overall long-term risk of suicide 
attempts together with a history of attempts and poor social support. A switch 
to bipolar disorder occurred mainly to type II, and was predicted by higher 
severity of MDD, and comorbid disorders. Having a positive family history of 
severe mental disorders was likely to be clinically associated with a significantly 
more adverse outcome.
ISBN 978-952-245-369-3
.!7BC5<2"HIGJMG!
Mikael Holma
Long-term Outcome of 
DSM-IV Major Depressive 
Disorder in Psychiatric Care
National Institute for Health and Welfare
P.O. Box 30 (Mannerheimintie 166)
FI-00271 Helsinki, Finland
Telephone: +358 20 610 6000
www.thl.fi
RE
SE
AR
CH
RE
SE
AR
CH
National Institute for Health and Welfare
Department of Mental Health and Substance Abuse Services
Helsinki, Finland
and
University of Helsinki
Department of Psychiatry
Helsinki, Finland
RESEARCH
Mikael Holma
Long-term Outcome of
DSM-IV Major Depressive Disorder
in Psychiatric Care
ACADEMIC DISSERTATION
To be presented with the permission of the Faculty of Medicine, Insitute of Clinical Medicine,
Department of Psychiatry, University of Helsinki, for public examination at the Christian Sibelius-
auditorium, Välskärinkatu 12, Helsinki, on December 10th, 2010, at 12 noon.
© Mikael Holma and National Institute for Health and Welfare
Cover photo: Mikael Holma
ISBN 978-952-245-369-3 (printed)
ISBN 978-952-245-370-9 (pdf)
ISSN 1798-0054 (printed)
ISSN 1798-0062 (pdf)
Helsinki University Print
Helsinki, Finland 2010
: MLayout arjut Grainger
Supervised by
Professor Erkki Isometsä, M.D., Ph.D.
Department of Psychiatry, University of Helsinki
and
Department of Mental Health and Substance Abuse Services
National Institute for Health and Welfare
and
Adjunct Professor Tarja Melartin, M.D., Ph.D.
Department of Psychiatry, University of Helsinki
and
Department of Mental Health and Substance Abuse Services
National Institute for Health and Welfare
Reviewed by
Professor Jukka Hintikka, M.D., Ph.D.
Department of Psychiatry, University of Eastern Finland
and
Professor Jyrki Korkeila, M.D., Ph.D.
Department of Psychiatry, University of Turku
Opponent
Professor Raimo Salokangas, M.D., Ph.D.
Department of Psychiatry, University of Turku
Svanvingar lågt över träden
Klagande vita trumpeter mot havet
Ljuset tänds över en björkstam
Mönstret i nävern kunde vara chiffert
i en dagbok som jag inte får tyda
Någonting sträcker halsen
Någon pekar och vill bli räddad
för att bära oss
(Birgit Holma: Vägen till eremiten, 1987)
To my family
Table of contents
                  ......................................................................................................................................Tiivistelmä                                                                                                               9
                  .................................................................................................................................Sammandrag                                                                                                               11
                  .................................................................................................................................Abbreviations                                                                                                            13
                  .................................................................................................................................1 Abstract                                                                                                                 16
                  .................................................................................................................................2 List of original publications                                                                                            18
                  .................................................................................................................................3 Introduction                                                                                                             19
                  .................................................................................................................................4 Review of the literature                                                                                                 21
                         ..........................................................................................................................4.1 Depression as an emotion                                                                                           21
                         ..........................................................................................................................4.2 Classification of mental disorders  22
                         ..........................................................................................................................4.3 Diagnosis of mood disorders                                                                                     23
                         ..........................................................................................................................4.3.1 Diagnosis of major depressive disorder (MDD)  24
                                    ...............................................................................................................4.3.1.1 Subgroups of MDD                                                                               25
                         ..........................................................................................................................4.3.2 Diagnosis of other depressive disorders  26
                         ..........................................................................................................................4.3.3 Diagnosis of bipolar disorder                                                                             26
                         ..........................................................................................................................4.4 Prevalence of mood disorders  28
                         ..........................................................................................................................4.4.1 Prevalence of MDD                                                                                        28
                         ..........................................................................................................................4.4.2 Prevalence of bipolar disorder  29
                         ..........................................................................................................................4.5. Aetiology and pathogenesis of MDD  30
                         ..........................................................................................................................4.5.1 Multifactorial aetiology                                                                                  30
                         ..........................................................................................................................4.5.2 Heritability and genetic risk factors  30
                         ..........................................................................................................................4.5.3 Psychosocial risk factors                                                                                  32
                                    ...............................................................................................................4.5.3.1 Early psychosocial factors                                                                     32
                                    ...............................................................................................................4.5.3.2 Recent psychosocial factors  33
                                    ...............................................................................................................4.5.3.3 Personality and temperamental factors  34
                         ..........................................................................................................................4.5.4 Structural and functional brain imaging findings  34
                         ..........................................................................................................................4.5.5 Neurochemical, neurotrophic and neuroendocrinological findings  36
                         ..........................................................................................................................4.6 Comorbidity of MDD                                                                                                38
                         ..........................................................................................................................4.6.1 Definition of the concept                                                                                 38
                         ..........................................................................................................................4.6.2 Comorbidity of MDD in general populations  39
                         ..........................................................................................................................4.6.3 Comorbidity of MDD in clinical cohorts  40
                         ..........................................................................................................................4.7 Course and outcome of major depressive episode (MDE)  41
                         ..........................................................................................................................4.7.1 Methodological aspects in defining outcome  41
                         ..........................................................................................................................4.7.2 Duration of MDE in general populations  42
                         ..........................................................................................................................4.7.3 Outcome of MDD                                                                                            42
                                    ...............................................................................................................4.7.3.1 Clinical factors as predictors of outcome  45
                                    ...............................................................................................................4.7.3.2 Comorbidity as a predictor of outcome  45
                                    ...............................................................................................................4.7.3.3 Psychosocial factors as predictors of outcome  46
                         ..........................................................................................................................4.7.4 Suicidal behaviour                                                                                       47
                                    ...............................................................................................................4.7.4.1 Classification of suicidal behaviour  47
                                    ...............................................................................................................4.7.4.2 Stress-diathesis model                                                                           47
                                    ...............................................................................................................4.7.4.3 Epidemiology and risk factor of suicidal ideation  48
                                    ...............................................................................................................4.7.4.4 Epidemiology of suicide attempts  49
                                    ...............................................................................................................4.7.4.5 Suicide attempts in patients with MDD  50
                                    ...............................................................................................................4.7.4.6 Epidemiology and risk factors of suicide  51
                                    ...............................................................................................................4.7.4.7 Suicide in patients with MDD  52
                                    ...............................................................................................................4.7.4.8 Prevention of suicidal behaviour  53
                         ..........................................................................................................................4.7.5 Switch to bipolar disorder                                                                                54
                             ...............................................................................................................4.7.5.1 Predictors of switch to bipolar disorder  55
                                    ...............................................................................................................4.8 Treatment of MDD                                                                                                  56
                         ..........................................................................................................................4.8.1 Antidepressant treatment                                                                                   56
                         ..........................................................................................................................4.8.2 Psychosocial treatment                                                                                    57
                         ..........................................................................................................................4.8.3 Electroconvulsive therapy (ECT)  58
                         ..........................................................................................................................4.8.4 Other treatment methods                                                                                    58
                         ..........................................................................................................................4.8.5 The realization of treatment                                                                              59
                  .................................................................................................................................5 Aims of the study                                                                                                        60
                  .................................................................................................................................6 Materials and methods                                                                                                    61
                         ..........................................................................................................................6.1 General study design                                                                                              61
                         ..........................................................................................................................6.2 Screening                                                                                                          61
                         ..........................................................................................................................6.3 Baseline evaluation                                                                                               62
                         ..........................................................................................................................6.3.1 Diagnostic measures                                                                                       62
                         ..........................................................................................................................6.3.2 Exclusion criteria                                                                                         63
                         ..........................................................................................................................6.3.3 Observer and self-report scales  63
                         ..........................................................................................................................6.3.4 Sosiodemographic and clinical features at baseline  63
                         ..........................................................................................................................6.4 Follow-up procedure                                                                                               64
                         ..........................................................................................................................6.4.1 Study participants                                                                                         64
                         ..........................................................................................................................6.4.2 Study drop-outs                                                                                            66
                         ..........................................................................................................................6.4.3 Outcome measures                                                                                          67
                                    ...............................................................................................................6.4.3.1 Life-chart methodology                                                                         67
                         ..........................................................................................................................6.5 Statistical methods                                                                                              68
                  .................................................................................................................................7 Results                                                                                                                  70
                         ..........................................................................................................................7.1 Long-term outcome of MDD (Study I)  70
                         ..........................................................................................................................7.1.1 Sosiodemographic and clinical characteristics of the sample  70
                         ..........................................................................................................................7.1.2 Overall outcome                                                                                          72
                         ..........................................................................................................................7.1.3 Time to full remission                                                                                   73
                                    ...............................................................................................................7.1.3.1 Predictors of time to full remission  74
                         ..........................................................................................................................7.1.4 Recurrence                                                                                               76
                                    ...............................................................................................................7.1.4.1 Predictors of recurrence                                                                         76
                         ..........................................................................................................................7.1.5 Time to first recurrence                                                                                  78
                                    ...............................................................................................................7.1.5.1 Predictors of time to first recurrence  78
                         ..........................................................................................................................7.1.6 Number of recurrences                                                                                      79
                                    ...............................................................................................................7.1.6.1 Predictors of number of recurrences  79
                         ..........................................................................................................................7.2 Risk factors of suicide attempts during the prospective follow-up (Study II)  82
                         ..........................................................................................................................7.2.1 Incidence of suicide attempts                                                                             82
                         ..........................................................................................................................7.2.2 Differences between suicide attempters and non-attempters  83
                         ..........................................................................................................................7.2.3 Predictors of suicide attempt during the follow-up  85
                         ..........................................................................................................................7.3 Switch to bipolar disorder during the prospective follow-up (Study III)  85
                         ..........................................................................................................................7.3.1 Differences between patients switching and not switching to bipolar disorder 85
                         ..........................................................................................................................7.3.2 Predictors of a switch to bipolar disorder during the follow-up  88
                         ..........................................................................................................................7.4 Family history and outcome of MDD  (Study IV)  89
                         ..........................................................................................................................7.4.1 Prevalence of family history                                                                             89
                         ..........................................................................................................................7.4.2 Family history of any of the mental disorders  90
                         ..........................................................................................................................7.4.3 Family history of mood disorders  93
                         ..........................................................................................................................7.4.4 Family history of alcoholism  93
                         ..........................................................................................................................7.4.5 Family history of psychotic disorders  94
                  .................................................................................................................................8 Discussion                                                                                                               95
                         ..........................................................................................................................8.1 Main findings                                                                                                     95
                         ..........................................................................................................................8.2 Methods                                                                                                          96
                         ..........................................................................................................................8.2.1 Representativeness of the cohort sample  96
                         ..........................................................................................................................8.2.2 Diagnostic measures                                                                                       97
                         ..........................................................................................................................8.2.3 Life-chart and definitions for outcome  97
                         ..........................................................................................................................8.2.4 Study limitations                                                                                         98
                         ..........................................................................................................................8.3 Long-term outcome of MDD (Study I) 100
8.4   Long-term risk factors of suicide attempts during the prospective 
                         ..........................................................................................................................follow-up (Study II)                                                                                           101
                         ..........................................................................................................................8.5 Switch to bipolar disorder during the prospective follow-up (Study III) 103
                         ..........................................................................................................................8.6 Family history and outcome of MDD  (Study IV) 105
                  .................................................................................................................................9 Conclusions and future implications 108
                         ..........................................................................................................................9.1 Conclusions                                                                                                     108
                         ..........................................................................................................................9.2 Clinical implications                                                                                           108
                         ..........................................................................................................................9.3 Implications for future research 110
                  .................................................................................................................................10 Acknowledgements                                                                                                        111
                  .................................................................................................................................11 References                                                                                                              114
9THL - Research 44/2010 Long-term Outcome of
DSM-IV Major Depressive Disorder
in Psychiatric Care
Tiivistelmä
Mikael Holma, Long-term Outcome of DSM-IV Major Depressive Disorder in Psychiatric Care
[DSM-IV vakavan masennustilan pitkäaikaisennuste psykiatrisessa hoidossa]
Terveyden ja hyvinvoinnin laitos (THL), Tutkimus 44. Helsinki 2010.
ISBN 978-952-245-369-3 (painettu), ISBN 978-952-245-370-9 (pdf)
Tämä tutkimus on osa Vantaan Depressioprojektia (VDS), joka on toteutettu yhteistyössä
Terveyden ja Hyvinvoinnin Laitoksen Mielenterveyden- ja päihdepalvelujen − osaston
(entinen Kansanterveyslaitoksen Mielenterveyden ja Alkoholitutkimuksen osasto) ja
Helsingin Yliopistollisen Keskussairaalan (HYKS) psykiatrian klinikan, Peijaksen sairaalan
psykiatrisen tulosyksikön kanssa. VDS on etenevä ja naturalistinen seurantatutkimus, jossa
on tutkittu 269 uutta DSM-IV vakavaa masennustilaa sairastavaa psykiatrista potilasta.
Tutkimuksen alussa seulottiin 806 aikuista potilasta (ikä 20-59 vuotta) masennusoireiden
suhteen alkaen 1.2.1997, jonka jälkeen haastateltiin puolistrukturoidun haastattelun
(SCAN, versio 2.0) avulla 542 tutkimukseen suostunutta potilasta. Haastattelujen
perusteella otettiin mukaan tutkimukseen 269 vakavaa masennustilaa sairastavaa potilasta,
jotka tutkittiin puolistrukturoiduin haastatteluin myös muiden psykiatristen
oheissairauksien osalta. Poissulkemiskriteereinä olivat DSM-IV kaksisuuntaisen
mielialahäiriön tyyppi I ja II, skitsoaffektiivinen häiriö, skitsofrenia tai muu psykoosi,
sekä orgaaninen tai päihteen aiheuttama mielialahäiriö.
Vakavan masennustilan ja oheissairauksien kulkua ja ennustetta tutkittiin
seurantahaastatteluin kuuden, 18 kuukauden ja viiden vuoden kohdalla toistetuilla
puolistrukturoiduilla haastatteluilla. Indeksiepisodin kesto ja mahdollisten sairauden
pahenemisvaiheet ja uusiutumiset ajoitettiin ja sijoitettiin graafiseen aikajanaan, joka
perustui DSM-IV-tautiluokituksen määritelmiin. Aika lähtötilanteen jälkeen jaettiin
kolmeen jaksoon: (1) täysi remissio (0 vakavan masennustilan oiretta), (2) osittainen
remissio (1-4/9 oiretta), (3) vakava masennusjakso (≥5/9 oiretta). Aikajanaan sijoitettiin
myös potilaiden saama lääkitys, psykososiaalinen hoito, sairauslomat, myönnetyt
työkyvyttömyyseläkkeet, itsemurhayritykset ja mahdolliset diagnoosimuutokset
Viisivuotisseurantahaastattelut suoritettiin 12.4.2002 − 27.4.2004 Vantaan psykiatrisilla
poliklinikoilla ja HYKS psykiatrian poliklinikalla, 182 potilasta osallistui
haastatteluihin. Haastatteluajankohtana lähes puolet (50%) potilaista olivat täydessä
remissiossa, lähes neljäsosa (24%) sairastivat ajankohtaisesti masennusta ja loput (26%)
olivat masennuksen suhteen osittaisessa remissiossa. Viiden vuoden seuranta-ajasta
potilaat olivat viettäneet keskimäärin puolet (49%) ilman masennusoireilua, viidesosan
(20%) vakavassa masennustilassa ja kolmasosan (31%) osittaisessa remissiossa. Lisäksi
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seitsemäsosa (15%) potilaista oli yrittänyt itsemurhaa ainakin kerran, ja 29 (12%)
potilasta sairastui seurannan aikana kaksisuuuntaiseen mielialahäiriöön. Lähes kaikki
potilaat (99%) toipuivat ainakin osittain vakavasta masennustilasta ja enemmistö (88%)
saavutti täydellisen remission 11 kuukauden mediaaniajan kuluessa. Suurin osa, lähes kolme
neljäsosaa (71%) sairastui seurannan aikana uudestaan masennukseen 21 kuukauden
mediaaniajan kuluessa indeksiepisodin lopusta. Masennuksen vaikeusaste ennusti
merkittävästi masennustilan uusiutumista ja uusiutumisjaksojen lukumäärää sekä pidensi
masentuneena vietettyä aikaa. Tunnettujen ennustetekijöiden kuten masennuksen kesto ja
samanaikainen dystymia lisäksi, myös samanaikainen sosiaalinen fobia ja cluster C
persoonallisuushäiriö huononsivat ennustetta.
Itsemurhayritysten esiintyvyys vaihteli voimakkaasti masennustilan mukaan ollen lähes
21-kertainen vakavien masennusjaksojen aikana ja nelinkertainen osittaisen remission
aikana verrattuina oireettomiin tiloihin. Vaikka aikaisemmat itsemurhayritykset ja
vähäinen koettu sosiaalinen tuki lisäsivät myös riskiä, oli masentuneena vietetty aika
keskeisin riskitekijä.
Runsas kymmenesosa (12%) masennuspotilaista sairastui seurannan aikana kaksisuuntaiseen
mielialahäiriöön (lähinnä tyyppiin II), joka on jonkin verran enemmän verrattuna
aikaisempiin tutkimuksiin. Sairastuminen tyypin I häiriöön tapahtui seurannan
alkuvaiheessa ja tyypin II tasaisemmin seurannan kuluessa. Aikaisemmin tunnettujen
riskitekijöiden lisäksi diagnoosin muutosta ennustivat masennustilan vaikeusaste,
samanaikainen sosiaalinen fobia, pakko-oireinen häiriö ja ryhmän B persoonal-
lisuushäiriöiden piirteet.
Suurimmalla osalla seuratuista potilaista oli sukuhistoriaa ei vain mielialahäiriöiden
(61%), vaan myös muiden vakavien häiriöiden suhteen (yhteensä 75%). Sukuhistoria oli
yhteydessä huonompaan ennusteeseen, johon liittyi kohonnut itsemurhayritysten riski,
kroonisempi sairaudenkulku ja samanaikaiset persoonallisuushäiriöt. Mielialahäiriöiden
sukuhistoriaan liittyi naisten keskuudessa vallitsevaa neurotisismiä ja miesten
keskuudessa suvun alkoholismi lisäsi tutkimuspotilaiden alkoholiriippuvuuden riskiä.
Kaiken kaikkiaan vakavan masennustilan pitkäaikaisennuste oli tämän modernin, keskiasteen
psykiatrisen hoidon enimmistöltään avohoitopotilaiden seurantatutkimuksen mukaan
vaihtelevampi verrattuna aikaisempiin, usein vanhempiin, yliopistoklinikoiden suorittamiin
ja sairaalapotilailla tehtyihin tutkimuksiin. Vakavan masennustila oli hyvin toistuva myös
tässä tutkimuksessa, mutta toistuvat jaksot näyttivät olevan lyhyempiä, masennuksen kulku
oli vähemmän krooninen.
Avainsanat: masennus, psykiatriset potilaat, ennuste, itsemurhayritykset, kaksisuuntainen
mielialahäiriö, sukuhistoria.
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Sammandrag
Mikael Holma, Long-term Outcome of DSM-IV Major Depressive Disorder in Psychiatric Care
[Långtidsprognosen av DSM-IV svår depression inom psykiatrisk vård]
Institutet för hälsa och välfärd (THL), Forskning 44. Helsingfors 2010.
ISBN 978-952-245-369-3 (trykt), ISBN 978-952-245-370-9 (pdf)
Denna studie är en del av "Vanda Depressionsprojekt" (VDS), genomfört i samarbete med
Institutet för Hälsa och Välfärd (THL), avdelningen för psykisk hälsa och missbrukarvård
(före detta Folkhälsoinsitutets avdelning för mental hälsa och alkoholforskning) och
Helsingfors Universitets Centralsjukhus (HUCS), Psykiatriska kliniken, Peijas sjukhus,
Vanda. VDS är en progressiv och naturalistisk kohortstudie med 269 öppenvårds- och
sjukhusvårdspatienter insjuknade i ny DSM-IV svår depressiv störning. Studien inleddes med
screening av 806 vuxna patienter (i åldern 20-59) för symptom på depression från och med
1.2.1997, de 542 patienter som gav sitt medgivande intervjuades med en semistrukturell
diagnostisk metod (SCAN, version 2.0). På basen av intervjuerna, blev 269 diagnostiserade
med DSM-IV svår depressiv störning och inkluderades i studien, och intervjuades vidare med
semistrukturella metoder för tilläggsdiagnoser. Uteslutningsdiagnoser bestod av DSM-IV
bipolär störning typ I och II, schizoaffektiv störning, schizofreni eller annan psykos,
samt affektiva störningar inducerade av någon organisk sjukdom eller av rusmedel.
Sjukdomsförlopp med en svår depressiv episod och komorbida tilläggsstörningar undersöktes
med hjälp av upprepade semistrukturella intervjuer 6 månader, 18 månader och 5 år efter
det studiens inletts. Den första depressiva episodens (index episod) varaktighet och
datering av återfall och relapser undersöktes prognostiskt med hjälp av en grafisk
livslinje, som byggde på DSM-IV definitioner. Tiden efter början av studien indelades i
tre perioder: (1) fullständig remission (inga symtom på svår depressiv störning), (2)
partiell remission (1-4/9 symtom), (3) svår depressiv episod (≥5/9 symtom). Förutom
symtom, värderingar och besök på mottagningarna, antecknades på livslinjen tidpunkter för
förändrat psykopatologiskt tillstånd med hjälp av betydelsefulla livshändelser och därtill
information om medicinering, psykosocial behandling, sjukledigheter, beviljade
invaliditetspensioner, självmordsförsök och eventuella förändringar i diagnos.
Fem-års uppföljningsintervjuer ägde rum 12.4.2002 − 27.4.2004 i Vanda psykiatriska
polikliniker och psykiatriska polikliniken vid Helsingfors Universitets centralsjukhus;
182 patienter (67.7%) deltog i intervjuerna. Vid tiden för intervjun, var hälften av
patienterna (50%) i fullständig remission, nästan en fjärdedel (24%) led av aktuell svår
depression och resten (26%) var i partiell remission. Av patienterna hade i genomsnitt
hälften (49%) tillbringat av tiden utan symtom på depression, en femtedel (20%) svårt
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deprimerade och en tredjedel (31%) i partiell remission. Dessutom hade en sjundedel (15%)
av patienterna försökt begå självmord minst en gång, och 29 (12%) hade insjuknat i bipolär
störning. Nästan alla patienter (99%) hade tillfrisknat åtminstone delvis från den första
depressiva episoden och majoriteten (88%) hade uppnått fullständig remission under en
median tid på 11 månader. De flesta, nästan tre fjärdedelar (71%) insjuknade på nytt i
svår depression under uppföljningstiden efter en median tid på 21 månader efter slutet på
indexepisoden. Svårighetsgraden av en depression förutspådde betydligt depressiva återfall
och antalet cykler av återfall samt förlängde tiden spenderad deprimerad. Kända
prognostiska faktorer, såsom varaktigheten av en depression och samtidig dystymi, samt
social fobi och cluster C personlighetsstörning försämrade prognosen.
Förekomsten av självmordsförsök varierade avsevärt beroende på det depressiva tillståndet
och var nästan 21-faldig under svåra depressiva episoder, och fyrfaldig under perioder av
partiell remission jämfört med perioder av fullständig remission. Även om tidigare
självmordsförsök och som lågt uppfattat socialt stöd också ökade risken, var tiden
spenderad i svår depression den viktigaste riskfaktorn.
Drygt en tiondedel (12%) av patienterna insjuknade under uppföljningstiden i bipolär
störning (främst typ II), vilket är en något högre andel jämfört med tidigare studier.
Insjuknande i typ I bipolär störning skedde i början av uppföljningstiden och i typ II
bipolär störning jämnt distribuerad under den tiden. Förutom tidigare kända riskfaktorer
förutspåddes diagnosförändringen av depressionens svårighetsgrad, samtidig social fobi,
obsessiv-kompulsiv störning och symtom på cluster B personlighetsstörning.
Majoriteten av uppföljda patienter hade en släkthistoria av inte bara affektiva störningar
(61%), utan även av andra allvarliga psykiska störningar (sammanlagt 75%). En sådan
släkthistoria var förknippad med sämre prognos med ökad risk för självmordsförsök,
kroniskt sjukdomsförlopp och samtida personlighetsstörningar. Hos kvinnor var en
släkthistoria av affektiva störningar förknippad med rådande neuroticism och hos män var
en släkthistoria av alkoholism förknippad med alkoholberoende hos forskningspatienter.
Allt som allt var långtidsprognosen för en svår depressiv störning på basen av denna
studie med mest öppenvårdspatienter inom modern psykiatrisk vård mera varierad än den i
tidigare, vanligen äldre studier utförda i Universitetskliniker och med sjukhuspatienter.
Återfallsrisken för svår depression var stor även i denna studie, men nya episoder verkade
vara kortare och sjukdomsförloppet vid en depression var mindre kroniskt.
Nyckelord: depression, psykiatriska patienter, prognos, självmordsförsök, bipolär
störning, släkthistoria.
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This study forms a part of the Vantaa Depression Study (VDS), a collaborative depression
research project between the Mood, Depression, and Suicidal Behaviour Unit of the National
Institute for Health and Welfare, Helsinki (former Department of Mental Health and Alcohol
Research of the National Public Health Institute, Helsinki), and the Department of
Psychiatry of Helsinki University Central Hospital (HUCH), Peijas Hospital, Vantaa. The
VDS is a prospective, naturalistic cohort study of 269 secondary-level care psychiatric
out- and inpatients with a new episode of DSM-IV major depressive disorder (MDD). The VDS
involved screening 806 adult patients (aged 20-59 years) in Peijas Hospital for depressive
symptoms beginning February 1, 1997, and interviewing the 542 consenting patients with a
semistructured interview (SCAN, version 2.0). On the basis of the interviews, 269 patients
were diagnosed with DSM-IV MDD and included in the study, and further interviewed with
semistructured methods to assess all additional psychiatric diagnoses. The exclusion
criteria were DSM-IV bipolar I and II, schizoaffective disorder, schizophrenia or another
psychosis, organic and substance-induced mood disorders.
The outcomes of major depressive episode (MDE) and the comorbid disorders were
investigated at six and 18 months, and 5 years after the baseline using repeated
semistructured interviews. The exact duration of the index episode and the timing of
possible relapses and recurrences were prospectively examined using a graphic life chart
based on DSM-IV criteria and definitions. Time after baseline was divided into three
periods: (1) state of full remission (none of the 9 MDE criteria symptoms), (2) state of
partial remission (1-4 of the 9 symptoms), or (3) state of MDE (5+ of the 9 symptoms). In
addition to symptom ratings and visits to attending personnel, change points in the
psychopathologic states using probes related to important life-events were inquired after.
In addition, received medications, psychosocial treatments, sick leaves, granted
disability pensions, suicide attempts, and possible changes of diagnoses were timed and
placed in the life chart.
The 5-year follow-up interviews took place in the psychiatric outpatient units in Vantaa
and Helsinki University Central Hospital (HUCH), between April 12, 2002 and April 27,
2004; 182 patients participated. At 5 years, nearly one-half (50%) of the patients were
currently in full remission, nearly one-fourth (24%) in major depressive episode (MDE),
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and the rest (26%) in partial remission. During 5 years the patients had spent on average
spent nearly half (49%) of the follow-up period in full remission, one-fifth (20%) of the
time in MDE, and one-third (31%) of the time in partial remission. Moreover, one-seventh
(15%) of patients had attempted suicide at least once, and 29 patients (12%) switched to
bipolar disorder. Over the 5-year follow-up, nearly all (99%) of patients achieved a
symptom state below major depressive episode (MDE) criteria, and the majority (88%)
reached full remission, within a median time of 11 months. The majority, nearly
three-fourths (71%) of the patients experienced a recurrence after a medium time of 21
months from the end of the index episode. Higher severity of MDD significantly predicted
the risk of recurrence, the number of recurrences and time spent ill. Besides known
predictors, such as longer episode duration and preceding dysthymic disorder, also
comorbid cluster C personality disorders and social phobia predicted a worse outcome.
The incidence rate of suicide attempts varied robustly depending on the level of
depression, being nearly 21-fold during MDEs, and 4-fold during periods of partial
remission compared to full remission. Although a history of previous attempts and poor
social support also indicated risk, time spent depressed was the central factor
determining overall long-term risk.
The overall switch rate (12%) from unipolar MDD to bipolar disorder (BD) (mostly to type
II) was to some extent higher than in previous studies. The switch to BD type I usually
occurred early, whereas the switch to type II took place more gradually over time. Besides
previously known predictors, a higher severity of MDD, comorbid social phobia, OCD, and
cluster B features predicted diagnostic switch.
The majority of the followed up patients had positive family histories not exclusively of
mood (61%), but also of other mental disorders (in all 75%). Having a positive family of
severe mental disorders was likely to be clinically associated with a significantly more
adverse outcome with an elevated risk for suicide attempts, more chronic courses, and
comorbid personality disorders. More specifically, a family history of mood disorders
appeared to be independently associated with high neuroticism among female, and that of
alcoholism with alcohol dependence among male patients.
According to the findings of the 5-year follow-up, long-term outcome of MDE appeared to be
more variable when outcome was investigated among modern, community-treated,
secondary-care mostly outpatients compared to previous older and mostly inpatient
tertiary-care studies. MDD was highly recurrent also in the current study, but the
recurrent episodes seemed shorter, and the outcome was unlikely to be uniformly chronic.
Keywords: depression, psychiatric care, outcome, suicide attempts, bipolar disorder,
family history
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3  Introduction
Depression  as  a  syndrome (Major  Depressive  Disorder,  MDD) is  related  to  the  normal
emotions of sadness and bereavement, but it does not remit when the external cause of
these emotions dissipates, and it is disproportionate to their cause (Belmaker and Agam,
2008). Melancholia which resembles the present term depression, was one of the earliest
human diseases described, having been recognized as an illness since ancient times as
Hippocrates (ca. 460 - 370 BC) was the first to systematically describe the patterns of
this illness. As defined in the Hippocratic writings, melancholia produced certain
symptoms that are very similar to those associated with depressive disorder today i.e.
persistent sleeplessness, lack of appetite, and despair, as well as suicidal behaviour and
seasonal variation. Although Hippocrates attributed melancholia to a chemical excess of
black bile, he also noted that symptoms of melancholia could be produced by lingering
grief and fear, suggesting that situational problems could also cause depression. The
founder of contemporary psychiatry Emil Kraepelin (1856 − 1926) described an illness
called manic depression which is now seen as comprising a range of mood disorders such as
recurrent major depression and bipolar disorder. He also believed the chief origin of
psychiatric illness to be biological and genetic malfunction. Thus, surprisingly many
features of contemporary psychiatry have been attributed to a major depressive disorder
for a long time.
MDD is a severe illness with high prevalence, multifactorial aetiology, and heterogenic
clinical picture characterized by a sad mood and an inability to experience pleasure,
often including serious abnormalities in cognition and physiological function. It imposes
a substantial burden by inflicting recurrent pain and suffering on individuals and their
families. MDD is also one of the most important mental disorders in terms of public health
impact. About a fifth of the population (Kessler et al., 1994; Kessler et al., 2003),
women more often than men, will experience a clinically significant episode of MDD at some
point in their lives. MDD involves a marked risk of functional disability (López et al.,
2006), self-destructive behaviour and premature death (Harris and Barraclough, 1997;
Sokero et al., 2005). MDD was in the year 2004 considered to be the third leading illness
in terms of global disease burden, and by the year 2030 it has been predicted it will be
the major disease or injury burden followed by ischaemic heart disease and road traffic
accidents (WHO, 2008).
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The high disease burden is also understandable from considerations of the nature and
course of depression. Previously viewed as an acute and self-limiting illness, it is now
clear that depression is not only highly prevalent but also a chronic, recurrent and
comorbid illness. Following this paradigm shift in the concept of depression, studies of
the natural history of MDE have come to be seen as essential for further understanding the
nature of the disorder and developing more effective treatment strategies (Judd, 1997).
Although the comorbid form of MDD is highly prevalent, there is a lack of studies
investigating the comprehensive importance of comorbid axis I and II disorders to the
outcome of MDD. Furthermore, much of what we now accept regarding the course of
depression and its comorbidity is derived from studies based on selected samples,
e.g. inpatients, patients of tertiary level university clinics, and samples predating
the era of the current new antidepressants and the now widespread use of maintenance therapies.
Despite this, it is known from epidemiological studies that most depressive persons in the
general population receive inadequate treatment or none at all (Kessler et al., 2003;
Hämäläinen et al., 2004).
The Vantaa Depression Study (VDS) is a prospective, naturalistic cohort study of 269
secondary-level care psychiatric out- and inpatients with a new episode of DSM-IV MDD. In
the VDS the predictors of outcome, recurrences, suicide attempts as well as functional and
work disability are investigated, and the adequacy of treatments evaluated. The present
thesis focuses on the outcome of depressive patients followed up for 5 years.
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4  Review of the literature
4.1 Depression as an emotion
The term depression is in everyday language used in a wide context ranging from limited
time of unhappiness and sorrow in ordinary life to a longer-lasting, incapacitating and
even life-threatening illness. Sadness is considered to be one of the seven basic emotions
together with fear, anger, joy, surprise, disgust, and contempt, which are thought to
constitute evolved functions that are shared between all human beings, both in terms of
phenomenology and communicative signals (Ekman, 1992; Sauter et al., 2010). Social or
moral emotions, such as guilt, shame, pride, or embarrassment, differ from basic emotions
in their external triggers, and their perception and expression differ culturally between
individualistic and collectivistic nations (Eid and Diener, 2001; Hari and Kujala, 2009).
Neuroimaging studies with positron emission tomography (PET), and functional magnetic
resonance imaging (fMRI) have been able to describe the functional neuroanatomy of
emotions, and according to them, different aspects of emotion, basic and social emotions
involve partly separate brain regions and neuronal circuits (Phan et al., 2002; Hari and
Kujala, 2009). Sadness is the core emotion accompanied with depressive affect. Transient
depressive feelings are normal reactions to experiences of loss and disappointment, and
may be even useful as they may motivate us to solve a problem, help us to give up on
hopeless goals, and to detach psychologically from an object of affection, admiration, or
identification. In some situations depressive affect might even be evolutionary useful in
adaptation to unpropitious situations, redefinition of goals, reallocation of efforts, and
by inhibiting potentially disruptive actions (Nesse, 2000). Depression as a syndrome is
related to the normal emotions of sadness and bereavement, but it does not remit when the
external cause of these emotions dissipates, and it is disproportionate to their cause
(Belmaker and Agam, 2008). In this thesis, depression refers to an entity including not
only mood, but also physical, mental and behavioral experiences that are associated with
more prolonged, impairing and severe conditions that may be clinically diagnosable as a
syndrome of depression.
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4.2 Classification of mental disorders
The majority of psychiatric diagnoses consist of syndromes where several symptoms exist
simultaneously indicating a likely course and outcome. The current psychiatric
classifications are categorical systems that divide mental disorders into different types
based on sets of criteria with defining characteristics. Classification and subtyping of
disorders, serve three purposes: prediction of treatment response, prognosis, and
etiologic research. The introduction of operationalized classification systems for mental
disorders, such as DSM-III, DSM-III-R, DSM-IV and DSM-IV-TR (APA, 1980; APA, 1987;
APA, 1994; APA, 2000a) by the American Psychiatric Association, and ICD-10 (WHO, 1992;
WHO, 1993; WHO, 2007) by the World Health Organization, have made a significant
contribution to the scientific development of psychiatry by exploiting objective criteria of
psychiatric diagnoses with specific thresholds and thus improving the diagnostic reliability
(Kendell and Jablensky, 2003). In addition, categorical diagnoses have helped with improving
treatment recommendations and clinicicians with treatment decisions, and statements about
prognosis (Kendell and Jablensky, 2003; Kraemer et al., 2004).
Strictly speaking, diagnostic categories defined by their syndromes should be regarded as
valid only if they have been shown to be discrete entities with natural boundaries that
separate them from other disorders (Kendell and Jablensky, 2003). Thus, one could argue,
that no psychiatric diagnosis is currently valid. However, if validity and utility of a
diagnosis are differentiated, it can be said that most current psychiatrc diagnoses have
substantial utility for clinicians (Kendell and Jablensky, 2003). In psychiatry, some
characteristic features of diagnostics challenge the definitions of diagnostic criteria.
Diagnoses are based mostly on interview and thus the patients’ abilities to observe and
describe their symptoms. Factors endangering the reliability, and thereupon the validity
of psychiatric diagnostics can be described as follows: 1) information variance (different
sources of information), 2) observation variance (patients are observed differently),
3) interpretation variance (observations are interpreted differently), 4) criteria variance
(the use of different definitions of symptoms and disorders), 5) case variance (variation
due to the individual characteristics of the patient), and 6) state variance (variation
due to fluctuations of the symptom state over time) (Spitzer and Williams, 1985). In their
recent essay, Kendler et al. discussed four different kinds of approaches to psychiatric
disorders: 1) essentialist kinds sharing an essence from which their defining features
arise; 2) socially constructed kinds being defined by the cultural context in which they
arise; 3) practical kinds focusing on useful definitions; and 4) mechanistic property
cluster kinds being defined in terms of complex, mutually reinforcing networks of causal
mechanisms (Kendler et al., 2010). They considered the latter approach to be the most
promising with a view of psychiatric disorders as sets of symptoms that are connected
through a system of causal relations.
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The classifications currently in use are the Diagnostic and Statistical Manual of Mental
Disorders (DSM-IV-TR) (APA, 2000a) and the International Statistical Classification of
Diseases and Related Health Problems (ICD-10) (WHO, 2007). In research, DSM-IV rather
than ICD-10 is usually used as it provides more detailed guidelines for case definition.
The concordance for any mental disorder for ICD-10 and DSM-IV has been found to be 68%,
and the concordance for major depressive episodes 83%, with the diagnostic threshold
for ICD-10 being lower than for DSM-IV disorders (Andrews et al., 1999). Categorical
diagnostic classifications have been criticized as they are likely to represent a
heterogeneous set of disorders that are derived from a wide range of etiological and
genetic factors (Charney and Manji, 2004). In attempting to solve this problem, some
researchers have suggested new, narrower or broader borders for mood disorders. Others
have suggested dimensional measuring of narrow symptoms instead of syndromes (Angst and
Merikangas, 1997). Developing the next generation of psychiatric classifications of DSM-V
and ICD-11 has for long been in progress, and DSM-V is to be published in May, 2013. The
aim has been to create more uniform classifications as well as to develop a more
dimensional approach, which would enable clinicians to access the severity of a patient’s
condition by rating factors such as subjective distress and degree of impairment in
addition to symptoms. Dimensions would also allow disorders to be deconstructed into
components that could be addressed separately (Miller and Holden, 2010). Along the
development, a more contemporary validation process have been created including building a
behavioural phenotype of clinical description and course, creating a neurobiological
profile, identifying genetic and familial patterns, considering the interaction between
biology and the environment, and emphasizing treatment response and follow-up studies
(Kupfer et al., 2008).
4.3 Diagnosis of mood disorders
Mood disorders are generally defined as illnesses in which the fundamental disturbance is
a change in affect or mood to depression (with or without associated anxiety) or to
elation characterized by different combinations of several co-occurring symptoms for a
defined period of time contributing to significant psychosocial impairment or marked
distress (APA, 2000a; WHO, 2007). In DSM-IV, mood disorders are divided into three groups:
depressive disorders, bipolar disorders, and other mood disorders. Unipolar forms of
primary mood disorders are further divided into three groups: major depressive disorder
(MDD), dysthymic disorder, and depression not otherwise specified (APA, 2000a). In ICD-10,
mood disorders are divided into manic episode, bipolar affective disorder, depressive
episode, recurrent depressive disorder, persistent mood (affective) disorders, and other
mood (affective) disorders (WHO, 2007).
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4.3.1 Diagnosis of major depressive disorder (MDD)
According to DSM-IV MDD is characterized by one or more major depressive episodes lasting
at least two weeks. In order to warrant a diagnosis of MDD, persistent (1) depressive mood
or (2) significant loss of interest or pleasure are the required core symptoms, which must
be accompanied by at least four associated symptoms (total of 5 or more symptoms) during
most of the day or nearly every day, e.g. (3) significant weight or appetite change, (4)
insomnia or hypersomnia, (5) psychomotor agitation or retardation, (6) fatigue or loss of
energy, (7) feelings of worthlessness or extreme or inappropriate guilt, (8) a diminished
ability to think or to concentrate or indecisiveness, and (9) recurrent thoughts of death
or suicidal ideation, or a suicide attempt or a specific plan for committing suicide (APA,
2000a). In addition, these symptoms must cause clinically significant distress or
impairment in social, occupational, or other important areas of functioning; are not due
to the direct effects of a substance or a general medical condition; are not better
accounted for by bereavement. DSM-IV also lists three levels of severity of MDD. Based on
the number of criteria symptoms, the severity of the symptoms and the degree of functional
disability and distress, MDD can be mild, moderate or severe (with or without psychotic
features). The symptoms must cause clinically significant distress or impairment in
social, occupational, or other important areas of functioning, and symptoms that are due
to a general medical condition, direct physiological effects of a substance,
mood-incongruent delusions or hallucinations, bipolar mixed episode, or bereavement must
be ruled out. The terms and codes in DSM-IV are mostly comparable with ICD-10 (WHO,
2007), and diagnosis of MDD is basically similar in both classifications. However, compared
with DSM-IV, ICD-10 splits one criterion (feelings of worthlessness and unreasonable guilt),
requires one symptom less for diagnosis, and also includes fatigue or loss of energy among
the core symptoms.
A simpler definition of MDD has been suggested, as studies have shown that treatment
providers have difficulties recalling all nine symptoms, and the somatic symptoms (weight
change, insomnia, loss of energy and psychomotor retardation) are difficult to apply in
patients with medical illnesses (Zimmerman and Galione, 2010). A recent study found, after
eliminating the four somatic criteria from the DSM-IV definition of MDD, a high level of
concordance between this simpler definition and the original DSM-IV classification
(Zimmerman et al., 2010). According to DSM-IV, periods of sadness are aspects of the human
experience, which should not be diagnosed as a MDE unless criteria are met for severity,
duration, and clinically significant distress or impairment (Maj, 2008). This clinical
significane criterion has also been criticized. Kendler et al. found similarities between
bereavement-related depression and depression related to other stressful life events
questioning the validity of the bereavement exclusion for the diagnosis of major
depression (Kendler et al., 2008), whereas Wakefield et al. recommended based on their
findings to extend the bereavement exclusion to even other uncomplicated loss-events
triggering depression (Wakefield et al., 2007; Wakefield et al., 2009). The proposed
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version of DSM-V emphasizes three basic dimensions of depression: depression with anxiety,
with substance abuse, and with suicidal behavior. In addition, a new diagnosis of mixed
anxiety depression has been introduced (www.dsm5.org) (Miller and Holden, 2010). In this
thesis, unless otherwise specified, depression refers to unipolar DSM-IV MDD.
4.3.1.1 Subgroups of MDD 
DSM-IV describes important distinctive features of an depressive episode for the purposes
of research or treatment choice (APA, 2000a). Psychotic features may be present in a
severe MDE, and include the presence of either hallucinations or delusions. Psychotic
symptoms appear to repeat over recurrent episodes (Coryell et al., 1994). Melancholic
features of DSM-IV MDE include (a) loss of pleasure in all, or almost all, activities,
(b) lack of reactivity to usually pleasurable stimuli, (c) a distinct quality of the
depressive mood, (d) depression regularly worse in the morning, (d) early morning
awakening, (e) marked psychomotor change, either retardation or agitation, (f) significant
loss of appetite or weight loss, and (e) excessive or inappropriate guilt (APA, 2000a).
Melancholic features and psychotic features may represent a distinctive form of severe
depression arising from a different pathophysiology than other forms of depression (Parker
and Manicavasagar, 2005). It has also been reported that patients with melancholic
depression respond better to biological therapies (e.g. tricyclic antidepressants [TCAs]
and/or eletroconvulsive therapy [ECT]) (Perry, 1996). The validity of the DSM-IV criteria
in differentiating melancholic and non-melancholic depression has been criticized with the
suggestion that observable psychomotor disturbances are the only necessary and sufficient
feature of the definition of melancholia, whereas the other features are prevalent in both
types and are thus non-specific (Parker, 2003). A previous report from the Vantaa
Depression Study (VDS) discovered no major differences in current co-morbidity, or course
of depression between melancholic and non-melancholic patients, and the consistency of
DSM-IV melancholic features across episodes appeared weak (Melartin et al., 2004a).
Atypical depressive features include (1) mood reactivity and (2) two or more of the
following features: (a) significant weight gain or increased appetite, (b) hypersomnia,
(c) leaden paralysis, and (d) a long-standing pattern of interpersonal rejection
sensitivity (APA, 2000b). It was previously recognized that patients with atypical
depression responded better to the monoamine oxidase inhibitors (MAOI) in contrast to
patients with melancholic depression (Stewart and Thase, 2007). The current definition of
atypical features appears problematic as interpersonal rejection sensitivity and leaden
paralysis may have their phenomenological base in anxiety rather than depression (Parker
et al., 2002). Rejection sensibility is in addition a prominent feature of borderline
personality (APA, 2000a). Seasonal pattern depressions have an apparent regular onset and
disappearance during certain times of the year. In the Northern hemisphere the most common
pattern is autumn or winter depression (SAD or seasonal  affective  disease).  Postpartum
onset specifier can be taken to a MDE if the onset is within 4 weeks after the delivery
(APA, 2000a).
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4.3.2 Diagnosis of other depressive disorders
According to DSM-IV (APA, 2000a) depressive disorders include in addition to MDD two
other forms: dysthymic disorder and depression not otherwise specified (NOS), which
includes several forms of briefer or milder periods of depression. Dysthymic disorder in
DSM-IV consists of chronic but milder symptoms than MDE. The diagnostic criteria include
(A) a depressed mood for most of the day or for more days than not for at least two years,
(B) the presence, while depressed at least two of the following: (1) poor appetite or
overeating, (2) insomnia or hypersomnia, (3) low energy or fatigue, (4) low self-esteem,
(5) poor concentration or difficulty in making decisions, or (6) feelings of hopelessness.
The symptoms cause clinically significant distress or impairment in important areas of
functioning. In addition, no major depressive episode (MDE) should have been present
during the first two years, i.e., the disturbance cannot be better accounted for as
chronic MDD or MDD in partial remission. A number of subjects with disabling depressive
symptoms fail to meet the diagnostic criteria for MDD or dysthymia, some of these
subsyndromal conditions are included in the category depression not otherwise specified 
(APA, 2000a). Appendix B in DSM-IV (APA, 2000a) defines diagnostic criteria for recurrent
brief depressive disorder, where the episodes are identical to MDE in the number and
severity of symptoms but do not meet the 2-week duration requirement lasting at least 2
days but less than two weeks. Episodes must recur at a minimum of once a month for a
period of 12 consecutive months (APA, 2000a). For minor depression, although not
considered an official clinical diagnosis, the American Psychiatric Association defined
research diagnostic criteria in Appendix B of DSM-IV (APA, 2000a). The essential features
are identical to MDE in duration, but involve fewer symptoms and less impairment. An
episode involves either a sad or depressed mood or loss of interest or pleasure in nearly
all activities. In total, at least two but less than five additional symptoms must be
present. Subsyndromal depressive symptoms were included to a clinical condition proposed
by Judd et al. in order to further analyse the pleomorphism of the depressive spectrum in
the National Institute of Mental Health (NIMH) Epidemiological Catchment Area (ECA)
Program (Judd et al., 1997). It was there defined as at least two current depressive
symptoms, present every day for most of the time, for at least two weeks, in persons not
meeting the criteria for MDD, minor depression or dysthymic disorder. Thus it could refer
to residual symptoms of a past MDE or a prodromal of a future MDE (Judd et al., 1997).
4.3.3 Diagnosis of bipolar disorder
Bipolar disorder, or manic-depressive illness as it was previously named, is a mental
disorder characterized by recurrent episodes of mania, hypomania, mixed states and
depression. Bipolar disorder is divided into bipolar I and bipolar II disorders, and
bipolar disorder not otherwise specified (NOS). Bipolar I disorder is characterized by one
or more manic or mixed episodes usually accompanied by major depressive episodes. Bipolar
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II disorder is characterized by at least by one hypomanic episode and one or more major
depressive episodes (APA, 2000a). There are no differences in DSM-IV criteria regarding
unipolar depression or major depressive episode of bipolar disorder.
The criteria of a manic episode include nearly every day over at least a 1-week period (or
any period if hospitalization is necessary) (A) a distinct period of abnormally and
persistently elevated, expansive, or irritable mood, lasting at least for 1 week (or any
duration if hospitalization is necessary) and (B) during the period of mood disturbance,
three (or more) of the following symptoms persisting (four if the mood is irritable) to a
significant degree: (1) inflated self-esteem or grandiosity, (2) decreased need for sleep,
(3) more talkative than usual or pressure to keep talking, (4) flight of ideas or a
subjective experience that subject’s thoughts are racing, (5) distractibility, (6)
increase in goal-directed activity or psychomotor agitation, or (7) excessive involvement
in pleasurable activities that have a high potential for painful consequences (APA,
2000a). The disturbance must be sufficiently severe to cause marked impairment in social
or occupational functioning, or to require hospitalization, or it is characterized by the
presence of psychotic features.
A mixed episode is characterized by a period of lasting at least one week in which the
criteria are met both for a manic episode and for a major depressive episode nearly every
day. In addition, the disturbance must be sufficiently severe to cause marked impairment
in social or occupational functioning, or to require hospitalization, or to include
psychotic features.
A hypomanic episode is characterized by a persistently elevated, expansive or irritable
mood lasting for at least four days. The mood disturbance is accompanied by inflated
self-esteem or grandiosity, decreased need for sleep, pressure of speech, flights of
ideas, distractibility, increased involvement in goal-directed activities or psychomotor
agitation and excessive involvement in pleasurable activities with a high potential for
painful consequences. A hypomanic episode must be clearly different from the individual’s
usual non-depressed mood, and there must be a clear change in functioning that is not
characteristic for the individual, and changes in mood and functioning must be observable
by others. The DSM-IV hypomania-specific criteria for a hypomanic phase (APA, 2000)
differ from the criteria for a manic phase in that the expression "abnormally changed" is
omitted from criterion (A), and a duration of only 4 days is required. Also, hypomania is
differentiated from mania in that the phase must not be severe enough to cause marked
impairment in social or occupational functioning, or to necessitate hospitalization, and
no psychotic features are present.
Bipolar disorder NOS is a coverall category, diagnosed when the disorder does not fall
within a specific subtype (APA, 2000a). Especially, when an individual aged over 50 years
has his/her first manic or hypomanic episode the possibility of an organic aetiology must
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be ruled out. Potential hypomanic and manic episodes must be evaluated when treating
depressive patients. The proposed DSM-V somewhat lowers the threshold for bipolar
diagnosis by allowing a bipolar episode diagnosis during antidepressant treatment if the
symptoms persist beyond the physiological effect of that treatment (www.dsm5.org).
4.4 Prevalence of mood disorders
The prevalence of depressive symptoms varies depending on the population studied and
criterion used, the variations in time frames, age ranges, diagnostic criteria and
interview schedules (DIS, CIDI) complicate the synthesis of findings. In addition, the
generalizability of diagnostic criteria across countries requires further confirmation
(Patten, 2003). Efforts to eliminate these problems have been made in order to unify
different study methods. WHO has created a large research consortium (WHO World Mental
Health Survey Initiative, 2004), where a wordwide survey has reported the prevalence and
severity of mental disorders and use of mental health services (Demyttenaere et al., 2004;
Wang et al., 2007).
4.4.1 Prevalence of MDD
It has been estimated that about a fifth of the population (Kessler et al., 1994; Kessler
et al., 2003), will experience a clinically significant MDE at some point in their lives.
The prevalence for females is about twice as high as for males (Paykel et al., 2005); it
is fairly low until the early teens, when it begins to rise in roughly linear fashion
(Kessler et al., 1994), the median age of onset being approximately 30 years (Kessler et
al., 2003).
General population studies have generally reported a 12-month prevalence of 4% to 9%, and
a lifetime prevalence of 13% to 18% of MDD. The National Comorbidity Survey Replication
(NCS-R), conducted in 2001-2002, found a 12-month prevalence of 6.6% and lifetime
prevalence of MDD of 16.2% among U.S. adults (Kessler et al., 2003). In Europe, The
European Study of the Epidemiology of Mental Disorders/ Mental Health Disability
(ESEMeD/MHDEA 2000) reported from six countries a 12-month prevalence of 4% and
lifetime prevalence of 13% (Alonso et al., 2004). In Finland, the Health 2000 project
reported a 12-month prevalence of 4.9% and lifetime prevalence of 17.7% (Pirkola et al.,
2005a; Suvisaari et al., 2009), while the 12-month prevalence was 9.3% in the Finnish
Health Care Survey (TERVA) (Lindeman et al., 2000). The use of a diagnostic interview with
strict exclusion criteria probably explains the lower prevalence in the more recent Health
2000 project. The Tampere Depression (TADEP) Study found clinical depression in a tenth of
primary care patients, and in one-half of patients in community mental heath centres
(Salokangas et al., 1996).
4  Review of the literature
29THL - Research 44/2010 Long-term Outcome of
DSM-IV Major Depressive Disorder
in Psychiatric Care
There have been opposing views on whether the prevalence of MDD has increased or not
(Compton et al., 2006; Hawthorne et al., 2008). The increasing usage of antidepressant
medications, granted disability pensions, and depressions diagnosed younger than before,
have led to the common interpretation that the prevalence of depression has also
increased. Those with a contrary view have argued with easier prescription and usage of
medications, higher alertness among clinicians to diagnose depression, changes in society
towards more open discussion about depressive feelings and false diagnoses among patients
with burn-out (Karlsson, 2009; Lönnqvist, 2009).
4.4.2 Prevalence of bipolar disorder
The lifetime prevalence of bipolar disorder (BD) type I is commonly estimated to be about
1%, but in more recent general population studies it has varied from 1.9% to 3.3% (ten
Have et al., 2002; Grant et al., 2005; Kessler et al., 2005b; Pini et al., 2005). The
12-month prevalence of BD has been reported to be from 0.1 to 2.0% (ten Have et al., 2002;
Mitchell et al., 2004; Kessler et al., 2005b; Pini et al., 2005). The differences in
prevalence have depended on the diagnostic instrument used.
In epidemiological studies BD II has been even more difficult to diagnose with certainty
and studies investigating lifetime prevalences separating BD I and II, which have been few
(Szadoczky et al., 1998; Scully et al., 2004), reported the lifetime prevalence of BD II
to be 0.1 and 2.0%, and of BD I 0.3 and 1.5%. The prevalence of hypomania in the
Epidemiological Catchment Area Study (ECA) was 0.5%, lower than the 0.8% for mania
(Weissman et al., 1988). In Finnish studies, the prevalence of BD has been estimated to be
lower than the international prevalences (Lehtinen et al., 1990b; Veijola et al., 1996;
Räsänen et al., 1998; Kieseppä et al., 2004). The most recent Finnish general population
study, Psychoses in Finland (PIF) (Perala et al., 2007), used several screening methods
and structured interviews by psychiatrists to confirm the diagnosis of patients screening
positive for psychotic symptoms. The study reported a lifetime prevalence of 0.24% for BD
I, and 0.42% with the inclusion of register diagnoses of BD I. The Tampere Depression
Project used the Present State Examination as a diagnostic instrument to evaluate the
prevalence of BD and MDD in primary care (N=437) and secondary care (N=435). In
community health centers, the 12 month prevalence of BD was 2.1%, and in community
mental health centres, 7.6% (Sorvaniemi and Salokangas, 2005).
4  Review of the literature
30 THL - Research 44/2010Long-term Outcome of
DSM-IV Major Depressive Disorder
in Psychiatric Care
4.5 Aetiology and pathogenesis of MDD
4.5.1 Multifactorial aetiology
The aetiology of MDD is understood as a multifactorial longitudinal process, where genetic
factors, temperament, early traumatic experiences, current stress and their interactive
and cumulative effects act as predisposing factors (Melartin and Isometsä, 2009).
Furthermore, MDD is a clinically heterogeneous disorder with a highly variable course
increasing the likelihood of a wide range of individual risk factors (Kendler et al.,
2002; Kendler et al., 2006a; Belmaker and Agam, 2008). Many levels of scientific
explanation, from molecular to sociological are needed; until now, despite many efforts an
integrative and pervasive model remains to be uncovered. The concept of depression has
shifted from one where genetic, biological, developmental and environmental risk factors
were thought to be unrelated to one where these risk factors are believed to be related
and interacting (Kendler et al., 2002; Caspi et al., 2003; Charney and Manji, 2004;
Kendler et al., 2006a). However, aetiological risk factors for MDD are not necessarily
similar to factors affecting the outcome and course of the disorder. Integrating the tools
of genomics and neural science is needed to reveal the causes of neuropsychiatric
illnesses and to suggest new strategies for treatment and prevention (Akil et al., 2010).
4.5.2 Heritability and genetic risk factors
Heritability is a concept that refers to the proportion of total variation in a trait that
can be attributed to variation in genetic factors. Heritability is estimated in relation
to a population, and can vary from one population to another depending on the relative
impact of heritable and environmental factors. Family-, twin- and adoption studies have
shown that psychiatric disorders exist often within families, and liability to depression
is at least partly inheritable (Oates, 1997; Rutter et al., 1999). According to them, the
offspring of depressed parents have a 3-fold risk of a mental disorder by the age of 35
(Weissman et al., 2006), and a 3- to 4-fold risk to MDD compared to those without a family
history (Sullivan et al., 2000); the risk of maternal depression is transmitted even
across generations (Weissman et al., 2005). When one of monozygotic twins suffers from
depression, the likelihood of depression in the other twin is about 50%, and among
dizygotic twins approximately 20% (Sullivan et al., 2000). In representative studies
investigating normal populations, the estimates of heritability have varied between 35 to
40%, and have been on an average somewhat higher in women (40-45%) compared to men
(25-30%) (Sullivan et al., 2000; Kendler et al., 2006c). The heritability of liability to
major depression can be even up to 75% in clinical cohorts of subjects with more
recurrent, difficult depressive episodes, and early age at onset (Uher, 2008). The
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heritability of liability to bipolar disorder is estimated to be as high as 85-90%
(McGuffin et al., 2003; Kieseppä et al., 2004). However, a more recent Swedish study
estimated a lower heritability of 59% for bipolar disorder (Lichtenstein et al., 2009).
A combination of genetic factors, early life stress and ongoing stress may ultimately
determine individual responsiveness to stress and vulnerability to depression (Caspi et
al., 2003; Uher and McGuffin, 2008; Caspi et al., 2010). According to several reports,
allelic variation of 5-HTT expression and function (length polymorphism in the promoter
region of human serotonin transporter gene [5-HTTLPR]) together with modelling life-events
may predispose to depression, and also predict the response to antidepressant treatment
(Caspi et al., 2003; Caspi et al., 2010). Genetic differences seem to affect the
serotonergic system, and the development of neural circuits already in childhood, and the
vulneralibity to stress in subjects with a short allele of this gene (S) can be observed
already in childhood (Jacobs et al., 2006). The potential mechanisms include a heightened
reactivity to emotional and stressful stimuli mediated by the serotonergic nerve system
(Canli and Lesch, 2007), and the regulation of hypothalamus-pituitary-adrenal (HPA) axis
(Gotlib et al., 2008; Chen et al., 2009; El Hage et al., 2009).
However, also evidence against these findings has emerged questioning the interpretations
of the findings by investigation methods, and effects of gender and age (Monroe and Reid,
2008), whereas a recent meta-analysis found no associations between 5-HTTLPR, stressful
life events, and risk of depression (Risch et al., 2009). The authors reasoned that the
prior probability of a positive finding would be extremely small. Therefore they excluded
studies that others have considered as best evidence. Animal models, for instance, would
justify a prior probability of the conventional 0.05. As vulnerability to early and adult
stress is also associated with disturbances in the regulation of the HPA-axis, candidate
genes affecting the corticotropin releasing hormone (CRH) system and glucocorticoid
receptors have also been investigated (Heim et al., 2008; McGowan et al., 2009). Different
candidate genes seem to have also significant interactions. Human serotonin transporter
and brain-derived neurotrophic factor (BDNF) genes likely regulate the functions of some
neural circuits, and may modulate the propensity to depression related to early stress
(Heim et al., 2008).
However, the heritability of liability can be estimated for groups, not individuals, and
the causation of major depression is probabilistic, not deterministic (Sullivan et al.,
2000). Genetic linkage studies in unipolar MDD suggest a number of candidate regions on
different chromosomes (Abkevich et al., 2003; Zubenko et al., 2003; Holmans et al., 2004),
but to date, no study has found a gene-variation that would directly explain the
occurrence of depression (El Hage et al., 2009). The liability of depression is affected
probably by several genes, which are of limited importance at the population level,
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despite their significance in individual families (Akil et al., 2010). Genes that
predispose to MDD are not specific to depression, for example, the genetic correlation
between depression and generalized anxiety disorder (GAD) is very high, and also
significant between other anxiety disorders (Kendler et al., 2007; Hettema, 2008).
4.5.3 Psychosocial risk factors
A majority of MDE’s emerge after a significant negative life event which includes
typically experiences of loss, separations, and other situations of humiliation, shame, or
entrapment (Kendler et al., 2003a). Psychosocial risk factors for depression can be
divided into early and recent risk factors. The former include experiences from childhood
and adolescence and the latter risk factors, such as stressful life events and poor social
support, preceed the occurrence of MDE (Kendler et al., 2002; Kendler et al., 2006a). It
has been hypothesized that high levels of early life trauma lead to illness through the
developmental interaction of genetic variants with neural circuits that regulate emotion,
mediating together risk and resilience in adults (Gillespie et al., 2009).
4.5.3.1 Early psychosocial factors
Several studies have demonstrated the relationship of serious negative life events and
difficult circumstances in childhood and the development of depression, and other mental
disorders in the adulthood. Such life events have ranged from physical or sexual abuse
(Heim et al., 2000; Gladstone et al., 2004; Kendler and Prescott, 2006), to a disturbed
family environment, such as poor parenting, parental loss or separation, and depression of
parents (Lyons-Ruth et al., 1986; Tennant, 1988; Kessler et al., 1997; Veijola et al.,
2004; Kendler and Prescott, 2006). It has been hypothesized that poor parenting increases
the risk for MDD through individual specific environment, i.e. individuals react to
parenting in different ways guided in part by genetically influenced characteristics e.g.
temperament (Kendler and Prescott, 2006).
Within the Health 2000 study in Finland, the impact of adverse environmental factors
during childhood seemed to include a wide range of factors from direct causal associations
to complex interacting environmental effects (Pirkola et al., 2005). Evidence has been
found to support the vulnerability hypothesis, i.e. the consequences of an unfavourable
childhood background might be worse if combined with adult adverse life-events (Korkeila
et al., 2005). Futhermore childhood adverse life-events have been found to associate with
adult depression-prone personality characteristics (Korkeila et al., 2004), and with an
increased likelihood of experiencing a high number of life events in adulthood and their
perceived burdensomeness (Korkeila et al., 2010). Early trauma can induce long-term
neuroendocrinological and biological effects, which in turn increase the emotional
sensitivity and risk of depression during stress (Korkeila et al., 2005; Danese et al.,
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2008; Heim et al., 2008). However, every individual with depression has not experienced
early trauma, and everyone with traumatic experiences does not become depressed.
Individuals may react to childhood experiences in different ways guided by genetically
influenced characteristics e.g. temperament, nurture, age, duration of stress and later
mending experiences (Karlsson et al., 2007; Kendler and Baker, 2007).
4.5.3.2 Recent psychosocial factors 
Together with genetic vulnerability and temperamental factors, adverse life events are
likely to form one of the key domains of liability to MDD (Kendler et al., 2002; Kendler
et al., 2006a). The relative risk of depression within 6 months after a significant
negative life event is estimated to be up to sixfold (Paykel, 1978; Kendler et al.,
2006a). Loss and humiliating events have been particularly demoralizing among depressives
(Farmer and McGuffin, 2003) and in epidemiologic twin studies (Kendler et al., 2003a). Men
have been more sensitive to divorce and work difficulties, and women to their social
network events (Kendler and Prescott, 2006). Different types of difficulties may lead to
different profiles of depressive symptoms (Keller et al., 2007). The role of psychosocial
stress may vary over time being largest at the beginning and diminishing over recurrent
depressive episodes, and may be less important in precipitating in melancholic or
psychotic subtypes of MDD (Kendler et al., 2000; Mitchell et al., 2003). Low social
support appears to increase the risk of recurrent MDE (Kendler et al., 2006a), and
depression may in term have significant negative consequences on the social support
available (Coryell et al., 1993; Leskelä et al., 2008).
In addition, the ability to receive and respond to support may be influenced by early
negative experiences and relationships to significant others. In gene-environment
interaction studies genetic risk has been found to influence overall liability to illness
and alterer an individual’s sensitivity to the pathogenic effects of the environment
(Kendler and Prescott, 2006). Genetic mediation by 5-HTTLPR of vulnerability to an adverse
environment has been reported in several studies (Caspi et al., 2010). Also, other gene-
environment interactions have been reported, e.g. serotonin receptor 2A gene may be
involved in the development of depression by influencing the ability of individuals to use
environmental support (Jokela et al., 2007) and the dopamine transporter gene, genotype
A2/A2, may be involved in the development of depressive symptoms in individuals with
adverse life-events (Elovainio et al., 2007). Other possible interactions are e.g. an
interaction between life-events and neuroticism, where neuroticism has a greater impact on
the risk of MDD at high rather than low levels of stressful life-events (Kendler et al.,
2004). According to a bidirectional model, partly genetically determined individual
differences in personality, influence world-view and the likelihood of experiencing
stressful life events, and the quality of interpersonal relationships, which in turn
influence the risk of depression (Kendler et al., 2003b). In the VDS, the majority of
patients attributed the onset of MDE to some adverse event, although no clustering of live
events appeared to associate with the time of onset (Leskelä et al., 2004).
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4.5.3.3 Personality and temperamental factors
Temperament has been seen as the early appearing core of later personality. It manifests
early in life remains relatively stable, is inherited and is based on biological
processes. Cloninger has described four dimensions of temperament, i.e. novelty seeking,
harm avoidance, reward dependence, persistence, and dimensions of character associated
with different aspects of self-concept, i.e. self-directedness, co-operativeness, and
self-transcendence (Cloninger et al., 1993). Personality can be conceptualized as a large
entity of individual differences including values, motives, attitudes, needs, coping
mechanisms, capabilities, attainments and self-esteem. Personality develops from
temperament through experiences, maturation and interaction with the environment (Pervin
et al., 2005). Two widely studied personality dimensions describing negative and positive
trait entities, neuroticism, and extraversion have been included in the largely supported
Big Five model or Five Factor Model together with agreeableness, conscientiousness and
openness to new experience (Goldberg, 1993). Personality dimensions have been found to
influence the risk for depression. High neuroticism has been considered a risk factor for
depression in prospective epidemiological twin (Kendler et al., 1993b; Kendler et al.,
2006b; Fanous et al., 2007), general population (Ormel et al., 2004) and clinical studies
(Angst and Clayton, 1986; Hirschfeld et al., 1989; Boyce et al., 1991). Moreover, low
extraversion has been suggested to be a vulnerability factor for depression (Hirschfeld et
al., 1989; Kendler et al., 2006b) and high extraversion to even exert some protective
effects against depression (Farmer et al., 2002). However, the role of extraversion as a
risk factor for depression is more obscure than that of neuroticism, as prospective
studies (Angst and Clayton, 1986; Hirschfeld et al., 1989; Boyce et al., 1991; Kendler et
al., 1993b; Fanous et al., 2007) have not proved low extraversion to be a risk factor. The
relationship between personality and affective disorders is complex. Personality features
may 1) have a common aetiology with affective disorders, 2) predispose an individual to
affective disorders, 3) be shaped by repeated episodes of the illness, 4) modify the
clinical picture of the illness, 5) be an attenuated expression of the disorder, or 6) be
state-dependent concomitants of affective disorders (Shea and Yen, 2003; Brandes and
Bienvenu, 2006).
4.5.4 Structural and functional brain imaging findings
In general, the structure of the brain is normal in patients with depression, but mild
abnormalities may exist. Magnetic resonance imaging (MRI) studies have demonstrated that
small hippocampal volumes associate with recurrent or severe MDD (Sheline et al., 1999),
and when compared with control subjects, MDD patients have had smaller volumes of the
orbital frontal cortex and anterior cingulated cortex (Videbech and Ravnkilde, 2004;
Campbell and MacQueen, 2006). MRI studies have also revealed decreased white matter
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volumes in the left anterior cingulated gyrus and right middle frontal gyrus among elderly
MDD patients (Bell-McGinty et al., 2002), whereas patients with familial MDD have shown an
enlarged middle genu area of corpus callosum (Lacerda et al., 2005). The increased rate of
white matter hyperintensities, possily implicating impairment of white matter tracts
connecting the cortex with the limbic areas, has been found in the frontal lobes and basal
ganglia in elderly MDD patients (Videbech, 1997; MacFall et al., 2001). More recently,
white matter abnormalities have been revealed also in first-episode, treatment-naïve
young adults in the frontal, temporal and parietal lobes with a modern MRI technique,
diffusion tensor imaging (DTI) (Ma et al., 2007). Postmortem studies have also revealed a
decrease in gliacells (astrocytes and oligodendrocytes) especially in the amygdala and
prefrontal regions of the brain (Rajkowska and Miguel-Hidalgo, 2007). It seems these
changes can sometimes be found already in the early stage of illness, and in young
adolescents with a familial risk of depression. Treatment likely modifies the effects of
illness, e.g. the previously decreased volume of amygdala increases with treatment for
depression (Fu et al., 2004). In addition, antidepressant medication may prevent the
reduction of hippocampal volume among patients with major depression (Sheline et al.,
2003).
A general picture of disturbed brain functioning is that during depression the metabolism
in frontal cortex is diminished and the metabolism of limbic system is increased; thus,
the enhanced activity in the regions central to emotions are beyond the control of the
central cortical regions. Functional neuroimaging techniques i.e. functional magnetic
imaging (fMRI), positron emission tomography (PET) and single-photon emission
computerized tomography (SPECT) have shown changes among MDD patients in several brain
areas, including the orbital and medial prefrontal cortex, the amygdala and related parts
of the striatum and thalamus (Drevets, 2000). Functional imaging studies of the brain
report that serotonin transporter polymorphism also associates with reduced hippocampal
volume (Frodl et al., 2004), or with greater amygdala neuronal activity (Hariri et al.,
2002). The normalization of the overactivity of the anterior part (Brodmanns area 25) of
the gyrus cingularis situated in the medial prefrontal cortex correlates strongly with a
good response to antidepressant medication, and has been the neuroanatomical target of the
experimental neuromodulation treatment (deep brain stimulation [DPS]) (Mayberg, 2009).
However, the clinical picture of depressive patients is very heterogenous and substantial
individual variations exist also in the findings of functional brain imaging studies.
Different brain regions probably correlate with discrete symptom domains of major
depression and together make up the MDD syndrome (Milak et al., 2005).
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4.5.5 Neurochemical, neurotrophic and neuroendocrinological findings
Noradrenergic and serotonergic systems originate deep in the brain and fan out over almost
the entire brain, suggesting a system capable of modulating many areas of feeling,
thinking, and behaving (Belmaker and Agam, 2008). The monoamine hypothesis of depression
developed while investigating antidepressants and their mechanism of action postulating
that a central illness mechanism is a deficiency in the brain monoamine (serotonin,
norepinephrine or dopamine) neurotransmission (Thase et al., 2002). However, in its
original form the hypothesis seems inadequate, and has evolved to include e.g. adaptive
changes in receptors to explain the delay in onset of the antidepressant effect
(Hirschfeld, 2000). Moreover, monoamine depletion has induced depressed mood in subjects
with a family history of MDD and in drug-free patients with MDD in remission, but in
healthy subjects only if they have a family history of depression, and have thus failed to
demonstrate a causal relation between dysfunction in the monoamine systems of serotonin
and noradrenalin (Ruhe et al., 2007). Therefore, disturbance in monoamine neural
transmission is related to the illness mechanisms of depression, but only as one factor
(Belmaker and Agam, 2008). The monoamine hypothesis has evolved into the direction of a
chemical or molecular hypothesis of depression, which presumes that mood disorders are
produced by long-term changes in the production or activity of molecules e.g.
neuropeptides, growth factors and their receptors and intracellular signalling molecules
in the brain (Manji et al., 2001; Castren, 2005). The network hypothesis proposes that
problems in information processing within neural networks, rather than changes in chemical
balance, might underlie depression, and that antidepressant drugs induce plastic changes
in neuronal connectivity e.g. by increasing the expression and signalling of BDNF, which
gradually lead to improvements in neuronal information processing and the recovery of mood
(Castren, 2005).
Stress promotes adaptation, but a disturbed diurnal rhythm or failed shut-off of mediators
e.g. glucocorticoids and growth hormone after stress leads over time to allostatic load
(wear and tear on the body) (McEwen, 2003). Abnormal, excessive activation of the
hypothalamic-pituitary-adrenal (HPA) axis is observed in approximately half of individuals
with depression. Hypercortisolism has been observed in subjects with severe and psychotic
depression, and hypocortisolism in subjects with atypical depression (Gold et al., 2002).
In addition to directly causing neuronal atrophy and hippocampal volume reduction, life
stress and glucocorticoids also reduce cellular resilience and neurogenesis (Sapolsky,
2000; Manji et al., 2001; Heim et al., 2008; McKinnon et al., 2009). An excessive amount
of glucocorticoids may also be partly responsible for the decreased level of BDNF and thus
the deficiency in neutotrophic support (Nestler et al., 2002). It has been observed that
not only the overall production of cortisol, but also enhanced corticotrophin releasing
factor (CRF) carry the responsibility for HPA-axis hyperactivity (Nestler et al., 2002).
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CRH predominantly acts through CRH-1 receptors to produce a number of anxiety- and
depression-like symptoms. Impaired corticosteroid receptor signaling has been suggested to
be a key mechanism in the pathogenesis of depression, and is a target of future
antidepressant development (Holsboer, 2000; Refojo and Holsboer, 2009).
The BDNF-hypothesis of depression postulates that loss of BDNF is directly involved in the
pathophysiology of depression, and its restoration may underlie the therapeutic efficacy
of antidepressant treatment. However, critical views have been presented for reassessing
this hypothesis and it is suggested that maybe the role of BDNF lies more in the
development of depressive symptoms than at the core of disease pathology (Groves, 2007).
Since the beginning of the 1990’s there have been findings that depression is
characterized by cell-mediated immune activation and inflammation (Maes, 1994). More
recently, it has been reported that, depression is an inflammatory disorder because the
plasma levels of cytokines are increased, i.e. interleukin-(IL)-6 and tumour necrosis
factor-alpha (TNFalpha) (Dowlati et al., 2010). These cytokines are stress-sensitive and
may cause depressive behaviours, which may be induced by an increased catabolism of
tryptophan, the precursor of serotonin, to neurotoxic agents. Most antidepressants have
also specific anti-inflammatory effects (Maes, 2010).
There is also growing evidence that, far from being a disorder with purely psychological
manifestations, MDD is a systemic illness with damaging effects on multiple organ systems
(Manji et al., 2001). It has been associated with alterations in endocrine, cardiovascular
and immune systems, as well as in bone metabolism (Michelson et al., 1996; Musselman et
al., 1998; Jiang et al., 2002), and appears to have adverse effects on comorbid medical
diagnoses, such as coronary artery disease, stroke, diabetes and osteoporosis
(Frasure-Smith et al., 1993; Michelson et al., 1996; Vataja et al., 2001; Lustman and
Clouse, 2002; Carney et al., 2003; Frasure-Smith and Lesperance, 2003). Generally,
evidence from research indicates that depression and vascular disease have a
bi-directional association, especially in the elderly (Thomas et al., 2004). Depression
has also been linked to memory deficits (impairments in verbal declarative memory)
associating with a hippocampal dysfunction (Bremner et al., 2004).
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4.6 Comorbidity of MDD
4.6.1 Definition of the concept
Comorbidity refers to the occurrence of two or more distinct disorders in a person in a
defined period of time (Klerman, 1990). The comorbidity concept originates in the
literature for the epidemiology of medical diseases. After that, it has been increasingly
applied in psychiatry, largely as a consequence of the introduction of the definite
descriptive, operational criteria for mental disorders (Feighner et al., 1972; Spitzer et
al., 1978; APA, 1980). In particular, DSM-III-R of the American Psychiatric Association
introduced the use of multiple diagnoses within a multiaxial classification system (APA,
1987). It has been discussed whether the concept of comorbidity refers to co-occurrence,
covariation (Lilienfeld, 2003), or multimorbidity (Kessler et al., 1994).
Different models of comorbidity have been described (Klein and Riso, 1993; Neale and
Kendler, 1995; Krueger and Markon, 2006). These include 1) the associated liabilities
model (each disorder is influenced by a latent liability factor, and these factors are
correlated), 2) the multiformity model (multiple pathways from the same liability lead to
different manifestations), 3) the causation model (one disorder directly causes another
disorder), 4) the independence model (comorbid disorders are independent conditions,
separate from other disorder), and 5) the spurious association model (some external
variable or set of variables creates spurious associations between disorders) (Krueger and
Markon, 2006). The associated liabilities model has been further developed converging for
comorbidity and common forms of psychopathology in a hierachical model. This includes two
superordinate liabilities: 1) internalizing (general liability toward negative-affect such
as mood and anxiety disorders), and 2) externalizing (general liability toward
disinhibitory disorders such as substance use disorders and antisocial behaviour
disorders) (Krueger, 1999; Vollebergh et al., 2001). The internalizing liability often
bifurcates into two subordinate liabilities, distress and fear (Watson, 2005).
Comorbidity has also been criticised for being an artefact produced by the categorical
diagnostic classification systems (Maj, 2005). Non-comprehensive definitions of
comorbidity, variations in diagnostic assessments, timing of diagnosing, time-frame (e.g.
lifetime or current), and different health care settings have led to substantial
discrepancies in the reported prevalence of comorbid disorders, producing a rather complex
picture of their significance (Weiss et al., 1992; Zimmerman, 1994; Wittchen, 1996;
Bogenschutz and Nurnberg, 2000; Vella et al., 2000). Arguments for a dimensional approach
have been made especially regarding personality disorders (Watson, 2005) where also
subsyndromal disorders would be of importance (Melartin et al., 2010). In this thesis,
unless otherwise specified, however, comorbidity refers to current categorical (DSM-IV)
diagnostic comorbidity.
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4.6.2 Comorbidity of MDD in general populations
A number of epidemiological studies have reported a high comorbidity of depression (Regier
et al., 1990; Angst, 1996; Kessler et al., 1996a; Kessler et al., 1996b; Kessler et al.,
2003; Hasin et al., 2005; Pirkola et al., 2005c), and comorbid depression is more of a
rule than an exception. In the National Comorbidity Survey Replication (NCS-R) study
(Kessler et al., 2003), about 80% of respondents with 12-month DSM-IV MDD had at least
one axis I comorbid disorder, anxiety disorders being the most common (67.8%), followed by
substance use disorders (27.1%). In the Finnish Health 2000 study, 32% of respondents with
12-month DSM-IV MDD had at least one comorbid disorder, anxiety disorder being the most
common (25%), followed by alcohol use disorder (9%) (Pirkola et al., 2005c). In the
National Epidemiologic Survey on Alcohol and Related Conditions (NESARC) study (Hasin et
al., 2005) in subjects with lifetime DSM-IV MDD, the most common comorbid axis I disorders
was any anxiety disorder (41.4%), followed by any alcohol use disorder (40.3%).
The assessment of comorbid personality disorders is more difficult especially in cross
sectional studies. A current depressive episode may for instance accentuate symptoms of
personality disorder. There is only a little information on the prevalence of MDD with
comorbid axis II disorders in the general population. Calculating from the figures of the
Baltimore site of the Epidemiological Catchment Area (ECA) study (Samuels et al., 1994), a
prevalence of 8% for comorbid axis II disorders was obtained. In the European Outcome of
Depression International Network (ODIN) study (Casey et al., 2004), conducted in five
European countries, and in the NESARC study (Hasin et al., 2005), 22% and 38% of
individuals with MDD respectively, had personality disorders. The most common comorbid
personality disorders in the ODIN study were cluster C personality disorders, whereas in
the NESARC study obsessive-compulsive personality disorder (18.3%), followed by paranoid
(15.1%), schizoid (10.2%), avoidant (9.6%), antisocial (8.1%), histrionic (5.3%), and
dependent (2.2%) personality disorders (borderline, schizotypal and narcissistic were not
included in the study). In a representative study from Norway (Torgersen et al., 2001),
the prevalence of personality disorders was 13.4% with avoidant (5.0%),
obcessive-compulsive (2.0%), paranoid (2.4%), schizoid (1.7%), dependent (1.5%) being
common, and borderline personality disorder being less common (0.7%) than usually
reported.
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4.6.3 Comorbidity of MDD in clinical cohorts
Comorbid disorders tend to be more common in clinical compared to epidemiological studies,
probably due to the more serious course of illness (Kessler et al., 1994). In psychiatric
settings, the reported prevalences of current comorbid disorders among patients with MDD
have varied widely. The reported prevalences of comorbid disorders appear too low in a
number of studies (Keller et al., 1983; Mueller et al., 1999; Kanai et al., 2003) as
compared with the prevalences reported more from the current perspective (Zimmerman et
al., 2000; Melartin et al., 2002). Many of the early studies focused on a single type of
comorbid disorder which may well inflate the prevalence of comorbidity found. The
prevalence of axis I disorders in MDD patients in psychiatric settings have varied widely,
but all in all approximately half of the patients have had a current anxiety disorder and
about one-fifth a current substance use disorder (Melartin et al., 2002). In the VDS, 70%
of patients with current MDD had at least one current axis I comorbid disorder, of which
57% had anxiety disorders, and 25% substance use disorders (Melartin et al., 2002). The
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study (Rush et al., 2005),
investigating 1376 outpatients with DSM-IV MDD assessessed the concurrent comorbidity of
MDD with the Psychiatric Diagnostic Screening Questionnaire, found 61.8% of cases having
at least one comorbid disorder, social anxiety disorder (20.8%) being the most common,
followed by GAD (18.8%), OCD (13.4%), PTSD (12.4%), bulimia (11.9%), any alcohol use
disorder (11.9%), panic disorder (11.1%) and agoraphobia (9.4%). There are only a few
studies of psychiatric comorbidity among primary care patients. MDD patients in primary
care or psychiatric out-patient settings have not been found to differ markedly in current
axis I comorbidity (Vuorilehto et al., 2007). In Primary Care-VDS (PC-VDS) of 137 patients
with DSM-IV MDD, 59% had at least one current comorbid axis I disorder, anxiety disorders
being the most common, 50% (GAD 20%, social phobia 16%, panic disorder 9% and simple
phobia 9%), followed by substance use disorder (16%) and somatoform disorder (14%)
(Vuorilehto et al., 2005).
The reported prevalence of comorbid personality disorders of MDD patients in psychiatric
settings has varied widely (18%-86%): overall, about half of the patients have had a
current personality disorder (Melartin et al., 2002). In the Rhode Island Methods to
Improve Diagnostic Assessment and Services (MIDAS) study of 859 outpatients, 51.3% with a
current DSM-IV MDD had at least one personality disorder, cluster C disorders being the
most common (27.3%), especially avoidant personality disorder (20.3%), followed by cluster
B (14.1%) and cluster A (7.3%) (Zimmerman et al., 2005). In VDS, 44% of patients with
current MDD had at least one personality disorder, cluster C personality disorders being
the most common (32%), followed by cluster A (19%) and B (14%) personality disorders
(Melartin et al., 2002). There have been some differences in the prevalences of
personality disorders between primary care and psychiatric care patients. In PC-VDS, 58%
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of DSM-IV MDD patients had a comorbid axis II disorder, cluster B (35%) and C (35%)
personality disorders being the most common, followed by cluster A (7%) personality
disorder (Vuorilehto et al. 2005). There are a few studies of the long-term stability of
personality disorders. In a study of 142 outpatients with MDD, the 10-year stability of
categorical personality disorder diagnosis was found to be relatively poor and not higher
than that for anxiety disorders (Durbin and Klein, 2006). However, the relative stability
of personality disorder dimensional scores was greater than that for categorical
diagnosis, generally reaching a moderate level, and approached the long-term stability of
normal-range personality traits. The findings from the VDS (Melartin et al., 2010) have
been similar: the categorical stability of concurrent personality disorder diagnoses
assigned when depressed was relatively poor, but the dimensional stability was moderate.
4.7 Course and outcome of major depressive episode (MDE)
4.7.1 Methodological aspects in defining outcome
The lack of a standard and valid set of outcome definitions has affected the study of the
naturalistic course of depressive disorders (Frank et al., 1991; Prien et al., 1991;
Keller, 2003; Keller, 2004). Descriptors for the clinical course of depressive illness,
concepts such as remission, relapse and recurrence have been incoherently used as measures
of outcome. The inconsistencies in definitions of outcome make the comparison and
interpretation of the findings difficult. The first effort to achieve a terminology
consensus was made by Frank et al., who suggested conceptual definitions for MDD outcome
(Frank et al., 1991). Unfortunately, partly because of incompatible and changing lengths
of duration used for remission and recovery in these criteria, they somewhat failed to
achieve consistency (Keller, 2003). Clinical experience indicates that remission is the
optimal outcome of treatment (Keller, 2003; Keller, 2004), and it has been proposed that
remission should optimally be a completely asymptomatic state, with absence of both
symptoms and functional impairment (Keller, 2003).
This standard for remission seems essential because the presence of residual symptoms is
considered a strong predictor of relapse or recurrence (Ramana et al., 1995; Judd et al.,
1998; Judd et al., 1999; Pintor et al., 2004), a more chronic course of depression (Judd
et al., 2000), shorter time between episodes (Judd et al., 1998), decreased likelihood of
recovery (Keller et al., 1992), and impaired social functioning (Kennedy and Paykel,
2004). Thus, the presence of even minimal residual symptoms may warrant continuation of
treatment. By some standards, however, patients may be considered to be in remission
despite one or two minor symptoms (Keller et al., 1982; Keller et al., 1983; Keller et
al., 1992). A broadening of the concept of remission beyond symptom levels to include
assessments of functioning and quality of life has been suggested (Zimmerman et al.,
2008).
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Many studies have reported only a cross-sectional outcome of depression i.e. reported the
status of the patient at the end of the follow-up period, thus ignoring relapses and
recurrences during the follow-up. This limitation has been overcome in some studies on
psychiatric patient populations, such as the NIMH-CDS (Keller et al., 1987) with the use
of life-chart methodology, based on multiple assessments during the longitudinal course of
psychiatric disorders in sufficient detail to provide the basis for calculating length of
episodes and time to remission. In this thesis the criteria of DSM-IV are used: in full
remission, during the past 2 months, no significant signs or symptoms of MDD are present,
in partial remission symptoms of MDD are present but the full criteria are not met, or
there is a period without any significant symptoms of MDD lasting less than 2 months from
the end of MDE, relapse refers to the return of symptoms fulfilling MDE criteria after a
period of more than two weeks but less than two months with symptoms below the MDE
threshold, and recurrence refers to the return of MDE after at least two consecutive
months of partial or full remission.
4.7.2 Duration of MDE in general populations
Kraepelin speculated that left untreated, major depressive episodes would tend to last
about 6 to 8 months in most cases (Kraepelin, 1921). Subsequent reports have generally
supported this assertion (Shobe and Brion, 1971; Angst, 1986; Posternak et al., 2006).
Studies on general populations (Sargeant et al., 1990; Angst and Merikangas, 1997; Eaton
et al., 1997; Spijker et al., 2002) show a somewhat better prognosis than in psychiatric
care. In population surveys (ECA, NEMESIS, NCS-R) half of all MDEs resolved rapidly in two
to four months (Eaton et al., 1997; Spijker et al., 2002; Kessler et al., 2003) or even
faster (Hämäläinen et al., 2008), but in about one-fifth of all subjects with MDD, the
course was chronic (Spijker et al., 2002). On the other hand, among incident cases of MDD
in a twin study, Kendler found that 98% of episodes resolved within one year (Kendler et
al., 1997). The duration of MDEs has been in clinical studies mostly closer to the top of
the range (Keller et al., 1982; Keller et al., 1992; Coryell et al., 1994a; Angst and
Preisig, 1995; Solomon et al., 1997; Furukawa et al., 2000; Kennedy et al., 2003).
4.7.3 Outcome of MDD
The outcome of MDD can be examined from different indicators: recovery or achieving full
remission, recurrence, or time spent in symptom states of major depressive episode (MDE)
or partial remission. On the basis of available studies of its outcome, MDD appears to be
a chronic illness with a high risk of recurrence over an individual’s lifetime. The
long-term rates of achieving full remission have been found to vary between 80% and 92%
(Keller et al., 1992; Thornicroft and Sartorius, 1993; Eaton et al., 1997; Kanai et al.,
2003; Kennedy et al., 2003) and the long-term risk of recurrence between 58% and 95% (Lee
and Murray, 1988; Maj et al., 1992; Surtees and Barkley, 1994; Mueller et al., 1999; Kanai
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et al., 2003; Kennedy et al., 2003). It seems that approximately 80% (between 58% and 95%)
of people experiencing MDE will have at least one more episode during their lifetime
(Angst, 1986; Lee and Murray, 1988; Maj et al., 1992; Surtees and Barkley, 1994; Mueller
et al., 1999; Kanai et al., 2003; Kennedy et al., 2003), and about 20% will have a chronic
course of MDE lasting over 2 years (Keller et al., 1992). Moreover, previous long-term
studies have shown that symptoms at subsyndromal level are common and persist for many
years after an episode of MDD (Angst et al., 1997; Judd et al., 1998), even with
antidepressant treatment (Kennedy and Paykel, 2004). According to a recent review of
subtreshold depression among older adults, subtreshold depression was at least 2-3 times
more prevalent than major depression, was associated with significant adverse health
outcomes, and approximately 8-10% developed to major depression per year (Meeks et al.,
2010). However, the long-term rates of achieving full remission of an individual
depressive episode have been high, between 80% and 92% (Keller et al., 1992; Thornicroft
and Sartorius, 1993; Eaton et al., 1997; Kanai et al., 2003; Kennedy et al., 2003), and
even after lengthy periods of illness, a significant proportion of patients have been
observed to approach remission (Mueller et al., 1996; Brodaty et al., 2001). The risk of
recurrence seems to increase with each successive recurrence and to decrease with longer
durations of recovery (Keller et al., 1992). A recent review of prevalence of recurrence
in clinical settings, concluded as recurrence rates of MDD after 5 years 60%, after 10
years 67% and after 15 years 85% which were much higher than in the general population
(35% after 15 years) (Hardeveld et al., 2010).
There are many aspects in the previous studies on long-term outcome that make the
generalizability more difficult: the majority of studies are mostly among inpatients, from
tertiary-level treatment centres or university hospitals, and the patients are likely to
have undergone many prior treatments which may produce bias towards more chronic, severe
and recurrent illnesses compared with more unselected cohorts of MDD patients. In
addition, studies have used different diagnostic criteria, are mostly from an era with
availability of only tricyclic antidepressants, lack of recommendations for widespread
continuation and maintenance phase treatments, have different definitions of outcome, or
have not used semistructured interviews or life-chart. Only a few studies have studied
long-term outcome among outpatients. Furthermore, the effect of comorbidity on the
long-term outcome of MDD has been studied in a surprisingly smaal number of cases. When
investigated, the reported prevalences of comorbid disorders appear too low to be credible
from the current perspective (Keller et al., 1992; Kanai et al., 2003). Table 1 lists
major studies which have investigated the long-term outcome of MDD in psychiatric
patients. Of these six out of thirteen studies have studied exclusively inpatients and
four out of thirteen mainly inpatients. Of the 2719 patients included in these cohorts
only 31% are outpatients. Of the thirteen studies only six studies (comprising overall 41%
of the 2719 patients) have been conducted during the era of SSRIs; in some of the other
studies SSRIs became available only after several years of initial follow-up. Thus, the
length of depressive episode and rate of recurrence can be expected to vary by the level
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of treatment setting and inpatient or outpatient status. Overall, whether the general view
of long-term outcome is also true for community psychiatric samples warrants
investigation.
Table 1. Long-term outcome studies among psychiatric patients.
Study          Author(s)       Year     Reported    N at      Outpatients/  Semistructured  Comorbid mental  Diagnostic      Life
                                     of       follow-up  baseline inpatients    interviews      disorders         criteria       chart
                                     intake                                                       systematically
                                                                                                  diagnosed    
  Zürich            Angst,           1959-    40 years    203       Inpatients    No              No                ICD-8,          No
  follow-up         1978             63                                                                             DSM-III in
  study                                                                                                             follow-up
  Sydney,           Kiloh,           1966-    25 years    145       Inpatients    SADS            No                ICD-8           No
  Australia         1972             70                                           (short form)
  WHO               Sartorius et     1972     11 years    573       62.8%         WHO/SADD       No                ICD-9           No
  Collaborative     al. 1980                                        inpatients
  Study
  Maudsley          Lee and          1965-    18 years    89        Inpatients    SADS-L          No                ICD-7,          No
  hospital,         Murray, 1988     66                                                                             RDC in
  England                                                                                                           follow-up
  Edinburgh         Surtees and      1976     12 years    80        Inpatients    No              No                ICD-8,          Yes
  Study             Barkley, 1994                                                                                   RDC in
                                                                                                                    follow-up
  NIMH-CDS          Keller et        1978-    20 years    431       77%           SADS            No                RDC             Yes
                    al.,1983         81                             inpatients
  Napels/Italy      Maj et al.,      1982-    5.5 years   72        62.5%         SADS-L          No                RDC             Yes
                    1992             83                             inpatients
  University of     Ilardi et        1987-    7 years     50        Inpatients    DIS, PDE        Axis II           DSM-III-R       Yes
  Colorado, USA     al., 1997        1991
  Cambridge         Ramana et al.,   1990-    11 years    70        76%           CID,            No                RDC,            Yes
  study             Paykel et al.,   92                             inpatients    SADS-L in                         DSM-III-R,
                    1995                                                          follow-up                         ICD-10 in
                                                                                                                    follow-up
  GLADS, Japan      Furukawa et      1992-    10 years    95        85%           PISA,           No                DSM-IV          Yes
                    al., 2000        95                             Outpatients   COALA
  Suffolk County    Naz et al.,      1989-    4 years     60        Inpatients    SCID            Axis I            DSM-III-R       Yes
  Mental Health     2007             1995
  Project (SCMHP)
  Barcelona,        Pintor et al.,   1991-    4 years     183       Outpatients   SCID            No                DSM-III-R       No
  Spain             2003             96
  Collaborative     Grilo et al.,    1996     6 years     668       43%           SCID            Axis I            DSM-IV          Yes
  Longitudinal      2010                                            outpatients,                   and II
  Personality                                                       12%
  Disorders Study                                                   inpatients
  (CLPS)
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4.7.3.1 Clinical factors as predictors of outcome
Preventing chronicity and recurrence of depressive episodes is the central aim of
treatment, and information on risk factors for chronicity and recurrences is important for
identifying patients at particularly high risk. A longer time to remission or non-recovery
have been predicted by severity of MDE, and longer durations of index episode (Keller et
al., 1984; Coryell et al., 1992; Keller et al., 1992; Ramana et al., 1995; Mueller et al.,
1996) and relapse or recurrence by number of prior MDEs, and longer duration of MDE
(Coryell et al., 1992; Maj et al., 1992; Surtees and Barkley, 1994; Ilardi et al., 1997;
Mueller et al., 1999). Severity of depression has either predicted relapse or recurrence
(Ramana et al., 1995; Kennedy et al., 2003; Melartin et al., 2004b) or not (Keller et al.,
1983; Sherrington et al., 2001), and has been considered a risk factor for partial
remission (Judd et al., 1998; Kanai et al., 2003). Individual studies have identified some
additional risk factors for poor outcome, including female gender (Kennedy et al., 2004),
younger (Eaton et al., 1997) or older age (Surtees and Barkley, 1994), endogenous or
melancholic depression (Kiloh et al., 1988), psychotic symptoms (Lee and Murray, 1988),
neuroticism (Grilo et al., 2010), psychosocial impairment (Solomon et al., 2004), and lack
of self-confidence (Surtees and Wainwright, 1996). High neuroticism (Surtees and
Wainwright, 1996; Gormley et al., 1999; Bock et al., 2010) and low self-esteem (Andrew et
al., 1993; Surtees and Wainwright, 1996; Sherrington et al., 2001) have also been related
to longer durations of MDE. The presence of residual symptoms or partial remission is
further considered a strong predictor of relapse or recurrence (Paykel et al., 1995; Judd
et al., 1998; Judd et al., 1999; Nierenberg et al., 2010), a more chronic course of
depression (Judd et al., 2000), shorter time between episodes (Judd et al., 1998), a
decreased likelihood of recovery (Keller et al., 1992), and impaired social functioning
(Kennedy and Paykel, 2004). A recent review of prevalence of recurrence in clinical
settings, concluded that the number of previous MDEs and subclinical residual symptoms to
be the most important predictors for recurrence (Hardeveld et al., 2010).
4.7.3.2 Comorbidity as a predictor of outcome
Despite comorbid MDD being common (Kessler et al., 1996b; Melartin et al., 2002;
Zimmerman et al., 2002), the effect of comorbidity on long-term outcome of MDD has been
studied in a surprisingly small number of cases. There is also relatively little information on
current axis I comorbidity and the risk of relapse/recurrence in clinical cohorts of depressive
patients. In the few studies, comorbid dysthymia (double depression), and Axis I comorbid
disorders have been associated with longer time to remission or non-recovery (Keller et
al., 1982; Keller et al., 1992; Mueller et al., 1996) and the probability of relapse or
recurrence with comorbid anxiety syndromes, and axis II disorders (Coryell et al., 1992;
Maj et al., 1992; Surtees and Barkley, 1994; Ilardi et al., 1997; Mueller et al., 1999;
Grilo et al., 2010). Depressed patients with panic disorder or with higher symptom ratings
4  Review of the literature
46 THL - Research 44/2010Long-term Outcome of
DSM-IV Major Depressive Disorder
in Psychiatric Care
of anxiety have shown a longer time to recovery (Coryell et al., 1988; Clayton et al.,
1991; Parker et al., 2000). The US National Institute of Mental Health (NIMH)
Collaborative Depression Study (CDS) found some anxiety syndromes, but not current
alcoholism, to be associated with higher risk of relapse (Coryell et al., 1992; Mueller et
al., 1994). CDS is the only study to have investigated the effects of current comorbid
alcoholism among patients with MDD, finding those with current alcoholism to be only half
as likely to recover from their MDE (Mueller et al., 1994).
In a few naturalistic outcome studies in which semistructured interviews for both MDD and
axis II disorders were used, personality disorders predicted longer time to remission
(Sato et al., 1993; Greenberg et al., 1995; Ilardi et al., 1997; Viinamäki et al., 2002;
Viinamäki et al., 2003; Bock et al., 2010), and risk of relapse (Alnaes and Torgersen,
1997; Ilardi et al., 1997; Grilo et al., 2010). Overall, the available evidence on the
effects of current comorbidity on the outcome of MDD in clinical cohorts is somewhat
difficult to interpret because of several methodological limitations. These include not
using semi/structured interviews for both MDD and comorbid disorders, or not controlling
for the effects of additional comorbid disorders, or not using life-chart methodology (and
thus reporting only cross-sectional findings). A recent review of personality pathology
and outcome in MDD, while pointing out many methodological problems in measurements,
suggests that comorbid personality pathology should not be seen as an impediment to good
treatment response (Mulder, 2002). Although comorbidity in MDD is prevalent, the effect of
overall comorbidity on the length of episode or risk of recurrence has not been
systematically and comprehensively investigated.
4.7.3.3 Psychosocial factors as predictors of outcome
The influence of adverse events on the outcome of depression has been unclear, despite
evidence on precipitating depressive episodes together with genetic vulnerability and
temperament factors (Kendler et al., 1993; Kendler et al., 2002; Kendler et al., 2004).
Stressful life events and a lack of social support are associated with worse outcomes of
depression in community studies and some clinical studies (Coryell et al., 1988; Paykel,
1994), while most prospective studies of severe and recurrent depression have found little
effect on time to remission or subsequent relapse (Andrew et al., 1993; Paykel, 1994;
Sherrington et al., 2001). Adverse events before the onset of a depressive episode have
also predicted even better outcomes in some studies (Reno and Halaris, 1990; Monroe and
Depue, 1991) possibly due to more reactive nature of depression. The role of adverse life
events has been less significant among patients with severe depression (Andrew et al.,
1993; Paykel et al., 1996; Sherrington et al., 2001). However, different kinds of patient
samples, and methods of measurement makes comparison between investigations difficult.
Adversities exerting their influence after the onset of depression may predict long-term
outcome more effectively. In a long-term study, the presence of stressful circumstances
predicted less improvement in depression (Swindle et al., 1989). Poor social support after
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the onset of depression has predicted a worse outcome for MDD, and the presence of more
supportive social resources has predicted more improvement in depression (Billings and
Moos, 1985; Swindle et al., 1989). In addition, being more independent, having less
conflicts, and supportive friends and activities, has predicted a more stable remission
(Moos et al., 1998), while having fewer closer relationships has predicted partial or non-
remission (Cronkite et al., 1998). However, social support has been less significant on
outcome among patients with severe depression (Sherrington et al., 2001). In VDS, the
medium-term outcome was significantly influenced by adverse life events and social support
especially for patients currently in full remission (Leskelä et al., 2006).
4.7.4 Suicidal behaviour
4.7.4.1 Classification of suicidal behaviour 
The concept of suicidal behaviour ranges from suicidal ideation to suicide attempts and
completed suicide and it may vary with respect to manifestation, performance, seriousness
and lethality (Beck, 1986). Suicidal ideation is usually defined as thoughts and wishes of
suicide in individuals who have not made any overt suicide attempts (Beck, 1986), and
includes suicide threats, suicidal preoccupations and expressions of the wish to die as
well as indirect indicators of suicide planning. Suicidal ideation appears to be an
important marker for identifying patients at risk of suicide (Brown et al., 2005). Suicide
attempt is defined by the American Psychiatric Association as a self-injurious behaviour
with a non-fatal outcome accompanied by evidence (either explicit or implicit) that the
person intended to die, where intent is defined as subjective expectation and desire for a
self-destructive act to end in death (APA, 2003). Also other terms have been used instead
of suicide attempt, such as deliberate self-harm in the U.K. Suicide is defined as a
self-inflicted death with evidence (either explicit or implicit) that the person intended
to die (APA, 2003). There has been debate on whether those attempting suicide and those
completing, present a single or two separate populations (Linehan, 1986; Beautrais, 2001).
It seems that they are overlapping populations, and the three types of suicidal behaviour −
suicidal ideation, suicide attempt and completed suicide, can be seen as a continuum of
self-harming behaviours (Beck et al., 1973).
4.7.4.2 Stress-diathesis model
Although suicidal behaviour is episodic and most likely occurs when a person is in major
depressive episode and not when they are in remission, not all people who suffer from
recurrent depression become suicidal, and some suicidal behaviour occurs in individuals
who are not clinically depressed. Thus, a psychiatric disorder is generally a necessary,
but insufficient condition for suicide. Mann et al. (1999) proposed a paradigmatic
stress-diathesis model in which the risk for suicidal acts is not determined merely by a
psychiatric illness (the stressor) but also by a diathesis. They wanted to develop a model
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to help determine who remains vulnerable, despite seeming to have recovered, and to what
extent this underlying vulnerability is associated with the acute suicidal state, i.e.
conceptualize suicidal acts as the outcome of the balance between trait- and state-related
predisposing and protective factors. The diathesis may be reflected in the tendencies to
experience more suicidal ideation and to be more impulsive and thus being more likely to
act on suicidal feelings. In their study Mann et al. (1999) found that a trait factor,
such as aggression or impulsivity, was significant in distinguishing past suicide
attempters from non-attempters (Mann et al., 1999). This categorized individuals at risk
from suicide attempts regardless of psychiatric diagnosis. Their model showed that
subjective depression, hopelessness and suicidal ideation were greater in suicide
attempters than in non-attempters despite comparable rates of objective severity for
depression or psychosis. One stressor is normally the onset or acute worsening of a
psychiatric disorder, but other types of stressors, such as a psychosocial crisis, can
also contribute. The diathesis for suicidal behaviour includes a combination of factors
such as sex, religion, familial and genetic components, childhood experiences,
psychological support system, availability of highly lethal suicide methods, substance
abuse, head injury and various other factors (Mann, 2002; Mann et al., 2008). However,
although the stress-diathesis model is a valid conceptual framework, it has one
significant limitation − it does not account for the role of time. However, we know that
major depression is a time-varying illness with besides depressive episodes, also periods
of partial and full remission, which are likely to be associated with different amounts of
risk for suicide behavior.
4.7.4.3 Epidemiology and risk factors of suicidal ideation
Suicidal thoughts are common; approximately 11-18% in population samples across Western
countries report having suicidal ideation at some point during their lives (Weissman et
al., 1999). However, huge differences exist worldwide in reported prevalence rates across
countries: from 3% to 25% of population have experienced suicidal ideation and from 1% to
16% made suicide plans (Weissman et al., 1999; Bertolote et al., 2005; Bernal et al.,
2007). Some of the differences across the sites are most probably affected, besides the
various ways of asking about suicidal ideation, by the differences in the readiness of
respondents from different cultures to report suicidal thoughts (Bertolote et al., 2005).
In the U.S., large population surveys (NCS, NCS-R) reported 12-month prevalence of
suicidal ideation at around 3% and of suicide plans around 1% (Kessler et al., 2005a). In
a Finnish study the 12-month prevalence was much higher, 15%, and contrary to most other
countries, the prevalence was higher in men than in women (Hintikka et al., 2001).
Suicidal thoughts in clinical patient samples are more frequent than in the general
population. While depression is a major risk factor for suicidal ideation, it is not
unexpected that among patients with MDD, more than a half in psychiatric settings (Sokero
et al., 2003) and a third in primary care have reported suicidal ideation (Ahrens et al.,
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2000). However, about half of individuals with suicidal thoughts do not perceive the need
for care, and many of those who do experience difficulties in receiving it (Brook et al.,
2006).
The most consistently identified risk factors of suicidal ideation have been depression
and hopelessness (Hintikka et al., 2001; Casey et al., 2006). In addition, suicidal
ideation has been associated with younger age, female gender and a low level of education
(Kessler et al., 2005a; Bernal et al., 2007). Getting older and having meaningful social
relations have acted as protective features (Casey et al., 2006). Other reported risk
factors consist of severe depression, and co-morbid dysthymia, anxiety and personality
disorders (Van Gastel et al., 1997; Hintikka et al., 1998; Alexopoulos et al., 1999;
Schaffer et al., 2000), as well as female gender, younger age and severe adverse life
events (Schaffer et al., 2000; Monroe et al., 2001; Casey et al., 2006). Previous suicide
attempts have also predicted suicidal ideation (Alexopoulos et al., 1999). In VDS,
independent risk factors for suicide ideation have been hopelessness, alcohol problems,
low level of social and occupational functioning and poorly received social support among
psychiatric in- and outpatients with MDD (Sokero et al., 2003).
4.7.4.4 Epidemiology of suicide attempts
A suicide attempt, especially if it is followed by death, is the worst complication of
depression. Most countries do not have official suicide attempt rates available. The
WHO/EURO Multicentre Project on Parasuicide gathered comparable information in 13
European countries in 1989-1992, and found the highest rate of suicide attempts to be in
Finland among males and the lowest in Spain representing a 7-fold difference (Schmidtke
et al., 1996). Around the world even higher variations across nations has been reported
(from 0.4% to 4.2%) (Bertolote et al., 2005). Part of this variation may be explained by
different cultural attitudes towards suicidal behaviour and by the willingness to report
suicide attempts (Schmidtke et al., 1996). Depending on the site, the ratios between
attempts, plans and thoughts of suicide seem to differ substantially and the burden of
undetected attempted suicide is high in many cultures (Bertolote et al., 2005). In the
WHO/EURO Multicentre Project on Parasuicide more than half of the suicide attempters made
more than one attempt, and nearly a fifth of the second attempts were within 12 months of
the first attempt (Schmidtke et al., 1996). Nearly all suicide attempters have suffered from
one or more psychiatric disorder (Suominen et al., 1996; Kessler et al., 2005a). In the
WHO/EURO Multicentre Project on Parasuicide, with only one exception (Helsinki), suicide
attempt rates were higher among women than men. In the majority of centres, the highest
rates were found in the younger age groups. Risk for suicide attempts has also been related
to being divorced or widowed, and to low educational levels (Kessler et al., 1999a).
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4.7.4.5   Suicide attempts in patients with MDD
The lifetime risk of a non-fatal suicide attempt in MDD is estimated at 16-40% (Malone et
al., 1995a; Oquendo et al., 2006). Of individuals with a lifetime diagnosis of MDD, 16%
acknowledged having attempted suicide at some point in their lifetime in the ECA survey
(Chen and Dilsaver, 1996); the first suicide attempt seems to occur within 5 years from
the onset of MDD in 40% of patients with depression (Malone et al., 1995a). One-fourth may
repeat the attempt within a year (Bradvik, 2003).
According to studies investigating suicide attempts, the risk factors have included a
history of suicide attempt or suicide in the family (Duggan et al., 1991; Malone et al.,
1995a; Mann et al., 1999; Maser et al., 2002; Oquendo et al., 2002; Oquendo et al., 2004;
Sokero et al., 2005), female gender (Mann et al., 1999; Oquendo et al., 2007), younger age
(Sokero et al., 2003; Oquendo et al., 2004), presence of MDE (Oquendo et al., 2002), early
age at onset (Malone et al., 1995a), severe or recurrent depression, or failure to achieve
remission (Oquendo et al., 2002; Sokero et al., 2005), hopelessness (Mann et al., 1999;
Maser et al., 2002; Oquendo et al., 2004), suicidal ideation (Mann et al., 1999; Oquendo
et al., 2004; Mann et al., 2008), melancholic (Oquendo et al., 2006), or psychotic subtype
of depression (Warman et al., 2004; Oquendo et al., 2006), comorbid personality disorder
(especially borderline) (Mann et al., 1999; Hawton et al., 2003a), alcohol dependence or
misuse (Duggan et al., 1991; Malone et al., 1995a; Mann et al., 1999; Maser et al., 2002;
Sokero et al., 2003; Oquendo et al., 2004), chronic physical illness (Duggan et al.,
1991), aggressive or impulsive traits (Malone et al., 1995a; Mann et al., 1999; Maser et
al., 2002; Oquendo et al., 2004; Mann et al., 2008), cigarette smoking (Mann et al., 1999;
Oquendo et al., 2004), and social factors (Malone et al., 1995a; Mann et al., 1999; Malone
et al., 2000; Sokero et al., 2003; Sokero et al., 2005). Sokero et al. investigated medium
term longitudinal variations in the risk for suicide attempts among psychiatric patients
with major depressive disorders (Sokero et al., 2005). The risk of attempts was almost
8-fold during major depressive episodes compared with a period of full remission, and they
were effectively predicted by time spent depressed, history of previous suicide attempts,
and the lack of a partner.
Despite its clinical importance, not all depressed patients at the time of the suicide
attempt are receiving treatment or adequate pharmacotherapy (Oquendo et al., 2002). Haw et
al. (2002) found that one-third of attempters were receiving treatment for depression in
psychiatric services and another in primary care (Haw et al., 2002). In a Finnish study
the majority of elderly suicide attempters had had recent contact with primary care, but
their mood disorders had often remained undiagnosed before the attempt (Suominen et al.,
2004a). Even in psychiatric hospitals a fourth of clinicians may fail to document the
history of suicidal behaviour in patients with MDD and past suicidal attempts (Malone et
al., 1995b).
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4.7.4.6 Epidemiology and risk factors of suicide 
Suicide is among the leading causes of death, and suicide accounts for more deaths than
the number due to HIV and AIDS combined, or due to homicide and war combined. Every year,
almost one million people die from suicide; a "global" mortality rate of 16 per 100,000,
or one death every 31 seconds. In the last 45 years suicide rates have increased by 60%
worldwide. Suicide is among the three leading causes of death among those aged 15-44 years
in some countries, and the second leading cause of death in the 10-24 years age group;
these figures do not include suicide attempts which are up to 20 times more frequent than
completed suicides (WHO, 2010a). In Finland the suicide rate is among the highest in
Europe (19.7/100 000 in 2004, 1033 suicides in 2008), although there has been a 30%
decline during the past 15 years. In the U.S., for example, the suicide rate is 13.9/100
000 (2002) and in Sweden 13.4 /100 000 (2001). The highest annual suicide rates exist in
Eastern Europe, especially in the Baltic countries and former Soviet republics (>27/100
000) and the lowest in Latin American and Islamic countries (<6.5/100 000). Men have a
higher rate of completed suicide than women, the male to female ratio being approximately
3-4:1 (WHO, 2010b). Almost everywhere in the world, suicide rates among males are much
higher than in female for all age groups (Schmidtke et al., 1996). As an exception, the
suicide rates in China are higher among female compared to males (Weiyuan, 2009). As
suicide acts are affected by culture, ethnicity and religion, the rates of suicide vary
significantly among the various age groups, gender and different countries (De Leo, 2002;
Oquendo et al., 2004b). In addition, the official rates depend on suicide legislation, the
death certification procedures (Schmidtke et al., 1996) and the prevalence of undetermined
deaths (Marusic et al., 2003).
The major obstacle to an understanding of suicide is that the victim cannot be interviewed
and the reason directly ascertained. Psychological autopsy is probably the most direct
technique for determining the relationship between particular risk factors and suicide
(Isometsä, 2001; Cavanagh et al., 2003). Psychiatric disorders, present in nine out of ten
suicide victims (Arsenault-Lapierre et al., 2004), are the most significant predictors of
suicide risk (Cavanagh et al., 2003) especially when necessitating hospital admission
(Bostwick and Pankratz, 2000; Mortensen et al., 2000; Pirkola et al., 2005b). Particularly
vulnerable periods seem to occur during admission and soon after discharge (Mortensen et
al., 2000). In the majority of suicides more than one psychiatric illness has been
present, most frequently affective disorders especially among women and substance use
disorders in men (Henriksson et al., 1993; Cheng et al., 2000; Cavanagh et al., 2003;
Arsenault-Lapierre et al., 2004; Mann et al., 2006). Medical illnesses increase the risk
for suicide (Koponen et al., 2007) especially in the elderly and in patients suffering
from disorders of the central nervous system (Breslau et al., 1991). In other potentially
fatal illnesses, such as cancer, the increase in risk is only modest unless a combined
psychiatric disorder is present (Henriksson et al., 1995).
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Hopelessness, defined as a state of negative expectations, is an important psychological
variable of suicidal behaviour which is believed to mediate the association between
depression and suicidal behaviour (Beck et al., 1993). Whether it leads to suicidal
behaviour depends upon the presence or absence of risk and protective factors (Beck et
al., 1993). Psychosocial and other environmental factors influencing the risk of suicidal
death are male gender, advancing age (Hawton et al., 2003b), lack of a social network,
recent adverse life events and socioeconomic difficulties (Cheng et al., 2000; Suokas et
al., 2001). Other risk factors of suicide are availability of lethal methods such as
domestic coal gas, barbiturates and firearms (Oliver, 1972; Kreitman, 1976; Wintemute,
1988),  and suicide stories  of  high publicity  (Hassan,  1995). A family history of suicide
has been shown to increase the the risk for suicide in other family members (Brent et al.,
1996; Cheng et al., 2000). Past suicidal behaviour, both ideation and attempts, are strong
risk indicators for future suicide (Brown et al., 2000). Within the year following a
suicide attempt, the risk of eventual death by suicide is about 100 times greater than
that of the general population (Hawton, 1987). Suicides seem to accumulate even years
after an attempt (Suominen et al., 2004b). It has been postulated that a lifetime history
of suicide attempts can lower the threshold of new attempts and thus suicide related
structures may become more easily triggered (Joiner and Rudd, 2000). It has to be
remembered, however, that over half of suicide victims die at their first suicide attempt
and thus, even if a suicide attempt is a powerful single predictor of completed suicide,
its sensitivity as a risk factor is limited (Isometsä and Lönnqvist, 1998).
4.7.4.7  Suicide in patients with MDD
A highly quoted meta-analysis of Guze & Robins (1970) suggested that 15% of psychiatric
patients with severe affective disorders will die due to suicide (Guze and Robins, 1970).
Thereafter this high figure has been uncritically generalized to concern all depressive
disorders and not until lately been debated and reassessed. Bostwick & Pankratz (2000)
have demonstrated a hierarchy of risk based on the intensity of the treatment setting;
they found a lifetime risk of 4.0% for suicide in their meta-analysis for affective
disorder patients hospitalized without specification of suicidality (Bostwick and
Pankratz, 2000). Furthermore, suicide mortality among depressed patients in primary care
has been shown to be much lower than in psychiatric settings (Simon and VonKorff, 1998).
In patients with depression the risk factors for completed suicide tend to overlap the
general risk factors for suicide attempt. Risk factors for completed suicide (Fawcett et
al., 1990; Angst et al., 2002; Hansen et al., 2003; Hoyer et al., 2004; Coryell and Young,
2005; Dumais et al., 2005; Mann et al., 2005; Oquendo et al., 2006; Gonda et al., 2007;
Oquendo et al., 2007) have been male gender, prior suicide behaviour, family history of
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suicide, hopelessness, suicidal ideation, psychotic symptoms, comorbid personality
disorders, alcohol dependence or misuse, and anxiety disorders, adverse events and
previous psychiatric hospitalizations. Especially in depressive men, impulsive-aggressive
personality and alcohol disorders may be independent risk factors (Dumais et al., 2005).
4.7.4.8   Prevention of suicidal behaviour
Though nearly 2% of those who harm themselves may die within the following year by
committing suicide (Owens et al., 2002), the aftercare in medical emergency units appear
varying and insufficient (Kapur et al., 1999): only about half of suicide attempters have
received psychosocial assessment and in most studies only a few get admission to
psychiatric services (Kapur et al., 1999; Suominen et al., 2004a). In a Finnish study,
half of young suicide attempters were not given any health care contact in the month
following their visit to the emergency unit (Suominen et al., 2004b), while most elderly
suicide attempters were referred for aftercare mainly to psychiatric services (Suominen et
al., 2004a). In addition, it has been reported that a minority of those offered medical
care stayed in contact (Haw et al., 2002), and that most suicide attempters have not
communicated their suicidal thoughts, even though the majority have had recent contact
with the medical services (Houston et al., 2003). A recent Finnish study, investigated the
associations between suicide risk, and different ways of organisizing mental-health
services, and concluded that the prominence of outpatient services was associated with the
lowest suicide rate compared to inpatient and emergency services (Pirkola et al., 2009).
To address the multiple causes of suicidal behaviour, prevention strategies usually
involve a multifaceted approach with particular attention to mental health. Primary
prevention of suicide requires focusing on preventive measures or protective factors such
as restricting access to lethal methods (firearms, pesticides, toxic gas, barbiturates
etc.), which is a major component of current international suicide prevention strategies
(WHO, 2010a), the toning down of reporting of suicides in the media and public education
campaigns to increase knowledge on mental illness and suicide (Mann et al., 2005).
Secondary prevention options include early detection of suicidal individuals as well as
accurate diagnosis and effective treatment of psychiatric disorders − another major
component of international prevention strategies (WHO, 2010a). While more than half of
those who die by committing suicide had recently contacted a primary care doctor (Luoma et
al., 2002) detection of their suicidal intent might have been possible in some cases.
However, in non-psychiatric patients with depression the suicidal intent has usually not
been communicated to health care professionals and the depression has remained untreated
(Isometsä et al., 1995).
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Despite their importance for planning, the relative impact of various strategies on
national suicide rates has been difficult to estimate. In a systematic review (Mann et
al., 2005) physician education, means restriction and gatekeeper education have been the
most promising interventions. Public education campaigns have increased knowledge and
improved attitudes toward mental illness and suicide, but measures for suicide prevention
have been insufficient (Mann et al., 2005). Studies examining suicidal behaviour in
response to primary care physician education programmes, mostly targeting depression
recognition and treatment in limited regions in Sweden, Hungary, and Japan (Rihmer et al.,
1995; Oyama et al., 2006; Szanto et al., 2007), have all reported an increased
prescription rate of antidepressants and often a decline in suicide rates.
Despite the huge burden caused by suicide mortality, the number of national policies for
preventing suicides is low; Finland was the first country worldwide to publish a national
strategy of suicide prevention and an action plan for implementation in 1991. It was a
part of the National Suicide Prevention Project, which was carried out from 1986 to 1996.
The aim was to stop the increasing trend and decrease suicide mortality by 20% by the year
1995. During the first years the number of suicides increased, followed by a reduction of
20% between 1991 and 1996, since then the suicide rate has decreased steadily and the
annual number of suicides has declined to below 1000 (Lönnqvist, 2007). However, Finland
still has a relatively high suicide rate compared with other Western EU countries
(Schmidtke, 1997), suicide being the leading cause of death in Finland among those under
the age of 35 years (Tilastokeskus, 2009).
4.7.5 Switch to bipolar disorder
A number of patients who initially suffer from major depressive episode (MDE) will over
time develop bipolar disorder, which has clinical consequences for both treatment and
prognosis. Bipolar disorder begins in approximately half of cases (51-60%) with depression
and in the other half with mania (34-79%); bipolar disorder type II begins more often
with a depressive episode, while bipolar type I begins more often with a manic episode
(Akiskal et al., 1985; Roy-Byrne et al., 1985; Tondo et al., 1998; Perugi et al., 2000;
Mantere et al., 2004; Goodwin and Jamison, 2007).The first hypomanic or manic episode
emerges after approximately 5 - 8 years from the onset of first MDE (Akiskal et al., 1983;
Mantere et al., 2004) In two foremost studies, the Zürich follow-up study and the NIMH
Collaborative Depression Study, 15.5% and 10.7% of subjects with unipolar MDD switched to
bipolar disorder, and of these 7.2% and 3.9% to type I, and 8.25% and 8.6% to type II,
respectively (Akiskal et al., 1995; Angst et al., 2005). The switch rates to types I or II
have ranged from similar to 2.3-fold to type II, and the switch to type I has occurred
twice faster compared to type II (Akiskal et al., 1995; Coryell et al., 1995; Goldberg et
al., 2001; Angst et al., 2005). The annual rate of subsequent diagnostic switch from type
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II to type I has been estimated to be about 2% (Angst et al., 2005) with a largest risk
during the first 5 years from age at onset, or in childhood and early adulthood
(approximately 3-5% per year), and thereafter being constant across the lifetime
(approximately 1% per year).
4.7.5.1 Predictors of switch to bipolar disorder
The switch from MDD to bipolar disorder has been predicted by bipolar family history
(Strober and Carlson, 1982b; Akiskal et al., 1983; Winokur et al., 1993; Angst and
Preisig, 1995; Goldberg et al., 2001; Othmer et al., 2007), younger age (Akiskal et al.,
1983; Winokur and Wesner, 1987), earlier age at onset (Akiskal et al., 1983; Winokur et
al., 1993; Angst and Preisig, 1995; Othmer et al., 2007), higher severity of depression
(Akiskal et al., 1995; Angst et al., 2005), psychotic depression (Strober and Carlson,
1982b; Akiskal et al., 1983; Weissman et al., 1984; Strober et al., 1993; Goldberg et al.,
2001; Othmer et al., 2007), higher number of depressive episodes (Angst, 1985; Winokur and
Wesner, 1987; Winokur et al., 1993; Angst and Preisig, 1995), atypical features of
depression (Akiskal et al., 1983), pharmacological hypomania (Strober and Carlson, 1982a;
Akiskal et al., 1983), postpartum episodes (Akiskal et al., 1983), and psychiatric
hospitalizations (Winokur and Wesner, 1987). The predictors of diagnostic switch to
bipolar disorder type I compared to type II haven been partly different, e.g. the switch
to type I has been predicted by male gender (Angst et al., 2005), positive family history
(Coryell et al., 1995), psychotic symptoms (Akiskal et al., 1995; Coryell et al., 1995;
Angst et al., 2005), and severity and acuteness of symptoms (Akiskal et al., 1995; Angst
et al., 2005); while the switch to type II has been predicted by female gender (Baldassano
et al., 2005), younger age (Coryell et al., 1995), early (Akiskal et al., 1995; Coryell et
al., 1995; Benazzi, 2007) or later (Angst et al., 2005) age at onset, atypical or mixed
depressive symptoms (Benazzi, 2007), chronicity of index episode (Coryell et al., 1995),
shorter well intervals (Akiskal et al., 1995), and mood lability (Akiskal et al., 1995;
Benazzi and Akiskal, 2005).
A number of methodological limitations exist in studies on diagnostic switch making the
diagnostics of especially hypomanic episodes more uncertain. Only a few studies have
investigated bipolar switch among outpatients (Akiskal et al., 1983; Othmer et al., 2007).
Studies showing the highest estimates of manic onset have used first hospitalization as
the onset criterion, which may lead to underestimation of bipolar disorder type II as
hypomanic and depressive states have required less frequently hospitalization (Goodwin and
Jamison, 2007). The majority have also been from tertiary-care studies from major
universities, which makes the epidemiological generalizability of these findings more
uncertain, especially regarding bipolar type II (Strober and Carlson, 1982a; Winokur and
Wesner, 1987; Coryell et al., 1995; Goldberg et al., 2001; Angst et al., 2005; Othmer et
al., 2007). In addition, only a few studies have used life-chart methods (Akiskal et al.,
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1995; Coryell et al., 1995), possibly leading to onsets of bipolar II being missed due to
lack of information on hypomanic episodes. Furthermore, few prospective studies have
investigated the role of psychiatric comorbidity in predicting diagnostic switch, and an
overall view of axis I and II disorders in predicting switch is missing. The diagnostic
criteria have changed over time especially regarding DSM-IV criteria of bipolar disorder
type II; thus, some type II disorders might have been earlier diagnosed as MDD. Since
switching is relatively uncommon, the follow-up periods should be long in order to achieve
adequate statistical power to detect significant differences.
4.8 Treatment of MDD
In order to improve the detection and treatment of MDD, several sets of evidence-based
treatment guidelines have been published during the last decade. These guidelines cover
the basics and objectives for the management of depression with various regimes, including
pharmacotherapy, psychotherapy, combination of pharmaco- and psychotherapy,
electroconvulsive therapy (ECT) and bright light therapy (Cohen and Guthrie, 1997;
Schulberg et al., 1998; Crismon et al., 1999; APA, 2000b; Bauer et al., 2002a; Bauer et
al., 2002b; NICE, 2004; Fochtmann and Gelenberg, 2005; Anderson et al., 2008; Suehs et
al., 2008; NICE, 2009; Patten et al., 2009; Suomen Psykiatriyhdistys, 2009). Other
treatments that have been used for MDD are among others exercise (Ernst et al., 2006) and
sleep deprivation (Wirz-Justice, 2006). There exists some variation in the
recommendations; the main treatment modalities in all of them, however, consist of
pharmacotherapy, psychotherapy and electroconvulsive therapy. The most used treatments for
MDD in Finland are antidepressant treatment with or without augmenting and adjunctive
medications; psychotherapy and ECT.
4.8.1 Antidepressant treatment
Adequate antidepressant treatment of MDD consists of an acute phase, during which
remission is induced, a continuation phase, during which remission is preserved, and a
maintenance phase, during which the vulnerable patient is protected against recurrence of
subsequent episodes (APA, 2000b; Suomen Psykiatriyhdistys, 2009). The more severe the
depression is, the more important the antidepressants are for the treatment of MDD. In
severe or psychotic depression antidepressant treatment is always indicated, whereas in
mild or moderate cases of depression, effective psychotherapy can be used alone or
combined with pharmacotherapy. In psychotic depression, the combination of antidepressants
and antipsychotics is recommended (Suomen Psykiatriyhdistys, 2009). The NICE guideline
from UK does not recommend antidepressants for mild depression, unless other treatments
have failed (NICE, 2009). The response to treatment and adverse events vary individually,
and there are some differences in the efficacy and tolerability between different
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antidepressants. A multiple treatments meta-analysis investigated 12 new-generation
drugs, and reported mirtazapine, escitalopram, venlafaxine, and sertraline to be
significantly more efficacious compared to others, and escitalopram and sertraline showing
the best profile of acceptability (Cipriani et al., 2009). The choice of medication
depends on the history of responses to medication, medication tolerability, adverse
effects and likelihood of adherence, concurrent with other medical conditions and drug
therapies and also the cost of medication (Suomen Psykiatriyhdistys, 2009). If full
remission is not achieved or the response is only partial, the dosage should normally be
increased until full remission is achieved or maximum dosage reached. If however, the
patient is experiencing significant adverse effects or the response is still inadequate, a
switch to another antidepressant should be performed (Suomen Psykiatriyhdistys, 2009).
In the STAR-D study (National Institute of Mental Health) of 2876 out-patients, 37%
remitted after the first antidepressant, 50% after two treatment steps and the theoretical
cumulative remission rate after four active treatment steps during 8 months was 67% (Rush
et al., 2006). An association between treatment response and marker alleles of e.g. the
GRIK4 (Paddock et al., 2007) and 5-HTR2A (McMahon et al., 2006) has been detected,
indicating that the individual variation in antidepressant treatment outcome seems to have
at least a partial genetic basis. Approximately 2/3 of MDD patients respond to
antidepressant medication and about half will be nearly symptom free after 6 to 8 weeks
treatment (Suomen Psykiatriyhdistys, 2009). The continuation phase should generally last 3
to 9 months after the induction of remission in order to prevent relapses, and after that,
maintenance phase treatment should be considered after 3 or more lifetime episodes to
prevent recurrences, or sooner if the depressive episodes have been particularly severe
(APA, 2000b; Suomen Psykiatriyhdistys, 2009). The factors that influence the decision
whether to use maintenance phase treatment include severity of the episodes (presence of
suicidality, severe functional impairments and psychotic features), the risk of recurrence
(residual symptoms between episodes, the presence of comorbid conditions and the number of
prior episodes), possible side effects and patient preference (APA, 2000b).
4.8.2 Psychosocial treatment
Psychosocial treatment consists of specific psychotherapy and social support. This
treatment should be considered regularly when substantial psychosocial stressors,
interpersonal difficulties, or coexisting developmental or personality disorders are
present (APA, 2000b). Specific psychotherapies that are used in the treatment of MDD
include cognitive and cognitive-behavioural therapy, interpersonal psychotherapy, brief
psychodynamic psychotherapy and certain problem-solving therapies (Roth and Fonagy, 2005).
In the acute phase treatment of mild or moderate depression, psychotherapy can be used
alone or in combination with antidepressants. In the continuation and maintenance phase
treatment, psychotherapy alone or in combination with antidepressants may reduce the risk
of a relapse or recurrence (APA, 2000b; Nierenberg et al., 2003; Suomen Psykiatriyhdistys,
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2009). The frequency of visits usually decreases in the maintenance phase (APA, 2000b;
Suomen Psykiatriyhdistys, 2009). The Canadian CANMAT guideline states that cognitive
therapy, cognitive behavioural therapy (CBT), and interpersonal therapy (IPT) have
efficacies equivalent to that of antidepressants for first-line treatment of mild or
moderate depression (Patten et al., 2009).
The combination of psychotherapy and medication is recommended for those with
psychosocial/interpersonal problems, or comorbid axis II disorder together with moderate
to severe MDD. The APA guidelines advise psychotherapy or antidepressant monotherapy,
depending on patient preference, but combination treatment if the patient has a history of
partial response to a single mode of treatment (APA, 2000b). A systematic review concluded
that combined antidepressant therapy and psychosocial treatment is associated with a
higher improvement rate than pharmacotherapy alone (Pampallona et al., 2004).
4.8.3 Electroconvulsive therapy (ECT)
Electroconvulsive therapy (ECT) was developed 70 years ago and since then it has been used
as a treatment for mental disorders. It has been found to be effective treatment for
severe and psychotic depression and should be considered for MDD patients who have
medication resistance or when rapid relief of depressive symptoms is needed e.g. severe
suicidality (Suomen Psykiatriyhdistys, 2009). Response rates of 80% or higher have been
reported with ECT although there are few comparisons between ECT and first-line
antidepressants (Kennedy et al., 2009). Evidence exists that ECT is effective for all
subtypes of MDD, but may be especially effective for psychotic depression (Petrides et
al., 2001) and depression with prominent suicidal ideation (Kellner et al., 2005). A
report from the Consortium for Research of ECT (CORE) concluded that antidepressant
medication treatment failure does not predict a lower response to ECT (Rasmussen et al.,
2007). In a review and meta-analysis on the efficacy of ECT, it was concluded that ECT is
an effective short-term treatment for depression, and is probably more effective than drug
therapy; bilateral ECT being moderately more effective than unilateral, and high dose ECT
more effective than low dose therapy (The UK ECT review group, 2006).
4.8.4 Other treatment methods
New treatments for MDD being evaluated include other neurostimulation therapies,
repetitive transcranial magnetic stimulation (rTMS), deep brain stimulation (DBS) and
vagal nerve stimulation (VNS) (Eitan and Lerer, 2006; Ressler and Mayberg, 2007; Kennedy
et al., 2009). Of these, rTMS is a safe treatment method with minimal adverse effects with
an efficacy resembling that of antidepressant medication (Gross et al., 2007). Evidence to
support VNS is less robust, and deep brain stimulation DBS is still an investigational
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treatment (Kennedy et al., 2009). Other targets for future agents include N-methyl-D-
aspartate (NMDA) antagonist ketamine (Machado-Vieira et al., 2009), neuropeptide Y,
vasopressin V1b, nicotinic cholinergic, delta-opiate, dopamine D1, cytokine, and
corticotrophin-releasing factor 1 receptors, as well as, GABA, intracellular messenger
systems, and transcription, neuroprotective and neurogenic factors (Manji et al., 2003;
Mann, 2005).
4.8.5 The realization of treatment
Despite of the high prevalence of MDD, a large proportion of depressed patients are still
out of treatment. In Finland, the Mini Finland Health Survey reported that only one-third
of those diagnosed with depression were actually receiving treatment, although they were
assessed to be in need of it (Lehtinen et al., 1990; Lehtinen and Joukamaa, 1994). The
Finnish Health Care Survey also found that a considerable proportion (41%) of patients
with even the most severe depression were not receiving any treatment (Hämäläinen et al.,
2004). More recently, the Health 2000 project reported that of subjects with MDD, only 34%
used health services (Hämäläinen et al., 2008). However, a Finnish study reported also
improved detection and pharmacotherapy of major depression from 1989 to 2001 in
psychiatric outpatient care, and concluded problems in care to be more related to
suboptimal intensity and monitoring of treatment than to mere lack of treatment. Among US
adults in the NCS-R, health care treatment for depression was found to be adequate in only
a fifth of the cases with 12-month MDD (Kessler et al., 2003). In the World Mental Health
Survey, although disorder severity was correlated with probability of treatment in almost
all countries, 35.5% to 50.3% of serious cases in developed countries and 76.3% to 85.4%
in less-developed countries received no treatment in the 12 months before the interview
(Demyttenaere et al., 2004).
In reports of treatments provided or used, the Health 2000 project reported that of
subjects with MDD, only 24% used antidepressants, and 17% received psychosocial treatment
(Hämäläinen et al., 2009). In the VDS, among patients in psychiatric care, most patients
(88%) received antidepressants in the early acute phase, but about half (49%) terminated
treatment prematurely. Moreover, the realization of maintenance treatment recommendations
among psychiatric patients was found to be poor, only 57% received treatment and only for
16% of the time indicated (Holma et al., 2008).
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5  Aims of the study
This study investigated the prospective 5-year outcome of a sample of 269 patients with
DSM-IV MDD in secondary level psychiatric care.
The specific aims of the study were:
I. To investigate the long-term outcome of MDD among psychiatric patients, and the
influence of various sociodemographic factors, clinical variables, temperamental, and
psychosocial factors.
II. To investigate long-term variations in incidence of attempted suicide between
psychiatric patients in states of MDEs, partial remission, and full remission, and whether
other risk and protective factors modify this risk.
III. To investigate the long-term rate, time course, and risk factors for a diagnostic
change from unipolar MDD to bipolar disorder among psychiatric patients.
IV. To investigate how family histories of mood disorders, alcohol use disorders, or
psychotic disorders correlate with psychosocial and clinical features, comorbidity, and
the prospective long-term outcome of MDD.
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6  Materials and methods
6.1 General study design
The Vantaa Depression Study (VDS) is a naturalistic and prospective cohort study
concerning major depressive disorder (MDD) in psychiatric care. It forms a collaborative
depression research project between the Mood, Depression, and Suicidal Behaviour Unit of
the National Institute for Health and Welfare, Helsinki (former Department of Mental
Health and Alcohol Research of the National Public Health Institute, Helsinki), and the
Department of Psychiatry of Helsinki University Central Hospital (HUCH), Peijas Hospital,
Vantaa, Finland. The Department of Psychiatry at Peijas Hospital (PMCD) provided secondary
care psychiatric services to all residents of Vantaa (179 856 inhabitants in 2002); these
included a psychiatric inpatient unit, a general hospital outpatient clinic, six community
mental health care centres − each covering a specified catchment area − and two day
hospitals. The Ethics Committee of Peijas Hospital approved the study on 2nd December
1996, and the 5-year follow-up study on 23rd January 2002.
6.2 Screening
All patients in the department of psychiatry in PMCD were screened with depressive
symptoms for a possible new episode of DSM-IV MDD between 1st February 1997 and 31st
May 1998 in the first phase of the study (Figure 1). These were patients (N=806) aged 20-59
years 1) seeking treatment at, 2) being referred to, or 3) already receiving care and now
showing signs of deteriorating clinical state. Patients with clinical diagnosis of ICD-10
schizophrenia or bipolar I disorder, were excluded at this stage. The screening instrument
included the five screening questions for depression from the WHO Schedule for Clinical
Assessment in Neuropsychiatry (SCAN), Version 2.0 (Wing et al., 1990). In addition, the
Scale for Suicidal Ideation (SSI) (Beck et al., 1979) was also completed to recognize
patients with moderate to severe suicidal ideation or plans. After receiving either 1) a
positive response to any of the SCAN screening questions, or 2) a score of six or more in
the SSI, irrespective of the presence of depressive symptoms, the patient was fully
informed about the study project, and written informed consent requested. Of the 703
eligible patients, 161 (22.9%) refused to participate in the study, but 542 (77.1%) agreed
and gave their written informed consent. The patients who refused did not differ
significantly (P>.05) by age or gender from those who consented.
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Figure 1. Flow-chart of the screening process in the Vantaa Depression Study. 
        Screening N=806                        Negative  N=103
        Positive  N=703                        Not consenting N=161
        Consenting N=542                       No MDD N=273
        DSM-IV MDD N=269
6.3 Baseline evaluation
6.3.1 Diagnostic measures
The 542 consenting patients were interviewed in the second phase of sampling face-to-face
using the WHO SCAN 2.0 by interviewers who had all received relevant training by a WHO
certified training centre. They investigated whether or not the current mood episode
fulfilled the criteria for (unipolar) DSM-IV MDD. All psychiatric and medical records in
the PMCD, including a standardized set of laboratory tests, were also available at the
interview. Patients currently abusing alcohol or other substances were interviewed after
two to three weeks of abstinence, in order to exclude substance-induced mood disorders. On
the basis of interviews, 269 patients were diagnosed with DSM-IV MDD and included in the
study (Figure 1). Diagnostic reliability was investigated using 20 videotaped diagnostic
interviews; the kappa coefficient for MDD was 0.86 [0.58-1.0] with 95% observed agreement
rate.
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The decision to include a patient in the study cohort was made by the researcher during
the interview, after which the entire SCAN interview was conducted to achieve a full
picture of axis I comorbid disorders. In addition, the Structured Clinical Interview for
DSM-III-R personality disorders (SCID-II) (Spitzer et al., 1987) was used to assess
diagnoses on axis II. Current axis III diseases were assessed via a self-report checklist
with 44 items (corresponding to ICD-10 diagnoses). Only axis III diseases diagnosed by a
physician and currently being treated were included.
6.3.2 Exclusion criteria
Patients with a diagnosis of DSM-IV bipolar I or II disorder, schizoaffective disorder,
schizophrenia or another psychotic disorder, organic or substance-induced mood disorder
were excluded from the study, although they fulfilled the symptom criteria of current MDE.
In addition, patients with a history of MDD, not fulfilling the criteria of the disorder
in the current episode were excluded.
6.3.3 Observer and self-report scales
The 17-item Hamilton Rating Scale for Depression (HAM-D) (Hamilton, 1960) and the 21-
item Beck Depression Inventory (BDI) (Beck et al., 1961) were used to assess severity
of depression, the Scale for Suicidal Ideation (SSI) for suicidal behaviour (Beck et al.,
1979); the Social and Occupational Functioning Assessment Scale for DSM-IV (SOFAS)
(Goldman et al., 1992) for functional level; the Interview for Recent Life Events (IRLE)
(Paykel, 1983), and the Interview Measure of Social Relationships (IMSR) (Brugha et al.,
1987) and the Perceived Social Support Scale Revised (PSSS-R) (Blumenthal et al., 1987)
for social support. Self-report scales, in addition to the BDI, included the Beck Anxiety
Inventory (BAI) (Beck et al., 1988), the Beck Hopelessness Scale (HS) (Beck et al., 1974),
the Social Adjustment Scale-Self Report (SAS-SR) (Weissman and Bothwell, 1976), and the
Eysenck Personality Inventory (EPI) (Eysenck and Eysenck, 1964). The distinction between
melancholic and non-melancholic depression was based on the SCAN and DSM-IV criteria.
6.3.4 Sosiodemographic and clinical features at baseline
At baseline, the majority of the patients in the cohort were females (73%) and outpatients
(83%), half (50%) were married or cohabited, and 60% were employed. Over a third (35%)
suffered from their first MDD. Their mean HAM-D value was 19.5 (SD=5.9), and mean BDI
27.7 (SD=8.6). Most (79%) of the patients (79%) suffered from at least 1 comorbid disorder,
and over half (54%) had 2 or more. Over half (57%) suffered from an anxiety disorder, a fourth
(25%) from alcohol abuse or dependence, and nearly half (44%) from at least 1 personality
disorder. At baseline, most patients (88%) received antidepressants, and, for the majority
(78%), the dosage was adequate for the acute phase. More than half (57%) received
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selective serotonin reuptake inhibitors (SSRIs) alone at baseline, about one-fifth (18%)
received newer antidepressants (tetracyclics, serotonin-norepinephrine reuptake inhibitors
SNRI, RIMA reversible inhibitors of monoamine oxidase), only 8% received tricyclic
antidepressants (TCAs), and 6% received combination treatment, usually an SSRI and a TCA.
Nearly all the patients (98%) received psychotherapeutic support in the early acute phase,
but only a few had weekly psychotherapy (16%) (Melartin et al., 2002; Melartin et al.,
2005).
6.4 Follow-up procedure
6.4.1 Study participants
After the baseline, patients were investigated at 6 and 18 months, and 5 years with a
life-chart methodology and the same observer and self-report scales used at baseline. Of
the total of 269 patients initially included in the study, 229 patients participated in
the 6-month follow-up, 207 in the 18-month follow-up, and 182 in the 5-year follow-up
(Figure 2). The median times of follow-up interviews were 6.5 and 18.8 months, and 65.2
months from baseline, respectively.
The 5-year follow-up interviews were performed individually by 2 interviewers (K.M.H. or
I.A.K.H.); all available medical and psychiatric records were used to complement the
information. The average duration of an interview was 2-3 hours and took place in
psychiatric outpatient units of Vantaa and HUCH, between April 12, 2002 and April 30,
2004. By 18 months, 13 patients’ diagnoses had switched to bipolar disorder; at the 5-year
follow-up, 16 patients were diagnosed as having bipolar disorder, 1 was diagnosed with
schizophrenia, and 2 were diagnosed with schizoaffective disorders. Ten patients had died,
one of whom had switched to bipolar disorder. Thus, after 5 years, 163 unipolar patients
(71.5% of those eligible [N=228]) remained for the analyses, and 65 patients dropped out.
Life-chart information on 142 of the 163 patients was available from the entire follow-up
period.
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Figure 2. Flow-chart of the follow-up process in the Vantaa Depression Study.
BASELINE
                                  DSM-IV MDD  N=269
FOLLOW-UP
                                  6 months  N=229
                                                                    Bipolar  N=29
                                  18 months  N=207                  Schizophrenic  N=3
                                                                    Died N=10 (1 bipolar)
                                  5 years  N=182
                                  Unipolar MDD  N=163
                                  Life-chart from
                                  entire follow-up
                                  N=142
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6.4.2 Study drop-outs
The causes for dropping out (N=65) from the 5-year follow-up were as follows: withdrawal
of consent (63.1%, N=41) patients unreachable despite several efforts (33.8%, N=22), and
patients living too far away (3.1%, N=2). The dropouts were younger (median age=35.3 vs.
42.3 years, Z=-2.20, p=.028), were more likely to be male (36.9% vs. 22.1%, χ2=5.28, df=1,
p=.022), were more likely to have been inpatients (24.6% vs. 12.3%, χ2=5.33, df=1,
p=.021), had greater percentages of alcohol dependence (26.2% vs. 6.7%, χ2=16.2, df=1, p <
.001) and psychotic depression (13.8% vs. 4.3%, χ2=6.50, df=1, p =.011), were more likely
to be not married or cohabiting (60.0% vs. 42.9%, χ2=5.42, df=1, p=.020), and had a
slightly lower level of functioning (median SOFAS score=50 vs. 55, Z=χ2.69, p=.007) than
patients included in the 5-year cohort.
In Cox’s proportional hazard analyses, all the information available for different lengths
of follow-up time was used. In this case, only patients not participating in any of the
follow-up interviews were dropped out (N=20). They were compared with participants who
remained in the study, at baseline younger (mean age: 33.0 years [SD=9.1] vs. 40.1 years
[SD=11.0]; t=2.81, p=.005), had a lower age at onset (mean age: 27.1 years [SD=8.8] vs.
31.8 years [SD=12.7]; t=2.22, p=.035), more often had dysthymia (35.0% vs. 10.0%; χ2=11.0,
df=1, p=.001) and panic disorder with agoraphobia (20.0% vs. 6.4%; χ2=4.96, df=1, p=.026),
had more antisocial personality disorder symptoms (z=-2.73, p=.006), perceived less social
support (t=2.01, p.046), were more often unemployed (70.0% versus 37.9%; χ2=7.93, df=1,
p=.005), and were less often married or cohabiting (80.0% vs. 47.4%; χ2=7.87, df=1,
p=.005).
Despite a number of characteristics often associated with a poorer outcome, the dropouts
did not differ from those participating, in terms of index episode duration, time to full
remission, number of relapses or recurrences during the period they participated in the
study; nor were they different in terms of suicidal ideation or attempts at baseline or
prior to entry. Thus it appears unlikely they would have significantly biased these
findings
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6.4.3 Outcome measures
After baseline, the patients were asked to complete the BDI monthly for six months. The
outcome of MDD and the comorbid disorders was investigated at six and 18 months by SCAN
2.0 and SCID-II interviews. In the 5-year follow-up, the SCID-I for DSM-IV-TR Axis I
Disorders (First et al., 2002) was used instead of SCAN. Besides that, all observer- and
self-report scales were included in the follow-up assessments. All available medical and
psychiatric records were used to fill in and check the interview information. The
diagnoses and timing of depressive episodes were based on the structured interviews as
well as patient records.
6.4.3.1 Life-chart methodology 
The duration of the index episode and the timing of possible relapses and recurrences
during follow-up were examined by gathering all available data, which were then integrated
into a graphic life chart after reviewing with the patient all the information from the
follow-up period. In order to improve the accuracy of assessment, in addition to symptom
ratings and visits to attending personnel, change points in the psychopathologic states
using probes related to important life-events were also asked
The life-chart was based on DSM-IV criteria and definitions. The time after the first
baseline interview was divided into three periods: (1) state of full remission (none of
the 9 MDE criteria symptoms), (2) state of partial remission (1-4 of the 9 symptoms), or
(3) state of MDE (5+ of the 9 symptoms). As a categorical variable, remission (further
specified as full or partial) was defined according to the DSM-IV, as at least two
consecutive months in which criteria for a MDE were not met. Relapse was defined as return
of symptoms fulfilling the DSM-IV criteria for MDE after a period of less than two months
(but more than 2 weeks) with symptoms below the MDE threshold. Recurrence was defined as
in the DSM-IV definition for 296.3x MDD, as a return of symptoms sufficiently severe to
satisfy criteria for an MDE after at least two consecutive months of partial or full
remission. Two alternative definitions for duration of the index episode after the first
baseline interview were used: (1) the uninterrupted duration of the episode in the state
of MDE (Time with full MDE criteria), and (2) time to the first onset of state of full
remission lasting at least two consecutive months (Time to full remission).
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6.5 Statistical methods
The Pearson chi-square statistic with Yates’ continuity correction test, and Fisher’s
exact test were used to evaluate categorical and parametric data, the Mann-Whitney or
Kruskal-Wallis test to compare continuous variables non-parametric, and the two-sample
t-test for continuous variables normally distributed. The multivariate analyses were based
on the hypotheses. After detailed univariate analyses, predictors for final models were
chosen by considering their clinical and statistical validity, significance, and
relevance. In all of these, multivariate methods were used to control for possible
confounding factors. Besides baseline values, also follow-up values of variables were used
in some analyses (time spent in MDE, partial or full remission; highest levels of HAM-D,
BDI, BAI; number of lifetime MDEs, and suicide attempts; lifetime anxiety, alcohol use,
and personality disorders, and psychotic depression; values of hopelessness [HS],
perceived social support [PSSS-R], neuroticism and extraversion [EPI] during the lowest
level of depression).
Statistically non-significant variables were omitted from the final models, but the
analyses were adjusted for age and gender, and; regression analyses were also controlled
for the time at risk. In these, censored data included (1) patients who did not
participate in any follow-up interview, (2) had not met the criteria for the endpoint
event of analysis, either by the end of the follow-up period, or by the time they left the
study and (2) patients whose diagnoses changed before the endpoint event from unipolar to
bipolar disorder or schizophrenia. A p-value <.05 was considered significant in hypothesis
testing, and p-values between .05 and .10 were reported as trends. Odds ratios with 95%
confidence interval not including 1 were considered significant. The Statistical Package
for Social Sciences software, version 17.0 (SPSS, Inc., Chicago), and an R package
(R Development Core Team, Vienna, Va.) were used.
Logistic models were used to adjust for confounding factors in analyses for the
propability of an event, and linear regression for number of events. The Kaplan-Meier
survival curves were used to estimate the probability of remaining ill, experiencing a
recurrence, switching to bipolar disorder, and attempting suicide during the 5-year
follow-up. Cox proportional hazards models (Cox, 1972) were used in the analyses for
predicting time to symptom state below MDE criteria or to full remission, time to first
recurrence, time to switch to bipolar disorder, and suicide attempts. The Poisson
regression model was used to investigate the univariate rate ratio for explanatory
variables for suicide attempts. The association between the concurrent level of depression
(full remission, partial remission, or major depressive episode) and suicide attempts in
the life chart was analyzed using the level of depression as a time varying covariate in
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the Cox proportional hazard model. For each individual, the follow-up assessment was
divided into time periods in which the value of the time varying variable (i.e., level of
depression) was constant. The interactions between the time varying phase and other risk
factors were tested using the Cox model with the likelihood ratio test. The model
describes how the hazard of event (suicide attempt) is predicted by the current values of
explanatory variables. For continuous variables, hazard ratios were calculated for 10-unit
increments. Simple random effects (frailty) term were included in the Cox model to take
into account variations between individuals (Therneau et al., 2003). The population
attributable fraction was calculated by comparing the time in major depressive episodes
with other phases and using a formula for multicategory exposures (Rockhill et al., 1998).
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7  Results
7.1 Long-term outcome of MDD (Study I)
7.1.1 Sosiodemographic and clinical characteristics of the sample
Table 2 summarizes the baseline sosiodemographic and clinical characteristics of the
unipolar patients participating to 5-year follow-up (N=163). A majority of the patients
were females (78%), outpatients (88%), married or cohabited (57%), employed (64%), had a
comorbid axis I disorder (64%), and two-fifths an axis II disorder (41%). At 5 years the
mean scores were for the 17-item HAM-D 9.8 (SD=8.3), for the 21-item BDI 10.3 (SD=10.2),
for the BAI 12.8 (SD=10.8), and 66.8 (SD=15.0) for the SOFAS, and over one-half (54.6%)
suffered from comorbid axis I disorders, and nearly two-fifths (38.7%) from axis II
disorders. At 5 years, 49.7% (N=81) of the patients did not receive any treatment.
One-fourth (24.5%, N=40) were currently receiving psychosocial treatment, 15.3% (N=25)
were receiving psychotherapeutic support, and 9.2% (N=15) weekly psychotherapy. Nearly
half (44.8%, N=73) were currently using an antidepressant. One-sixth (14.7%, N=24) had
been hospitalized between the 18-month and 5-year follow-ups (median number of psychiatric
hospitalizations=1.0, SD=1.2).
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Table 2. Baseline sociodemographic and Clinical Characteristics in 
the Vantaa Depression Study, 5-year follow-up (unipolar, N=163). 
Characteristic        N        %     Characteristic          N        %
  Sex                                                                                           
     Female                        127 (77.9)   Axis I comorbidity                  104 (63.8)
  Outpatient                       143 (87.7)   Dysthymia                            17  (10.4)
  Married or cohabiting            93 (57.1)   Anxiety disorders                    89  (54.6)
  Professional education           60 (36.8)      Phobic/ Nonphobic                 60  (36.8)
  Employed                         105 (64.4)      Panic disorder                    24  (14.7)
  Low income                       64 (39.3)         with/                          9   (5.5)
  Recidential area (east Vantaa)   62 (38.0)         without agoraphobia            15  (9.2)
  Melancholic                      51 (31.3)      Agoraphobia without panic         16  (9.8)
  Atypical                         18 (11.0)      Specific phobia                   43  (26.4)
  Psychotic                        7 (4.3)       Social phobia                     22  (13.5)
                                                         OCD                               7   (4.3)
                                 Mean   SD        GAD                               26  (16.0)
                                                      Alcohol use disorders                29  (17.8)
  Age (years)                      40.7 (11.3)     Dependence                         11  (6.7)
  Age at onset of MDE              33.0 (12.7)      Abuse                             18  (11.0)
  HAM-D                            18.6 (5.8)    Axis II comorbidity                     
  BDI                              27.0 (8.6)    Personality disorders                66  (40.5)
  BAI                              21.3 (10.6)      Cluster A                         26  (16.0)
  SOFAS                            53.5 (9.4)       Cluster B                         21  (12.9)
  Hopelessness (HS)                10.2 (4.7)       Cluster C                         46  (28.2)
  Neuroticism a                    17.2 (3.7)                                                  
  Extroversion a                    9.8 (4.5)
  Size of social network            7.8 (3.6)                                Mean  (SD)
  PSSS-R                           39.1 (12.7)
  Negative life events b            4.0 (11.0)       No. of psychiatric disorders     2.8 (1.6)
                                                      Axis III comorbidity                     
                                     Quar-       No. of current somatic diseases    0.7 (1.2)
                                     tiles               No. of all axis I-III disorders    3.5 (2.1)
  Suicidal ideation (SSI)            25th  0.0                                               
                                     50th  0.0
                                     75th 12.0
  Number of previous MDEs            25th  0.0
                                     50th  1.0
                                     75th  2.0
  MDE length prior to entry          25th  2.0
  (months)                           50th  3.4
                                     75th  6.0
a Eysenck Personality Inventory: for dimensions of neuroticism and extroversion.
b Interview for Recent Life Events: objective measure of negative impact of adverse life events.
Abbreviations:
HAM-D  = Hamilton Rating Scale for Depression
BDI    = Beck Depression Inventory
BAI    = Beck Anxiety Inventory
HS     = Beck Hopelessness Scale
SSI    = Scale for Suicidal Ideation
SOFAS  = Social and Occupational Functioning Assessment Scale
OCD    = Obsessive-Compulsive Disorder
GAD    = Generalized Anxiety Disorder
PSSS-R = Perceived Social Support Scale-Revised
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7.1.2 Overall outcome
At 5 years, nearly one-half were currently in full remission (49.7%), nearly one-fourth in
MDE (23.9%), and the rest (26.4%) in partial remission. During 5 years the patients on
average spent over half of the follow-up period in full remission (median 37.4 months,
SD=21.6), one-fifth of the time in MDE, (median 7.5 months, SD=14.6), and one-third of the
time in partial remission (median 17.2 months, SD=16.8) (Figure 3). The proportion of time
spent in major depressive episodes per follow-up year was highest during the first year of
observation (mean: 3.9 months [SD=3.6]), declining thereafter during the second to sixth
year (mean: 2.5, 2.1, 2.1, 1.3, 1.5 months, respectively [SD=4.1, 3.5, 3.6, 2.2, 3.6]).
For descriptive purposes, the cohort was divided into 3 groups on the basis of time spent
in various symptom states, i.e. most of the time spent in full remission, partial
remission, or MDE. On the basis of this division, half (54.9%) of the patients had a quite
good outcome, one-tenth (10.6%) a poor outcome, and one-third (34.5%) an intermediate
outcome (Figure 4).
Figure 3. Time spent in a major depressive episode (MDE), in partial remission, and in
full remission in the Vantaa depression study over a 5-year follow-up (N=142).
20%
31%
49%
MDE
Partial remission
Full remission
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Figure 4. Type of outcome and time spent in a major depressive episode (MDE), in partial
remission, and in full remission in the Vantaa depression study over a 5-year follow-up 
(N=142).   
10%
16%
74%
18%
60%
22%
73%
22%
 5%
MDE
Partial remission
Full remission
A. Good outcome, 55% (78/142)
B. Intermediate outcome, 34.5% (49/142)
C. Poor outcome, 10.5% (15/142)
7.1.3 Time to full remission
By 5 years, nearly all followed-up patients (98.8%) recovered to a symptom state below MDE
criteria. The median index episode duration (time with full criteria) was 1.6 months from
baseline and 5.5 months when taken into account MDE beginning prior to baseline. Within 5
years, 88.4% of the patients (130/147) reached full remission lasting at least 2 months.
The median time to first full remission was 11.0 months (95% CI 7.4-14.6) (Figure 5).
Seven percent of patients (10/142) suffered from MDE continuously for 2 years or more, and
2 patients (1.2%) during the entire period.
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Figure 5. Survival curve to full remission of a major depressive episode (MDE) or to 60 
months.
7.1.3.1  Predictors of time to full remission
In univariate analyses, several individual factors predicted the time to full remission
(Table 3). Predictors for the final models were chosen on the basis of the primary
hypothesis, but their clinical and statistical validity and relevance (e.g. state vs.
trait) were considered before inclusion. In the final Cox proportional hazards model, the
predetermined independent variables comprised age, gender, duration of MDE before entry,
mean BDI (severity of depression), BAI (severity of anxiety), HS (hopelessness), SSI
(suicidal ideation), melancholic or psychotic subtype of depression, comorbid dysthymia,
anxiety disorders, personality and alcohol use disorders, mean PSSS-R (perceived social
support), mean extraversion, and professional education. After removing all non-significant
findings, in multivariate Cox proportional hazards analyses, preceding dysthymia (HR=1.96,
95% CI 1.07-3.58, p=.028), cluster C personality disorder (HR=1.43, 95% CI 1.02-2.01,
p=.041), and longer MDE preceding entry (HR=1.28, 95% CI 1.06-1.54, p=.011) prolonged the
time to full remission significantly. Median time to full remission increased over twice
for patients with preceding dysthymia (14.2 vs. 6.5 months), nearly twice with cluster C
personality disorder (11.5 vs. 6.1 months), and three times with longer MDE prior to entry
(15.2 vs. 5.5 months). Among cluster C personality disorders, avoidant personality was the
strongest predictor for prolonged recovery (HR=1.49, 95% CI 1.02-2.17, p=.040). Severity
of MDD predicted a longer time to full remission only as a trend (HR=1.02, 95% CI
1.00-1.05, p=.096).
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Table 3. Univariate predictors of time to full remission in the Vantaa depression
study, 5-year follow-up.
    Predictor at entry        HR       95% CI          P   
  Age (yrs)                        1.02 [1.00 - 1.03] .011
  Gender (male)                    0.94 [0.66 - 1.32] n.s.
  Outpatient status                1.09 [0.70 - 1.70] n.s.
Clinical features of MDD       
  Age of onset (yrs)               1.00 [0.99 - 1.02] n.s.
  Longer MDE prior entry           1.30 [1.08 - 1.57] .006
  No. of previous episodes         1.00 [0.93 - 1.08] n.s.
Symptoms and functional ability 
  17-item HAM-D                    1.02 [1.00 - 1.05] .094
  21-item BDI                      1.02 [1.00 - 1.04] .057
  BAI                              1.02 [1.00 - 1.03] .052
  HS                               1.03 [1.00 - 1.07] .039
  SSI                              1.18 [0.99 - 1.40] .061
  SOFAS                            0.99 [0.97 - 1.01] n.s.
Axis I comorbidity               
  Dysthymia                        1.96 [1.07 - 3.57] .029
  Anxiety disorders                0.97 [0.72 - 1.31] n.s.
     Phobic/ Nonphobic             0.99 [0.73 - 1.34] .037
     Panic disorder with/          0.79 [0.38 - 1.62] n.s.
     without agoraphobia           0.95 [0.56 - 1.58] n.s.
     Agoraphobia without panic     0.97 [0.59 - 1.57] n.s.
     Specific phobia               1.12 [0.79 - 1.59] n.s.
     Social phobia                 0.76 [0.51 - 1.14] n.s.
     OCD                           0.80 [0.39 - 1.65] n.s.
     GAD                           1.08 [0.68 - 1.71] n.s.
  Alcohol use disorders            0.71 [0.48 - 1.05] .085
     Dependence                    0.69 [0.41 - 1.18] n.s.
     Abuse                         0.77 [0.47 - 1.28] n.s.
Axis II comorbidity             
  Personality disorders            1.21 [0.89 - 1.64] n.s.
     Cluster A                     0.82 [0.54 - 1.24] n.s.
     Cluster B                     1.00 [0.65 - 1.55] n.s.
     Cluster C                     1.42 [1.01 - 2.00] .041
  No. of psychiatric disorders     1.03 [0.94 - 1.13] n.s.
Axis III comorbidity             
     Number of current somatic     
     diseases                      1.06 [0.93 - 1.20] n.s.
  No. of all axis I-III disorders  1.04 [0.97 - 1.11] n.s.
MDD subtype features             
  Melancholic                      0.72 [0.53 - 0.98] .039
  Atypical                         0.76 [0.46 - 1.25] n.s.
  Psychotic                        1.71 [0.95 - 3.08] n.s.
Psychosocial and personality     
factors                                 
  Size of social network           0.97 [0.93 - 1.01] n.s.   
  PSSS-R                           0.99 [0.97 - 1.00] .015   
  Negative life events a           0.97 [0.94 - 1.01] n.s.   
  Neuroticism b                    1.03 [0.99 - 1.07] n.s.   
  Extroversion b                   0.97 [0.93 - 1.00] .044   
  Married or cohabiting            1.13 [0.84 - 1.53] .412   
  Income                           0.94 [0.67 - 1.30] .701   
  Employed                         0.86 [0.62 - 1.18] .351   
  Professional education           1.35 [0.98 - 1.84] .063   
  Residential area (east)          1.62 [1.19 - 2.21] .002   
Cox proportional hazards models; all analyses controlled for age and gender; risk reported
for increasing time.
a Interview for Recent Life Events: objective measure of negative impact of adverse life events.
b Eysenck Personality Inventory: for dimensions of neuroticism and extroversion.
Abbreviations:
HAM-D= Hamilton Rating Scale for Depression   SOFAS  = Social and Occupational Functioning Assessment Scale
BDI    = Beck Depression Inventory              OCD    = Obsessive-Compulsive Disorder
BAI    = Beck Anxiety Inventory                 GAD    = Generalized Anxiety Disorder
HS     = Beck Hopelessness Scale                PSSS-R = Perceived Social Support Scale-Revised
SSI    = Scale for Suicidal Ideation
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7.1.4 Recurrence
Within 5 years, over two-thirds (70.7%, 99/140) of followed-up patients had a recurrence
(return of symptoms sufficiently severe to satisfy criteria for an MDE after at least two
consecutive months of partial or full remission). The median duration of recurrent
episodes was 2.9 months (SD=1.4), i.e., shorter than the index episodes (median 5.5
months).
7.1.4.1  Predictors of recurrence
Recurrence was predicted by several baseline factors (Table 4). In the final logistic
regression model, the predetermined inependent variables comprised age, gender, inpatient
status, age at onset, number of previous MDEs, mean HAM-D (severity of depression), BAI
(severity of anxiety), HS (hopelessness), SSI (suicidal ideation), SOFAS (social and
occupational functioning), anxiety disorders, and neuroticism. However, after removing
non-significant variables, younger age (baseline age under 30) (OR=0.96, 95% CI 0.92-0.99,
p=.018), higher severity of depression (HAM-D) (OR=1.11, 95% CI 1.04-1.20, p=.003), and
social phobia (OR=8.26, 95% CI 1.04-66.7, p=.045), remained significant in multivariate
logistic regression analyses. There was also a non-significant trend for number of previous
episodes to predict recurrence (OR=1.31, 95% CI 0.99-1.74, p=.062). Recurrence was
experienced by 88% (59/67) of patients with severe or psychotic depression, 66% (55/84) of
patients with moderate, and 56% (5/9) of patients with mild depression (χ2=11.75, df=2,
p=.003). A majority of patients with social phobia, 94% (16/17), had a recurrence compared
to those without social phobia [68% (83/123) (χ2=6.55, df=1, p=.017)].
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Table 4. Univariate predictors of recurrence in the Vantaa depression study,
5-year follow-up. 
    Predictor at entry        HR       95% CI          P   
  Age (yrs)                        0.97   [0.94 - 1.00] .070
  Gender (male)                    0.91   [0.40 - 2.08] n.s.
  Outpatient status                0.27   [0.06 - 1.25] .094
Clinical features of MDD              
  Age of onset (yrs)               0.96   [0.92 - 1.00] .069
  Longer MDE prior entry           0.96   [0.91 - 1.02] n.s.
  No. of previous episodes         1.34   [1.01 - 1.77] .038
Symptoms and functional ability        
  17-item HAM-D                    1.12   [1.04 - 1.20] .002
  21-item BDI                      1.07   [1.02 - 1.13] .008
  BAI                              1.03   [1.00 - 1.07] .084
  HS                               1.07   [0.99 - 1.16] .098
  SSI                              1.07   [1.01 - 1.13] .018
  SOFAS                            0.96   [0.92 - 1.00] .073
Axis I comorbidity                      
  Dysthymia                        0.72   [0.24 - 2.20] n.s.
  Anxiety disorders                1.06   [0.51 - 2.21] n.s.
     Phobic/ Nonphobic             1.54   [0.70 - 3.38] n.s.
     Panic disorder with/          1.25   [0.13 - 12.1] n.s.
     without agoraphobia           0.53   [0.17 - 1.67] n.s.
     Agoraphobia without panic     1.04   [0.31 - 3.51] n.s.
     Specific phobia               1.04   [0.45 - 2.44] n.s.
     Social phobia                 8.93   [1.14 - 71.4] .037
     OCD                           1.39   [0.27 - 7.24] n.s.
     GAD                           1.00   [0.35 - 2.84] n.s.
  Alcohol use disorders            1.31   [0.47 - 3.66] n.s.
     Dependence                    1.50   [0.29 - 7.63] n.s.
     Abuse                         1.15   [0.34 - 3.92] n.s.
Axis II comorbidity                    
  Personality disorders            1.21   [0.56 - 2.58] n.s.
     Cluster A                     2.14   [0.67 - 6.76] n.s.
     Cluster B                     1.38   [0.41 - 4.59] n.s.
     Cluster C                     2.00   [0.82 - 4.83] n.s.
  No. of psychiatric disorders     1.22   [0.95 - 1.55] n.s.
Axis III comorbidity                    
     Number of current somatic            
     diseases                      1.05   [0.41 - 2.13] n.s.
  No. of all axis I-III disorders  1.10   [0.92 - 1.31] n.s.
MDD subtype features                    
  Melancholic                      1.68   [0.75 - 3.76] n.s.
  Atypical                         0.79   [0.22 - 2.76] n.s.
  Psychotic                        0.61   [0.13 - 2.79] n.s.
Psychosocial and personality            
factors                                        
  Size of social network           0.95   [0.86 - 1.04] n.s.   
  PSSS-R                           0.99   [0.96 - 1.02] n.s.   
  Negative life events a           0.98   [0.90 - 1.07] n.s.   
  Neuroticism b                    1.09   [0.99 - 1.20] .071   
  Extroversion b                   0.96   [0.89 - 1.04] n.s.   
  Married or cohabiting            1.24   [0.59 - 2.58] n.s.   
  Income                           0.85   [0.39 - 1.86] n.s.   
  Employed                         1.56   [0.72 - 3.37] n.s.   
  Professional education           1.38   [0.63 - 3.01] n.s.   
  Residential area (east)          1.33   [0.63 - 2.81] n.s.   
Logistic regression models; all analyses controlled for age and gender, and time at risk.
a Interview for Recent Life Events: objective measure of negative impact of adverse life events.
b Eysenck Personality Inventory: for dimensions of neuroticism and extroversion.
Abbreviations:
HAM-D= Hamilton Rating Scale for Depression   SOFAS  = Social and Occupational Functioning Assessment Scale
BDI    = Beck Depression Inventory              OCD    = Obsessive-Compulsive Disorder
BAI    = Beck Anxiety Inventory                 GAD    = Generalized Anxiety Disorder
HS     = Beck Hopelessness Scale                PSSS-R = Perceived Social Support Scale-Revised
SSI    = Scale for Suicidal Ideation
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7.1.5 Time to first recurrence
During the follow-up, the median time to first recurrence was 25.4 months (95% CI
11.4-39.4) from baseline and 21.2 months (95% CI 9.5-32.9) from the end of the index
episode excluding time with full MDE criteria (Figure 6).
Figure 6. Survival curve to first recurrence of a major depressive episode (MDE) or to 60 
months.
7.1.5.1  Predictors of time to first recurrence 
Time to first recurrence after the baseline was predicted in univariate analyses by many
baseline factors (Table 5). In the final Cox proportional hazards model, the predetermined
inependent variables comprised age, gender, inpatient status, age at onset, number of
previous MDEs, mean HAM-D (severity of depression), BAI (severity of anxiety), HS
(hopelessness), SSI (suicidal ideation), SOFAS (social and occupational functioning),
comorbid anxiety and personality disorders, alcohol dependence, and neuroticism. However,
after removing non-significant variables, higher severity of MDD (HR=0.94, 95% CI
0.92-0.98, p=.001) and social phobia (HR=0.41, 95% CI 0.25-0.66, p<0.001) remained
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significant in the Cox model. The mean time to first recurrence was 26.8 months (95%
CI=20.2 to 33.3) for patients with severe or psychotic depression, 42.9 months (95%
CI=36.6 to 49.2) for patients with moderate, and 50.9 months (95% CI=35.4 to 66.4) for
patients with mild depression (log-rank χ2=14.6, df=2, p= .001). Patients with social
phobia experienced a recurrence over twice as fast compared to those without social
phobia, i.e., after a mean time of 17.9 months vs. 40.1 months (95% CI 9.4-26.3 vs.
35.1-45.2) (log-rank χ2=12.0, df=1, p=.001).
7.1.6 Number of recurrences
Within 5 years, the patients experienced a median of one recurrence (SD=1.7). Nearly
one-third (29.3%, 41/140) of patients had no recurrences, and over one-fourth (27.9%,
39/140) experienced 3 or more recurrences (Figure 7 a).
7.1.6.1  Predictors of number of recurrences 
The number of recurrences during the 5-year follow-up was predicted in univariate linear
regression analyses significantly by baseline higher severity of depression (HAM-D and
BDI), anxiety (BAI), suicidal ideation (SSI), social phobia, and alcohol dependence, and
as a trend by inpatient status, higher number of previous MDEs, hopelessness, neuroticism,
and number of comorbid psychiatric disorders. After multivariate linear regression
analyses, severity of depression (HAM-D), social phobia, and younger age at onset as a
trend remained significant (β=.04, 95% CI=0.02 to 0.06, p=.001; β=.60, 95% CI= 0.21 to
0.99, p=.003; and β=-.01, 95% CI=-0.02 to 0.002, p=.084, respectively). Figure 7 b shows
the difference in number of recurrences between mild or moderate, and severe or psychotic
depression (z=-3.40, p=.001).
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Table 5. Univariate analyses of predictors of time to first recurrence of major 
depressive disorder (MDD) in the Vantaa depression study during
a 5-year follow-up.
    Predictor at entry        HR       95% CI          P   
  Age (yrs)                        1.00   [0.98 - 1.01] n.s.
  Gender (male)                    1.06   [0.70 - 1.58] n.s.
  Outpatient status                1.68   [1.04 - 2.71] .034
Clinical features of MDD              
  Age of onset (yrs)               1.02   [1.00 - 1.04] .031
  Longer MDE prior entry           0.98   [0.95 - 1.02] n.s.
  No. of previous episodes         0.91   [0.86 - 0.96] .001
Symptoms and functional ability        
  17-item HAM-D                    0.95   [0.92 - 0.98] .001
  21-item BDI                      0.97   [0.95 - 0.99] .002
  BAI                              0.98   [0.96 - 1.00] .019
  HS                               0.96   [0.92 - 1.00] .039
  SSI                              0.97   [0.95 - 0.99] .005
  SOFAS                            1.02   [1.00 - 1.04] .036
Axis I comorbidity                      
  Dysthymia                        0.99   [0.52 - 1.89] n.s.
  Anxiety disorders                0.84   [0.58 - 1.21] n.s.
     Phobic/ Nonphobic             0.70   [0.49 - 1.01] .056
     Panic disorder with/          0.83   [0.30 - 2.30] n.s.
     without agoraphobia           0.84   [0.42 - 1.65] n.s.
     Agoraphobia without panic     1.03   [0.59 - 1.81] n.s.
     Specific phobia               0.86   [0.57 - 1.28] n.s.
     Social phobia                 0.42   [0.26 - 0.68] <.001
     OCD                           0.80   [0.37 - 1.72] n.s.
     GAD                           0.97   [0.56 - 1.68] n.s.
  Alcohol use disorders            0.72   [0.46 - 1.14] n.s.
     Dependence                    0.55   [0.31 - 0.98] .041
     Abuse                         1.00   [0.54 - 1.83] n.s.
Axis II comorbidity                    
  Personality disorders            0.81   [0.56 - 1.17] n.s.
     Cluster A                     0.67   [0.43 - 1.04] .073
     Cluster B                     0.75   [0.45 - 1.26] n.s.
     Cluster C                     0.74   [0.50 - 1.10] n.s.
  No. of psychiatric disorders     0.86   [0.77 - 0.96] .005
Axis III comorbidity                    
     Number of current somatic            
     diseases                      1.01   [0.86 - 1.18] n.s.
  No. of all axis I-III disorders  0.92   [0.85 - 1.00] .040
MDD subtype features                    
  Melancholic                      0.86   [0.59 - 1.25] n.s.
  Atypical                         0.83   [0.46 - 1.52] n.s.
  Psychotic                        1.23   [0.54 - 2.82] n.s.
Psychosocial and personality            
factors                                        
  Size of social network           0.99   [0.94 - 1.04] n.s.   
  PSSS-R                           1.01   [0.99 - 1.02] n.s.   
  Negative life events a           1.00   [0.96 - 1.04] n.s.   
  Neuroticism b                    0.95   [0.90 - 1.00] .044   
  Extroversion b                   1.02   [0.97 - 1.06] n.s.   
  Married or cohabiting            0.85   [0.59 - 1.22] n.s.   
  Income                           0.95   [0.64 - 1.39] n.s.   
  Employed                         0.82   [0.55 - 1.21] n.s.   
  Professional education           0.89   [0.62 - 1.29] n.s.   
  Residential area (east)          0.97   [0.66 - 1.42] n.s.   
Cox proportional hazards models; all analyses controlled for age and gender; risk reported for increasing time.
a Interview for Recent Life Events: objective measure of negative impact of adverse life events.
b Eysenck Personality Inventory: for dimensions of neuroticism and extroversion.
Abbreviations:
HAM-D= Hamilton Rating Scale for Depression   SOFAS  = Social and Occupational Functioning Assessment Scale
BDI    = Beck Depression Inventory              OCD    = Obsessive-Compulsive Disorder
BAI    = Beck Anxiety Inventory                 GAD    = Generalized Anxiety Disorder
HS     = Beck Hopelessness Scale                PSSS-R = Perceived Social Support Scale-Revised
SSI    = Scale for Suicidal Ideation
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Figure 7. Number of recurrences in the Vantaa depression study over a 5-year follow-up, 
(N=140).
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7.2. Risk factors of suicide attempts during the prospective
follow-up (Study II)
7.2.1 Incidence of suicide attempts
During the 5-year follow-up, one-seventh of the patients (14.5%, N=36/249) attempted
suicide at least once. More than half of the patients (N=19/249) attempted suicide at
least twice, one eight times, and one attempted suicide even 13 times. In all, there were
106 suicide attempts (SAs) per 1,017.9 patient-years (incidence: N=104.1 per 1,000
patient-years [95% CI=86.0-127.1]). The incidence rate corresponded for women and men
(N=111 [92.2-134.8] vs. N=83 [65.9-102.7]; z=-0.55, p=0.58). The majority, 73% (N=73/100)
of the SAs took place during MDE, 19% (N=19/100) in the state of partial remission, and 8%
(N=8/100) of full remission. The timing of six attempts was uncertain, i.e., one patient
attempted several times. One SA took place during antidepressant-induced hypomania. During
the follow-up, 219.6 patient-years were spent in MDE, 308.4 patient-years in partial
remission, 489.6 patient-years in full remission. Therefore, the incidence rate of SAs
during MDEs was 332 per 1,000 patient-years (95% CI=258.6-419.2), during partial
remission 62 per 1,000 patient-years (95% CI=34.6-92.4), and full remission 16 per 1,000
patient-years (95% CI=11.2-40.2) (Figure 8). The risk of SA was highest within the first
year of observation 219.4 per 1,000 patient-years [95% CI=191.3-250.5] declining after
that during the second to fifth year (45.0-114.2 [95% CI 32.8-137.2] per 1,000
patient-years respectively). The risk ratio of SAs during MDE (linear effect per year) was
0.88 (95% CI=0.76-1.02), and during periods not in MDE (combined full and partial
remission) 0.55 (95% CI=0.40-0.75) according to the Poisson analyses. Therefore, the risk
of SAs in depressive episodes relative to time remained unchanged, but during the other
periods it declined over the 5 years.
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Figure 8. Incidence per 1000 patient years of suicide attempts during a major depressive 
episode (MDE), partial remission, and full remission over a 5-year follow-up (N=249).
(Based on Poisson distribution.)
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7.2.2 Differences between suicide attempters and non-attempters
Patients who attempted suicide during the follow-up period differed significantly from
those who did not in terms of age, inpatient status, severity of depression (HAM-D),
anxiety (BAI), levels of suicidal ideation (SSI), hopelessness (HS), functional ability
(SOFAS), comorbidities, size of social network, perceived social support (PSSS-R), and
income level (Table 6).
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Table 6. Differences in characteristics between those who did and those who 
did not attempt suicide during a 5-year prospective follow-up (baseline values 
if not otherwise specified).
                 No suicide Suicide  Total 
                                    attempt attempt              
    Characteristics                N  %  N  %  N  %  P
Total                                       213   85.5  36   14.5 249   100   
Sociodemographic features                                                       
  Gender                                                                           n.s.
     Male                                       56   26.3   8   22.2  64   25.7
     Female                                    157   73.7  28   77.8 185   74.3
  Married or cohabiting                        117   54.9  14   38.9 131   52.6
  Income lower                                  84   43.3  20   64.5 104   46.2
  Employed                                     130   62.5  21   60.0 151   62.1
  Professional education                        85   39.9  12   33.3  97   39.0
  Outpatient status                            185   86.9  23   63.9 208   83.5 .001
Psychiatric comorbidity                                                          
Axis I comorbidity                           138   64.8  24   66.7 162   65.1 n.s.
  Dysthymia                                     23   10.8   2    5.6   25   10.0 n.s.
  Anxiety disorders                            120   56.3  22   61.1 142   57.0 n.s.
  Alcohol use disorders during follow-up        71   33.3  24   66.7  95   38.2 <.001
Axis II comorbidity                                                              
  Personality disorder during follow-up        114   53.5  26   72.2 140   56.2 .036
Depression-related characteristics                                           
  Psychotic features during follow-up           25   11.7  11   30.6   6   14.5 .003
  Melancholic features                          78   36.6  14   38.9  92   36.9 n.s.
  Atypical features                             21    9.9    1    2.8   22    8.8  n.s.
History of suicidal behavior                                                     
  Suicide ideation prior to entry              131   61.5  28   80.0 159   64.1 .034
  Suicide attempt prior to entry                63   29.6  22   61.1  85   34.1 <.001
                 Mean  SD Mean  SD Mean  SD  P
Sociodemographic features                                                
  Age years                                    40.8 11.1 36.2 10.0 39.6 11.1 .020
Clinical features of MDD                                                     
  Age of onset years                           32.2 12.9 29.6 11.3 31.5 12.5 n.s.
  No. of previous episodes                      1.7   2.6   1.9   3.7   1.7   2.7  n.s.
Symptoms and functional ability                                                
  HAM-D max a                                  19.3 16.2 23.4  7.6  19.7  6.5  <.001
  BDI max b                                    27.2  8.2  31.7  8.8  27.9  8.4  .003
  BAI max c                                    24.2 10.9 29.2 11.5 24.7 10.9 .011
  SSI                                           5.1   7.1  12.5  9.9   6.4   8.1  <.001
  HS (HAM-D min) d                              6.1   4.7   8.7   6.0   6.9   5.1  .020
  SOFAS                                        52.7 10.5 48.2 12.5 51.8 10.9 .021
Comorbidity                                                                      
  No. of cluster A symptoms                     2.3   2.5   3.4   2.6   2.5   2.6  .012
  No. of cluster B symptoms                     3.8   4.3   5.1   6.0   4.1   4.8  n.s.
  No. of cluster C symptoms                     5.9   4.5   6.5   4.0   6.0   4.5  n.s.
  No. of comorbid psychiatric disorders         2.9   1.7   3.6   2.1   3.1   1.8  .027
  No. of current somatic diseases               0.6   1.1   0.4   0.8   0.6   1.1  n.s.
  No. of suicide attempts prior to entry        0.6   1.7   1.7   3.6   0.7   2.0  <.001
Psychosocial and personality factors                                            
  Perceived social support (HAM-D min) e       43.3  2.9  39.3 13.9 41.9 13.3 n.s.
  Size of social network (HAM-D min) f          7.9   3.9   5.9   2.9   7.5   3.8  .002
  Negative life events g                        8.3   4.5   9.3   4.6   8.5   4.5  n.s.
  Neuroticism h                                17.2  4.0  18.1  2.9  17.4  3.9  n.s.
  Extroversion h                               10.1  4.6   9.4   4.4  10.0  4.6  n.s.
Statistical methods:
Categorical variables: Chi-square test with Yates’ continuity correction, or Fisher’s exact test when the expected cell count less than 5 in the 2x2 table.
Continuous variables: two-sample t-test for normal distribution; Mann-Whitney and Kruskal-Wallis tests for non-normal distribution.
a  Maximum score of HAM-D during follow-up                   e  Perceived social support  when minimum score of HAM-D during follow-up (trait)
b  Maximum score of  BDI during follow-up                    f  Size of social network when minimum score of HAM-D during follow-up
c  Maximum score of BAI during follow-up                     g  Interview for Recent Life Events: objective measure of negative impact of adverse
d  HS when minimum score of HAM-D during follow-up (trait)      life events
                                                             h  Eysenck Personality Inventory: for dimensions of neuroticism and extroversion
Abbreviations:
MDD    = Major Depressive Disorder              HS     = Beck Hopelessness Scale
MDE    = Major Depressive Episode               SSI    = Scale for Suicidal Ideation
HAM-D  = Hamilton Rating Scale for Depression   SOFAS  = Social  and Occupational Functioning Assessment Scale
BDI    = Beck Depression Inventory              OCD    = Obsessive-Compulsive Disorder
BAI    = Beck Anxiety Inventory                 GAD    = Generalized Anxiety Disorder
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7.2.3 Predictors of suicide attempt during the follow-up
After removing non-significant variables, SAs were predicted by 1) time spent in MDEs,
2) time spent in partial remission, 3) previous suicide attempt, 4) lower age, and 5) lower
perceived social support in the the Cox proportional hazards model. Time spent in MDE was
the strongest predictor, increasing the risk of SA nearly eightfold (Table 2).
Incorporating individual frailty in the model, the variance of random effect was 3.77,
with a p value <.001 (e.g., relatively high compared with fixed effects), indicating a
significant individual variance. No significant interaction was detected between high-risk
time periods (MDE) and other risk factors. The adjusted population attributable fraction
(PAF) of time spent in MDEs for suicide attempts was 78% (95% CI=59-86).
7.3. Switch to bipolar disorder during the prospective follow-up
(Study III)
Within 5 years 29 patients (11.7%) who previously suffering from unipolar MDD switched to
bipolar disorder (BD) type I or II. A diagnostic change to BD type II was 3 times more
common: e.g., 22 (8.9%) to type II vs. 7 (2.8%) patients to type I. Therefore, the annual
incidence of switch was 2.8% (95% CI 1.86-4.04): 0.68% for type I (95% CI 0.27-1.40) and
2.14% for type II (95% CI 1.34-3.23). Four (57.1%) BD type I patients had experienced
mixed episodes. Three of the followed-up patients experienced substance-induced hypomanic
or manic episodes. The median (SD) time to the first hypomanic or manic episode was 22.0
(SD=13.0) months from baseline: to manic episode, 4.2 (SD=0.5) months and to hypomanic
25.0 (SD=4.7) months (χ2=10.7, df=1, p=.001). The median (SD) time from age at onset to
diagnostic switch was 7.7 (SD=1.9) years: to BD type I, 2.8 (SD=0.6) years and to type II,
7.7 (SD=2.7) years (Figure 9).
7.3.1 Differences between patients switching and not switching to bipolar
disorder
The sociodemographic characteristics of unipolar MDD patients and bipolar patients were
not significantly different. All BD type I patients were female, but this was
statistically insignificant because of the small number of patients in this subgroup. The
clinical characteristics differed in some respects, bipolar patients having younger age at
onset, more severe, and psychotic MDD at baseline, more comorbid psychiatric disorders,
especially Axis I comorbid disorders, more social phobia, OCD, and alcohol dependence than
unipolar patients (Table 7). BD type I patients suffered at baseline more from psychotic
symptoms compared with BD type II and unipolar patients (42.9% vs. 9.1% and 6.8%, χ2=11.9,
df=2, p=.003), while BD type II patients had significantly more MDEs prior to the switch
than type I patients, i.e., mean number of 4.7 (SD=2.7) vs. 2.1 (SD=0.7) episodes,
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(t=-3.77, df=24.0, p=.001). There were also differences in comorbidity: BD type I patients
compared with type II and unipolar MDD patients had more alcohol dependence (57.1% vs.
13.6% and 11.9%, χ2=12.0, df=2, p=.002), phobic anxiety disorders (85.7% vs. 45.5% and
37.4%, χ2=6.97, df=2, p=.031), panic disorder with agoraphobia (28.6% vs. 9.1% and 5.5%,
χ2=6.27, df=2, p=.043), and OCD (28.6% vs. 22.7% and 4.6%, χ2=15.6, df=2, p<.001); BD
type II patients had significantly more social phobia than the other 2 groups (36.4% vs.
28.6% and 16.0%, χ2=6.12, df=2, p=.047). Patients who switched to BD received antidepressant
treatment for a significantly longer time than patients who remained unipolar (t=-2.21,
df=246, p=.028). However, the difference was insignificant after adjusting for the number
of MDE recurrences, suggesting that these patients were proportionally more ill during
their follow-up.
Figure 9. Survival curve to switch to bipolar disorder I and II of unipolar MDD.
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Table 7. Sociodemographic and clinical characteristics of subjects who switched
from unipolar depression to bipolar disorder (N=29) vs. unipolar subjects (N=219)
in the Vantaa Depression Study, 5-year follow-up.
    Predictor at entry             OR       95% CI          P   
  Age                                     0.98 [0.94 - 1.01]  0.175
  Gender (female)                         1.40 [0.54 - 3.64]  0.487
  Employed                                0.61 [0.27 - 1.37]  0.233
  Professional education                  1.14 [0.51 - 2.52]  0.748
  Residential area (east)                 1.20 [0.54 - 2-67]  0.646
  Income                                  0.59 [0.25 - 1.39]  0.226
  Married or cohabiting                   0.73 [0.33 - 1.59]  0.423
  Professional education                  1.14 [0.51 - 2.52]  0.748
  Outpatient status                       0.73 [0.33 - 1-59]  0.423
  Age at onset                            0.81 [0.66 - 0.99]  0.041
  Number of previous MDEs                 1.06 [0.88 - 1.29]  0.519
  MDE duration prior entry                0.88 [0.76 - 1.01]  0.060
  Melancholic                             1.47 [0.67 - 3.25]  0.338
  Psychotic                               2.90 [0.96 - 8.85]  0.060
  HAM-D                                   1.10 [1.02 - 1.17]  0.008
  BDI                                     1.04 [0.99 - 1.08]  0.144
  BAI                                     1.03 [1.00 - 1.07]  0.087
  SOFAS                                   0.99 [0.96 - 1.03]  0.752
  HS                                      0.99 [0.91 - 1.07]  0.759
  SSI                                     0.98 [0.93 - 1.03]  0.440
  Size of social network                  0.97 [0.86 - 1.09]  0.612
  PSSS-R                                  1.00 [0.97 - 1.04]  0.883
  Negative life events a                  1.10 [0.99 - 1.21]  0.067
  Neuroticism b                           1.08 [0.96 - 1.21]  0.192
  Extroversion b                          0.98 [0.90 - 1.07]  0.599
Axis I comorbidity                     2.43 [0.89 - 6.67]  0.084
  Dysthymia                               1.20 [0.33 - 4.39]  0.781
  Anxiety disorders                       1.76 [0.77 - 4.08]  0.182
  Alcohol use disorders                   1.61 [0.67 - 3.91]  0.290
     Dependence                           2.52 [0.94 - 6.71]  0.066
     Abuse                                0.62 [0.14 - 2.79]  0.529
Axis II comorbidity                       
  Personality disorders                   1.23 [0.56 - 2.71]  0.609
     Cluster A                            1.57 [0.62 - 4.00]  0.344
     Cluster B                            1.21 [0.42 - 3.48]  0.725
     Cluster C                            1.60 [0.72 - 3.56]  0.253
  No. of psychiatric disorders            1.32 [1.08 - 1.62]  0.007
Axis III comorbidity                 
     No. of current somatic diseases      0.58 [0.30 - 1.14]  0.112
  No. of all axis I-III disorders         1.16 [0.97 - 1.38]  0.116
Logistic regression models; all analyses controlled for age and gender, and time at risk.
a Interview for Recent Life Events: objective measure of negative impact of adverse life events.
b Eysenck Personality Inventory: for dimensions of neuroticism and extroversion.
Abbreviations:
HAM-D= Hamilton Rating Scale for Depression   SOFAS  = Social and Occupational Functioning Assessment Scale
BDI    = Beck Depression Inventory              OCD    = Obsessive-Compulsive Disorder
BAI    = Beck Anxiety Inventory                 GAD    = Generalized Anxiety Disorder
HS     = Beck Hopelessness Scale                PSSS-R = Perceived Social Support Scale-Revised
SSI    = Scale for Suicidal Ideation
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7.3.2 Predictors of a switch to bipolar disorder during the follow-up
The probability and time to a diagnostic switch from unipolar MDD to BD were predicted by
many univariate variables (Table 8). However, after removing all non-significant factors,
in multivariate Cox proportional hazards analyses, severity of MDD (HAM-D; HR=1.08, 95%
CI 1.00-1.15, P=.036), OCD (HR=5.00, 95% CI 2.04-12.5, P<.001), social phobia (HR=2.33,
95% CI 1.00-5.26, P=.050), and a large number of cluster B personality disorder symptoms
(HR=1.10, 95% CI 1.02-1.20, P=.022) predicted the switch to BD type I or II most
significantly. Within cluster B personality disorders, the numbers of narcissistic
(HR=0.72, 95% CI 0.57-0.90, p=.003) and antisocial (HR=0.47, 95% CI 0.30-0.74, p=.001)
personality disorder symptoms were the strongest predictors. After multivariate analyses
of different cluster B items, only attention seeking predicted a switch to BD as a trend
(OR=2.57, 95% CI0.93-7.14, p=.069).
Table 8.  Significant baseline univariate predictors for switch from unipolar depression
to bipolar disorder in the Vantaa Depression Study, 5-year follow-up. 
    Predictor at entry                         HR       95% CI          P   
  17-item HAM-D                                       1.10   [1.03 - 1.16]  0.003
  No. of anxiety disorder symptoms                    1.09   [1.04 - 1.15]  <0.001
  No. of phobic disorder symptoms                     1.10   [1.03 - 1.19]  0.007
  Social phobia                                       2.78   [1.27 - 5.88]  0.010
  OCD                                                 5.88   [2.50 - 14.3]  <0.001
  Alcohol dependence                                  2.94   [1.23 - 7.14]  0.014
  Psychotic MDD                                       3.33   [1.25 - 9.09]  0.016
  No. of psychiatric disorders                        1.30   [1.08 - 1.56]  0.004
  No. of cluster A personality disorder symptoms      1.16   [1.03 - 1.32]  0.015
  No. of cluster B personality disorder symptoms      1.19   [1.10 - 1.28]  <0.001
  No. of cluster C personality disorder symptoms      1.09   [1.01 - 1.16]  0.025
  Negative life events a                              1.10   [1.00 - 1.19]  0.048
Cox proportional hazards models; all analyses controlled for age and gender
a Interview for Recent Life Events: objective measure of negative impact of adverse life events
Abbreviations:
HAM-D= Hamilton Rating Scale for Depression
OCD    = Obsessive-Compulsive Disorder
MDD    = Major Depressive Disorder
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7.4. Family history and outcome of MDD (Study IV)
7.4.1 Prevalence of family history
Three-fourths of the followed up patients (74.9%, N=137/183) had a FH of mood disorders,
alcoholism, or psychotic disorders; more specifically, three-fifths had (60.7%, N=111) a
family history of mood disorders, over one-third (36.6%, N=67) of alcoholism, and a tenth
(10.9%, N=20) of psychotic disorders. Only two patients reported FH of bipolar disorder.
An overlap of FH was common (Figure 10), one-fourth (24.6%, N=45) having histories of both
mood disorders and alcoholism. Eight patients (4.4%) had a first-degree relative, who had
died by committing suicide, all also having suffered from mental disorders (seven of mood
disorder, six of alcoholism). Women and men reported nearly equally positive FHs of any of
the mental disorders (75.7% vs. 71.8%, NS).
Figure 10. Overlap of family history of mood disorder (N=111), alcohol use disorder
(N=67), and psychotic disorder (N=20) in the Vantaa Depression Study. 
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7.4.2 Family history of any of the mental disorders
Patients with and without a FH of any of the mental disorders (mood disorder, alcohol use
disorder, and psychotic disorders) had differences in sociodemographic and clinical
features in many aspects: those with FH were older, had significantly more previous and
lifetime MDEs, suffered from a higher severity of depression and anxiety, more neuroticism
(during mildest depression), had attempted suicide during their lifetime more often, had a
larger number of lifetime suicide attempts, and spent more time in MDE during the
follow-up (Table 9). They also had significantly more comorbid psychiatric disorders, and
specifically cluster C personality disorders (Table 10). In the final multivariate
logistic regression model, the predetermined independent variables comprised gender, age,
duration of follow-up, age at onset, lifetime number of MDEs, highest level of depression
(Ham-D), and anxiety (BAI) during follow-up, lifetime suicide attempt, perceived social
support, hopelessness, neuroticism (during lowest depression), time spent in MDE, comorbid
anxiety and personality disorders. However, after removing non-significant variables,
lifetime suicide attempt (OR=3.75, 95% CI 1.57-8.93, P=.003), and cluster C personality
disorder (OR=2.92, 95% CI 1.18-7.19, P=.021) persisted in the logistic regression model.
The number of suicide attempts prior to or during follow-up was nearly four-fold among
patients with a FH of mental disorders (mean number 1.31 [SD=3.34] vs. 0.30 [SD=0.81])
compared to those without this FH. Of different cluster C personality disorders, avoidant
personality disorder associated the strongest with FH. The associations remained unchanged
in sensitivity analyses, after omitting from analyses, or adjusting for, patients
switching to bipolar disorder during follow-up.
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Table 9. Sociodemographic and clinical features of patients with or without a family history of mental disorders,
mood disorders, or alcohol use disorders during a 5-year follow-up of the Vantaa Depression Study 
(baseline values if not otherwise specified).
                      Mental disorder a Mood disorder    Alcoholism           
                                                Yes           No                   Yes           No                   Yes           No
    Characteristics               N / % / N / % / P N / % / N / % / P N / % / N / % / P
                                               mean SD mean SD mean SD mean SD mean SD mean SD
  Total                                         137   (74.9)    46   (25.1)          111   (60.7)    72   (39.3)           67   (36.6)   116   (63.4)
Sociodemographic features
  Gender                                         28   (20.4)    11   (23.9)  n.s.     21   (18.9)    18   (25.0)  n.s.     16   (23.9)    23   (19.8)  n.s.
      Male                                      109   (79.6)    35   (76.1)  n.s.     90   (81.1)    54   (75.0)  n.s.     51   (76.1)    93   (80.2)  n.s.
      Female                                    41.4  (11.2)   36.4  (10.6)  .008    41.6  (10.8)   38.1  (11.5)  .037    41.5  (11.5)   39.4  (11.0)  n.s.
  Age (years)                                   116   (84.7)    42   (91.3)  n.s.     96   (86.5)    62   (86.1)  n.s.     58   (86.6)   100   (86.2)  n.s.
  Outpatient status                              75   (54.7)    27   (58.7)  n.s.     62   (55.9)    40   (55.6)  n.s.     38   (56.7)    64   (55.2)  n.s.
  Married or cohabiting                          1.7   (0.8)    2.1   (0.8)  n.s.     1.7   (0.7)    2.1   (0.9)  n.s.     1.7   (0.7)    1.9   (0.8)  n.s.
  Number of minor children                       7.8   (3.6)    7.8   (3.4)  n.s.     7.9   (3.5)    7.7   (3.7)  n.s.     7.4   (3.8)    8.0   (3.4)  n.s.
  Size of social network                        38.5  (12.7)   42.7  (11.2)  n.s.    38.7  (12.8)   40.8  (11.9)  n.s.    36.5  (12.4)   41.3  (12.2)  .011
  PSSS-R score                                   8.3   (4.5)    8.2   (4.6)  n.s.     8.7   (4.7)    7.7   (4.3)  n.s.     8.3   (4.8)    7.9   (4.5)  n.s.
  Negative life events b                         54   (43.9)    18   (43.9)  n.s.     46   (44.7)    26   (42.6)  n.s.     22   (38.6)    50   (46.7)  n.s.
  Income (lower)                                 91   (67.4)    26   (59.1)  n.s.     70   (64.2)    47   (67.1)  n.s.     46   (69.7)    71   (62.8)  n.s.
  Employed                                       52   (38.0)    17   (37.0)  n.s.     43   (38.7)    26   (36.1)  n.s.     22   (32.8)    47   (40.5)  n.s.
  Professional education                         49   (36.0)    20   (43.5)  n.s.     39   (35.5)    30   (41.7)  n.s.     25   (37.3)    44   (38.3)  n.s.
  Residential area (socioeconomically poorer)     8    (6.9)     0    (0.0)  n.s.      7    (7.3)     1    (1.7)  n.s.      6   (10.5)     2    (2.1)  (.056)
  Family history of suicide                     33.0  (12.6)   31.3  (12.4)  n.s.    32.9  (12.1)   32.2  (13.3)  n.s.    32.3  (12.9)   32.8  (12.3)  n.s.
Clinical features
  No. of previous episodes                       1.8   (2.8)    0.9   (1.3)  .006     1.7   (2.5)    1.3   (2.6)  (.074)    1.9   (3.5)    1.3   (1.7)  n.s.
  Highest HAM-D during follow-up                21.1   (5.9)   18.2   (5.8)  .005    21.1   (5.6)   19.2   (6.4)  .035    21.4   (5.9)   19.7   (5.9)  (.060)
  Highest BDI during follow-up                  29.0   (8.5)   26.3   (9.4)  (.070)   28.6   (8.2)   28.0   (9.6)  n.s.    30.4   (8.3)   27.2   (8.8)  .018
  Highest BAI during follow-up                  25.5  (10.5)   20.8  (11.0)  .010    25.2  (10.4)   23.0  (11.3)  n.s.    27.3  (10.1)   22.7  (10.9)  .005
  SSI                                            6.1   (7.9)    5.1   (7.5)  n.s.     6.3   (7.7)    5.2   (7.9)  n.s.     5.7   (7.3)    6.0   (8.1)  n.s.
  HS during lowest depression                    6.6   (4.7)    5.2   (4.7)  (.080)    6.6   (4.6)    5.7   (4.9)  n.s.     6.4   (4.5)    6.1   (4.8)  n.s.
  SOFAS                                         52.7  (10.4)   54.8   (7.3)  n.s.    53.5  (10.5)   52.9   (8.5)  n.s.    51.0  (10.7)   54.5   (8.9)  .025
  Melancholic features                           48   (35.0)    14   (30.4)  n.s.     40   (36.0)    22   (30.6)  n.s.     21   (31.3)    41   (35.3)  n.s.
  Atypical features                              14   (10.2)     4    (8.7)  n.s.     12   (10.8)     6    (8.3)  n.s.      9   (13.4)     9    (7.8)  n.s.
  Psychotic features                             10    (7.3)     2    (4.3)  n.s.      9    (8.1)     3    (4.2)  n.s.      5    (7.5)     7    (6.0)  n.s.
  Neuroticism (during mildest depression) c     14.2   (5.3)   11.5   (5.3)  .007    14.4   (4.7)   12.1   (6.1)  .015    14.3   (6.0)   12.9   (5.1)  n.s.
  Extroversion (during mildest depression) c    11.0   (4.3)   12.1   (4.4)  n.s.    10.7   (4.3)   12.1   (6.1)  (.056)   11.1   (3.9)   11.5   (4.6)  n.s.
  Lifetime suicide attempt                       59   (43.1)     8   (17.4)  .003     46   (41.4)    21   (29.2)  (.092)    22   (38.6)    29   (29.9)  n.s.
  Number of lifetime suicide attempts            1.3   (3.4)    0.3   (0.8)  .002     1.1   (2.7)    1.1   (3.4)  n.s.     1.4   (3.5)    0.9   (2.6)  (.100)
  Lifetime number of MDEs                        3.5   (3.2)    2.3   (1.9)  .006     3.3   (2.9)    2.9   (3.0)  n.s.     3.7   (3.7)    2.8   (2.3)  (.062)
  Time spent in MDE (months)                    12.5  (14.0)    8.5  (11.7)  .017    12.8  (14.1)    9.6  (12.5)  n.s.    14.2  (15.7)   10.0  (12.0)  .042
Statistical methods:
Categorical variables: Chi-square test with Yates’ continuity correction, or Fisher’s exact test when the expected cell count was less than 5 in the 2x2 table.
Continuous variables: two-sample t-test for normal distribution; Mann-Whitney and Kruskal-Wallis tests for nonnormal distribution.
a Mental disorder= Psychotic disorder, mood disorder, or alcoholism.
b Interview for Recent Life Events: objective measure of negative impact of adverse life events.
c Eysenck Personality Inventory: for dimensions of neuroticism and extroversion.
Abbreviations:
PSSS-R = Perceived Social Support Scale-Revised BAI    = Beck Anxiety Inventory
MDE    = Major Depressive Episode               HS     = Beck Hopelessness Scale
HAM-D  = Hamilton Rating Scale for Depression   SSI    = Scale for Suicidal Ideation
BDI    = Beck Depression Inventory              SOFAS  = Social and Occupational Functioning Assessment Scale
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Table 10. Comorbid disorders of patients with or without a family history of mental disorders, mood disorders, 
and alcohol use disorders in the Vantaa Depression Study (VDS) (baseline values if not otherwise specified).
                      Mental disorder a        Mood disorder          Alcoholism           
                                                Yes           No                    Yes           No                    Yes           No
    Characteristics               N / % / N / % / P    N / % / N / % / P    N / % / N / % / P
                                               mean SD mean SD    mean SD mean SD    mean SD mean SD
Axis I comorbidity                       94    (68.6)   28    (60.9)  n.s.     73    (65.8)   49    (68.1)   n.s.     50   (74.6)    72   (62.1)  (0.083)
  Dysthymia                                     17    (12.4)    2     (4.3)  n.s.     14    (12.6)    5     (6.9)   n.s.     13   (19.4)     6    (5.2)  0.005
  Anxiety disorders during follow-up            94    (68.6)   24    (52.2)  (0.066)   74    (66.7)   44    (61.1)   n.s.     47   (70.1)    71   (61.2)  n.s.
      Phobic                                    57    (41.6)   15    (32.6)  n.s.     43    (38.7)   29    (40.3)   n.s.     29   (43.3)    43   (37.1)  n.s.
      Panic disorder                            45    (32.8)   10    (21.7)  n.s.     37    (33.3)   18    (25.0)   n.s.     25   (37.3)    30   (25.9)  n.s.
           with/                                23    (16.8)    2     (4.3)  (0.060)   18    (16.2)    7     (9.7)   n.s.     12   (17.9)    13   (11.2)  n.s.
           without agoraphobia                  24    (17.5)    5    (10.9)  n.s.     19    (17.1)   10    (13.9)   n.s.     16   (23.9)    13   (11.2)  0.040
      Agoraphobia without panic                 20    (14.6)    4     (8.7)  n.s.     13    (11.7)   11    (15.3)   n.s.     11   (16.4)    13   (11.2)  n.s.
      Specific phobia                           48    (35.0)   15    (32.6)  n.s.     38    (34.2)   25    (34.7)   n.s.     27   (40.3)    36   (31.0)  n.s.
      Social phobia                             30    (21.9)    7    (15.2)  n.s.     23    (20.7)   14    (19.4)   n.s.     14   (20.9)    23   (19.8)  n.s.
      OCD                                       22    (16.1)    8    (17.4)  n.s.     19    (17.1)   11    (15.3)   n.s.     11   (16.4)    19   (16.4)  n.s.
      GAD                                       27    (19.7)    4     (8.7)  n.s.     23    (20.7)    8    (11.1)   n.s.     10   (14.9)    21   (18.1)  n.s.
  Alcohol use disorders during follow-up        52    (38.0)   14    (30.4)  n.s.     42    (37.8)   24    (33.3)   n.s.     29   (43.3)    37   (31.9)  n.s.
      Dependence                                35    (25.5)   10    (21.7)  n.s.     27    (24.3)   18    (25.0)   n.s.     23   (34.3)    22   (19.0)  0.032
      Abuse                                     17    (12.4)    4     (8.7)  n.s.     15    (13.5)    6     (8.3)   n.s.      6    (9.0)    15   (12.9)  n.s.
Axis II comorbidity (Personality disorders)   59    (43.1)   17    (37.0)  n.s.     46    (41.4)   30    (41.7)   n.s.     33   (49.3)    43   (37.1)  n.s.
      Cluster A                        23    (16.8)    5    (10.9)  n.s.     20    (18.0)    8    (11.1)   n.s.     13   (19.4)    15   (12.9)  n.s.
      Number of cluster A symptoms              2.5    (2.7)   1.7    (2.2)  (0.073)   2.5    (2.7)   2.0    (2.5)   n.s.    2.9    (2.9)   1.9    (2.4)  0.028
      Cluster B                                 20    (14.6)    7    (15.2)  n.s.     13    (11.7)   14    (19.4)   n.s.     12   (17.9)    15   (12.9)  n.s.
      Number of cluster B symptoms              3.5    (3.8)   3.4    (3.5)  n.s.     3.0    (3.2)   4.3    (4.3)   0.075   4.2    (4.3)   3.1    (3.3)  (0.082)
      Cluster C                                 48    (35.0)    8    (17.4)  0.039    36    (32.4)   20    (27.8)   n.s.    26    (38.8)    30   (25.9)  (0.096)
      Number of cluster C symptoms              6.1    (4.8)   5.5    (3.9)  n.s.     6.0    (4.8)   5.9    (4.3)   n.s.    6.9    (5.0)   5.4    (4.3)  (0.051)
  Number of psychiatric disorders               3.2    (1.9)   2.5    (1.5)  0.033    3.1    (1.8)   2.9    (1.9)   n.s.    3.4    (2.0)   2.8    (1.7)  0.037
Axis III comorbidity                      68    (52.7)   25    (56.8)  n.s.     56    (53.3)   37    (54.4)   n.s.    32    (50.8)    61   (55.5)  n.s.
      Number of current somatic diseases        0.7    (1.2)   0.4    (1.0)  n.s.     0.7    (1.1)   0.5    (1.2)   n.s.    0.7    (1.2)   0.6    (1.1)  n.s.
  Number of all Axis I-III disorders            3.8    (2.2)   3.0    (1.8)  0.011    3.7    (2.1)   3.4    (2.2)   n.s.    4.1    (2.2)   3.3    (2.1)  0.019
Statistical methods:
Categorical variables: Chi-square test with Yates’ continuity correction, or Fish er’s exact test when the expected c ell count less than 5 in the 2x2 t able.
Continuous variables: two-sample t-test for normal distribution; Mann-Whitney and  Kruskal-Wallis tests for nonnormal  distribution.
a Mental disorder = Psychotic disorder, mood disorder, or alcoholism.
Abbreviations:
OCD    = Obsessive compulsive disorder
GAD    = Generalized anxiety disorder
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7.4.3 Family history of mood disorders
Patients who had a positive FH of mood disorders were significantly older, had more severe
depression, higher neuroticism (during their mildest depression), and also tended to have
lower extroversion and have attempted suicide during their lifetimes more often, than
those without FH. Among women the association with lower extroversion and FH was
significant (t=2.11, p=0.037), but among men it was not. Patients with FH were not
significantly different in terms of age at onset, time spent in MDE, or time to their
first recurrence (Table 9). In addition, the prevalence of comorbid psychiatric disorders
was not significantly different (Table 10). In the multivariate logistic regression model,
the predetermined independent variables comprised gender, age, duration of follow-up, age
at onset, highest severity of depression during follow-up (Ham-D), lifetime suicide
attempt, neuroticism (during lowest depression), comorbid anxiety, and personality
disorders. After removing non-significant variables, only higher neuroticism (OR=1.08, 95%
CI 1.02-1.15, P=.014) persisted in the logistic regression model. There was a gender
difference, as the association with neuroticism existed only in women (OR=1.12, p=0.005
vs. in men OR=1.01, p=0.798). Patients with higher neuroticism had significantly more
comorbid personality disorders, especially cluster C disorders. When adjusting in the
model for FH of alcoholism, the findings persisted. However, the association became weaker
in sensitivity analyses, after omitting from analyses patients switching to bipolar
disorder during follow-up omitting patients switching to bipolar disorder during
follow-up: neuroticism remained associated with FH, but only as a non-significant trend
(OR=1.06, p=0.078).
7.4.4 Family history of alcoholism
Patients who reported FH of alcoholism perceived significantly less social support, had
more severe depression, anxiety, lower social and occupational functioning, and spent more
time in MDE during the follow-up, compared to those without (Table 9). In addition, they
had more comorbid somatic and psychiatric disorders, more often alcohol dependence,
dysthymia, panic disorder, and comorbid cluster A personality disorder symptoms, and
cluster B and C symptoms as a trend (Table 10). In the multivariate logistic regression 
model, the predetermined independent variables comprised gender, age, duration of
follow-up, highest severity of depression during the follow-up (BDI), of anxiety (BAI),
social and occupational functioning (SOFAS), lifetime number of depressive episodes,
neuroticism (during their lowest depression), perceived social support, time spent in MDE,
comorbid dysthymia, anxiety, alcohol use disorders, and personality disorders. After
removing the non-significant variables, alcohol dependence during follow-up (OR=2.27, 95%
CI 1.01-5.08, P=.047), larger number of comorbid cluster B personality disorder symptoms
(OR=1.11, 95% CI 1.01-1.23, P=.030), and comorbid dysthymia (OR=4.35, 95% CI 1.51-12.5,
P=.007) persisted in the logistic regression model. There were gender differences: in men,
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alcohol dependence (OR=4.13, p=0.063) and cluster B personality features (OR=1.34,
p=0.064), in women dysthymia (OR=6.67, p=0.001) were significantly associated with
familial alcoholism. When FH for mood disorder was adjusted in the model in order to
eliminate the possible role of confounding, alcohol dependence during the follow-up
remained associated with familial alcoholism, but only as a non-significant trend
(OR=2.04, p=0.059). However, the association with number of cluster B personality disorder
symptoms lost significance in sensitivity analyses, after omitting from the analyses the
patients switching to bipolar disorder during follow-up.
7.4.5 Family history of psychotic disorders
Patients who reported FH of mood disorders spent significantly more time in MDE, less time
in full remission, and had more depressive episodes prior to the baseline. They were not
significantly different in terms of psychotic symptoms, or cluster A personality
disorders. In the multivariate logistic regression model, the predetermined independent
variables comprised gender, age, duration of follow-up, time spent in full remission,
number of previous depressive episodes, psychotic symptoms, and comorbid cluster A
personality disorder. After removing non-significant variables, shorter time spent in full
remission persisted in the logistic regression model (OR=0.97, 95% CI 0.96-1.04, P=.039).
The associations remained unchanged in sensitivity analyses, after omitting from analyses,
or adjusting for, patients switching to bipolar disorder during the follow-up.
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8  Discussion
8.1 Main findings
The long-term outcome of major depressive disorder (MDD) in psychiatric (community-care)
patients seems to be more variable than in earlier, mostly inpatient studies. Only
one-tenth of these secondary-care MDD patients had a poor outcome, while half had a
favourable outcome. Almost all patients recovered over time from their index episode, with
88% reaching full remission at some point. Nevertheless, nearly three-fourths experienced
at least 1 recurrence within 5 years, but most of these recurrences were briefer than the
index episode.
During the 5-year follow-up, one-seventh of patients attempted suicide at least once, and
three-fourths of suicide attempts (SAs) took place during major depressive episodes
(MDEs). The incidence rate of SAs was 21-fold during time depressed and fourfold during
time in partial remission compared with time in full remission. Besides longer time spent
in depressive states, previous suicide attempt, younger age, and lower perceived social
support also independently increased the risk of SA.
Within 5 years, over a tenth of patients previously suffering from unipolar MDD switched
to bipolar disorder (BD), and of these the majority (three-fourths) switched to type II.
The switch to BD type I usually occurred much faster than to type II, when estimated both
from both age at onset and baseline. In multivariate Cox proportional hazards analyses,
higher severity of MDD, OCD, social phobia, and higher number of cluster B personality
disorder symptoms independently predicted a diagnostic switch to BD.
Positive family histories (FHs) of various psychiatric disorders were found to be very
common. Three-fourths of patients had a FH of some mental disorder, including in
three-fifths of mood disorder, over one-third of alcoholism, and one-tenths of psychotic
disorder. Furthermore, a significant overlap in FHs existed; a fourth of the patients had
FH of both mood and alcohol use disorders. All types of FHs appear to be associated with a
poorer clinical outcome; with an elevated risk for suicide attempt, a more chronic course,
and comorbid personality disorders. More specifically, FH of mood disorders appeared
independently associated with high neuroticism among female, and that of alcoholism with
alcohol dependence among male patients. However, among patients with familial mood and
alcohol use disorders the temperamental associations found relied partly, and personality
associations significantly, on patients who switched to BD over time.
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8.2 Methods
8.2.1 Representativeness of the cohort sample
The present naturalistic study (I-IV) involved a prospective, long-term follow-up
assessment of a representative cohort of both outpatients and inpatients with MDD,
effectively representing psychiatric patients with a new episode of MDD in the city of
Vantaa. The study was initiated during the era of modern antidepressants in 1997-1999 in a
community psychiatric setting. On the basis of an epidemiological survey, two-thirds of
all depressed patients in the general population of Vantaa seeking treatment from
psychiatrists were treated in the PMCD (Rytsälä et al., 2001). Clinical studies conducted
on representative unselected samples of commonly met, highly comorbid, depressive patients
are very sparse. Although the outcome of MDD has been extensively investigated in short-
and medium-tem studies, a limited number of major studies have explored the long-term
(five years or more) course of the illness. The different diagnostic criteria, the
availability of only tricyclic antidepressants, and the lack of recommendations for
widespread continuation and maintenance phase treatments are all major changes that
undermine the generalizability of earlier findings to current practice. Only a few studies
have studied long-term outcome among outpatients. The majority of the previous studies
have been inpatient or tertiary-care studies from major universities, which compromises
the epidemiological generalizability of their findings.
The familiar tendency for patients to have undergone many prior treatments in studies
conducted in tertiary-level treatment centres may produce bias towards more chronic,
severe and recurrent illnesses compared with more unselected cohorts of MDD patients
(Furukawa et al., 2000; Roy-Byrne et al., 2000; Spijker et al., 2002). In addition, some
studies have not used life-chart methods or structured or semistructured interviews.
Furthermore, despite comorbid MDD being common, the effect of comorbidity on long-term
outcome of MDD has been surprisingly the subject of few studies. In many studies, the
reported prevalences of comorbid disorders appear too low to be plausible from the current
perspective. There is also a lack of studies investigating the impact of both axis I and
II comorbidity on the long-term outcome of depression.
This study (I-IV) is from the modern era in terms of the use of DSM-IV diagnoses and
definitions, modern antidepressants, and maintenance treatment recommendations. It seems
that no previous study has investigated the impact of both axis I and II comorbidity on
the long-term outcome of depression. We used structured and semistructured measures, both
objective and subjective, investigating a broad range of factors from several other
domains; sociodemographic factors, clinical variables, temperamental, and psychosocial
factors. We used a life-chart methodology, which enabled us to investigate the impact of
variations in clinical state and longitudinal outcome.
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8.2.2 Diagnostic measures
At intake, the patients were diagnosed using semi-structured interviews with excellent
reliability (kappa=0.86) for the diagnosis of MDD with SCAN, Version 2.0 (Wing et al.,
1990). However, the reliability of comorbid disorders is unknown. In addition, diagnoses
of axis III disorders were based on self-report, although only those diagnosed by a
physician were included. Axis II diagnoses were assessed using the semi-structured SCID-II
interview for DSM-III-R, as the SCID-II for DSM-IV was not yet available in February 1997.
This was also used in the 5-year follow-up interviews. Differences between DSM-III-R and
DSM-IV were taken into account by excluding masochistic personality disorder. Passive-
aggressive personality disorder was included because it belongs to the personality
disorder NOS in DSM-IV. Patients were also interviewed with the SCID-II during their
depression, which may (Stuart et al., 1992; Peselow et al., 1994; Ferro et al., 1998), or
may not (Loranger et al., 1991) have influenced the prevalence of personality disorders.
This, as well as the inclusion of patients with current alcohol use disorders, was done
deliberately in order to investigate the persistence and effects of these disorders in the
follow-up. In the 5-year follow-up, the SCID-I for DSM-IV-TR Axis I Disorders (First et
al., 2002) was used instead of SCAN. Sensitivity analyses to ensure uniformity of ratings
were conducted, and inner consistencies (Cronbach alphas) of the rating scales were also
checked. No reliability problem that could bias the findings was uncovered.
8.2.3 Life-chart and definitions for outcome
A number of methods for the longitudinal measurement of psychopathology have been
developed. Probably one of the most influential measurements is the Longitudinal Interval
Follow-up Evaluation (LIFE) methodology, first used to investigate the outcome of
depression in the NIMH-CDS (Keller et al., 1987). LIFE is a semi-structured interview and
rating system for assessing the longitudinal course of psychiatric disorders in sufficient
detail to provide the basis for calculating the length of episodes and time to remission
(Keller et al., 1987). In the VDS the outcome of MDD was investigated by using a graphic
life chart, which is similar, but not identical to LIFE. Besides symptom ratings and case
notes by attending personnel, we also asked the patients about change points in the
psychopathological states, using probes related to important life-events in order to
improve the accuracy of the assessment. In cases of conflicting information the
researchers weighted and integrated all available information, creating a best estimate.
Unlike LIFE, patients’ follow-up time was classified into periods of DSM-IV MDE, or
partial (1-4 criteria symptoms) or full (no symptoms) remission. The major advantage of
this classification is that it counts episodes and defines recurrences precisely, as does
any clinician when using the DSM-IV. However, comparison of the findings with studies
using LIFE can be undertaken only with some caution. For example, it appears that the
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criteria for full remission in the VDS were more stringent than those used for recovery in
the CDS (Psychiatric Status Ratings, 1-2; no symptoms or 1 to 2 symptoms to a mild
degree). Nevertheless, in most longitudinal studies, recurrence/relapse follows a period
of remission, which is relatively consistently defined as the presence of only one or two
minimal symptoms of major depression to a mild degree, or complete absence of symptoms for
at least two months (Keller, 2003). So, having used the same criteria for duration for
remission, it is likely that the findings from the VDS are comparable to other studies.
8.2.4 Study limitations
The attrition rate of 5-year follow-up was 28.5% of those living and not having switched
to bipolar disorder (BD). The causes for dropping out (N=65) from the study were as
follows: withdrawal of consent (63.1%, N=41), patients unreachable despite several efforts
(33.8%, N=22), and patients living too far away (3.1%, N=2). However, the drop-out rate
from the main follow-ups was quite low, as only 21 patients (7.8%) dropped out from all
follow-up interviews. Patients diagnosed during follow-up of BD or non-affective psychotic
disorder, remained in the cohort until they were censored at the change of diagnosis. The
use of Cox proportional hazards model enabled analyses of information on patients
remaining in the study for different lengths of time. In addition, logistic regression
analyses were adjusted for the duration of follow-up. Despite having characteristics often
associated with poor outcome, it appears unlikely that the dropouts would have
significantly biased the findings regarding the likelihood of recurrence, as they did not
differ from those included in terms of index episode duration, time to full remission, or
number of relapses or recurrences during the period they participated in the study. In
addition, the dropouts did not differ in terms of suicide attempts or suicidal ideation at
or before the baseline. However, the possibility that the dropouts may have affected the
results at least to some extent cannot be excluded.
Despite of access to patient records, a long follow-up period, 3.5 years between the last
two interviews, could have affected the accuracy of information regarding longitudinal
outcome in the life charts. The recurrence rate during the time most remote from the
five-year interview after 18 months was probably slightly underestimated (approximately by
10% overall). When comparisons are made with other studies, it should be also noted that
the definition for full remission in this study was strict (Melartin et al., 2004b).
Because of the naturalistic nature of our study, the treatment received was not controlled
for.
Regarding the study concerning risk factors for suicide attempts (SAs) (study II), similar
to any study with retrospective assessment, it is possible that SAs might bias recall of
depression. Effort after meaning and circularity as a result of diagnostic criteria could
in theory affect the timing of when the SAs and when the MDEs were estimated to have
happened. However, although patients or the interviewer might have retrospectively
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attributed SAs to MDEs, collateral information on the patients’ state at the time of the
attempts was also available from psychiatric and medical records. We did not have reliable
information on impulsive-aggressive behaviour and traits, which could modify risk during
MDEs. However, they often correlate with comorbid cluster B personality disorders and
alcohol abuse or dependence. We could only investigate average risk for the time spent in
risk states. The risk for SAs likely covaries with variations in levels of hopelessness,
depression, and anxiety, none of which could be measured on a daily basis.
Regarding the study concerning the switch to bipolar disorder (BD) (study II), the
follow-up period of five years was only moderately long for investigation of a phenomenon
that may occur even after decades of a follow-up (Angst, 1985; Angst et al., 2005). In
particular, the number of BD type I patients (N=7) was insufficient for differentiation of
predictors for both bipolar types. A long follow-up interval between the last two
interviews, might also affect the temporal accuracy of information and recall of
especially hypomanic episodes. Also due to the four-day limit in DSM-IV criteria on
hypomanic episodes, the number of BD type II patients may be an underestimate. As DSM-IV
criteria were strictly followed, episodes, such as depressive mixed states (Benazzi, 2007)
were not investigated, as they are not included in the DSM-IV classification. In addition,
the predictive value of bipolar family history on bipolar switch could not be reliably
investigated.
Regarding the study on associations of family history (FH) of mental disorders, and
outcome of MDD (study IV), only 68% could be included in the analyses of family history as
we inquired about FH only at five-years, not in the previous phases of the follow-up.
Unlike most family studies, but similar to most clinical and epidemiological FH studies,
FH was ascertained only by an interview of the proband, and the family members themselves
were not interviewed which limits the accuracy of the assessment, and may have resulted in
underestimates. Because of variations in the patients’ age and number of relatives, the
analyses did not seperate whether they were pedigrees, siblings, or parents, nor the
number of relatives with psychiatric disorders. Only FHs of psychiatric disorders for
which the most reliable information could be obtained were investigated, and for this
reason did not include information on, for example, familial anxiety disorders (Hardt and
Franke, 2007). FH of BD could be detected in only two patients which is very likely an
underestimate because of clinically unrecognized familial bipolar type II disorders. The
subgroup of patients with a positive FH of a non-affective psychosis was small. Finally,
only information on first-degree relatives was reported, which does not exclude the
possibility of a positive FH in more distant relatives.
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8.3 Long-term outcome of MDD (Study I)
The long-term outcome of this mainly outpatient cohort of clinical secondary care patients
was as excepted more variable than in earlier mostly inpatient studies. Studies with
mostly inpatients have generally reported larger proportions of incapacitation over time
(Lee and Murray, 1988; Thornicroft and Sartorius, 1993; Surtees and Barkley, 1994; Kennedy
et al., 2003), and smaller proportions of patients having a good outcome (Lee and Murray,
1988; Andrews et al., 1990; Surtees and Barkley, 1994). Moreover, a number of studies have
found chronicity to be a major problem. By contrast, in this study, the proportion of
patients never achieving even partial remission was small (1.2%), and the rate for
chronic, uninterrupted MDE lasting 2 years or more (7%) was lower than in other studies
(Keller et al., 1992; Angst et al., 1996; Kennedy et al., 2003). Also, compared to
previous studies, the median index episode duration (1.6 months from the baseline, 5.5
months altogether) was much shorter (Surtees and Barkley, 1994; Mueller et al., 1999;
Furukawa et al., 2000). However, the median time to full remission was longer (11 months
vs. 3-7 months) (Keller et al., 1992; Mueller et al., 1999; Furukawa et al., 2000; Kennedy
et al., 2003) indicating the problem of incomplete recovery (partial remission), although
the proportion of time spent in partial remission during the 5 years was still lower than
reported in the CDS and the Cambridge cohorts (Judd et al., 1998; Kennedy et al., 2004).
The overall more varying outcome in this study is likely to be due to the less selected
nature of this cohort compared with previous predominantly inpatient cohorts from a
preceding treatment era. It seems that the prevailing psychiatric view of MDD as a
uniformly chronic disorder needs to be revised. Respectively, the estimates of lifetime
suicide mortality related to MDD have undergone a similar revision, as the earlier high
estimates of 15% of depressed patients dying by suicide were based on biased
generalizations from inpatient populations (Bostwick and Pankratz, 2000).
The probability of recurrence (71%) in this study was somewhat lower compared to previous
studies (Keller et al., 1992; Surtees and Barkley, 1994; Angst et al., 1996) but this
figure may an underestimate. However, unlike the situation for inpatient studies, the
pattern of recurrence resembled that of community samples, i.e., the recurrent episodes
were shorter than the index episode (Spijker et al., 2002). The low rate of
hospitalizations (15% after 18 months) also likely reflects milder recurrences during the
follow-up. Time to first recurrence and median number of recurrences were similar to the
results of previous studies (Solomon et al., 2000). However, the more heterogeneous
baseline severity of depression in this cohort allowed us to verify the marked impact of
severity on the probability of recurrence.
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Previous studies have largely either excluded comorbid patients or ignored the role of
psychiatric comorbidity in the long-term outcome of MDD. Comorbid cases were deliberately
included and account the effect of these disorders were taken into account together with
known predictors, and a major role in outcome was observed. Sequenced Treatment
Alternatives to Relieve Depression, STAR*D (Rush et al., 2006), a large outpatient
clinical trial, has taken into account the role of comorbid Axis I disorders on the
outcome of MDD, but has not studied the effect of Axis II disorders at all, and does not
include investigation of long-term outcome.
In the present study, cluster C personality disorders, especially avoidant personality and
preceding dysthymic disorder, significantly delayed the time to full remission. The time
to full remission was twice as long for patients with preceding dysthymic disorder or
cluster C personality disorder as for those without these diagnoses. Preceding dysthymic
disorders reducing the chances for recovery were similar to the findings in CDS (Keller et
al., 1992). In addition, previous short- and medium-term studies, have found comorbid
cluster C personality disorders to be associated with slower recovery and a longer time to
response or non-response in different stages of MDD treatment (Viinamäki et al., 2002;
Morse et al., 2005).
Social phobia was also found to be associated with overall risk of recurrence, a shorter
time to first recurrence, and number of recurrences. Earlier community studies have
indicated associations between anxiety disorders or social phobia and the development of
first MDE or relapse (Coryell et al., 1992; Kessler et al., 1999b; Bittner et al., 2004).
However, it seems that they have not specifically investigated the association of social
phobia with MDE recurrences. Temperamental predispositions, a tendency for social
isolation due to avoidance, or a more cyclic course might explain why comorbid social
phobia appears to increase the vulnerability to recurrence. Overall, the predictors for
outcome of MDD may, to some extent, be different among outpatient samples than among the
previously mostly investigated severely ill inpatients. Further investigation is required
on social phobia as a putative predictor of recurrence.
8.4 Long term risk factors of suicide attempts during the
prospective follow-up (Study II)
There is a lack of long-term studies investigating variations in the incidence of suicide
attempts (SAs) during different levels of depression among patients with unipolar MDD. In
this study, the incidence rate was strongly variable with time spent in different states,
being nearly 21-fold during MDEs compared with states of full remission. This was
consistent with findings of the 18-month follow-up assessment of VDS (Sokero et al.,
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2005), and in the Jorvi Bipolar Study (JoBS), a comparable study investigating bipolar
disorder (Valtonen et al., 2008). Another medium-term study (Oquendo et al., 2002)
reported a sevenfold hazard of SAs during depressive episodes, which was similar to the
estimates of the present study (HR=7.7). The incidence rate of SAs during MDEs (0.33 per
patient-year) was similar to these earlier estimates (0.30-0.42 per patient-year). In
accordance with most prospective studies, the risk of SA was highest during the first year
of follow-up evaluation, which likely reflected the decline in the time spent in MDE after
the first follow-up year. However, the incidence rate of SAs during MDEs remained
constant. Shortcomings in the continuity and provision of acute phase, continuation, and
maintenance antidepressant and psychosocial treatments are obvious, both in this cohort
(Melartin et al., 2005; Holma et al., 2008) and in other settings (Oquendo et al., 2002),
and have concerned patients with MDD overall as well as for those attempting suicide.
Given the importance of high-risk states for overall risk, reducing the time at risk by
effective treatments could be crucial for reducing SAs in the long-term.
Evidence for other risk and protective factors affecting the likelihood of SAs was also
found. In the earlier 18-month follow-up assessment of the VDS, the risk of SAs was
effectively predicted by besides the time spent in MDEs, also lack of a partner, and
previous SAs (Sokero et al., 2005). A history of SA has been consistently associated with
elevated risk of a later attempt (Fawcett et al., 1990; Duggan et al., 1991; Malone et
al., 1995a; Mann et al., 1999; Angst et al., 2002; Maser et al., 2002; Oquendo et al.,
2002; Oquendo et al., 2004a; Sokero et al., 2005; Oquendo et al., 2006). Also in the
present long-term study, the risk was more than fourfold in patients with compared to
those without previous SAs. Also, lack of a partner increased risk as a trend (HR=2.32),
repeating the findings of our 18-month follow-up assessment. Marriage has been associated
with a lower risk of SAs (Malone et al., 1995a), which could reflect protectiveness toward
the family, and child-related concerns (Malone et al., 2000). A partner is often a major
factor increasing objective and perceived social support, which in the VDS protected
patients from SAs both at baseline (Sokero et al., 2003) and in long-term. In contrast to
hypotheses, comorbid cluster B personality disorders were not significantly related to
risk. No significant statistical interactions were detected between high-risk time periods
(MDEs) and other risk factors, but this does not exclude the possibility that important
risk modifying interactions could exist. The significance of individual frailty in the Cox
model suggests that unmeasured trait factors (e.g., impulsivity and aggressivity) may well
significantly influence suicide attempts. However, the findings of this study do strongly
emphasize the significance of state and time varying factors in the risk of suicidal acts.
8  Discussion
103THL - Research 44/2010 Long-term Outcome of
DSM-IV Major Depressive Disorder
in Psychiatric Care
8.5 Switch to bipolar disorder during the prospective follow-up
(Study III)
During the present 5-year follow-up the risk of a diagnostic switch from unipolar MDD to
bipolar disorder (BD) was 2.8% annually, which is slightly higher than in previous
studies, where the rate has been 1% to 2% (Akiskal et al., 1995). However, the switch rate
to BD type I was somewhat low (0.7% per year), which may be due to this study cohort
comprising, in contrast to most previous studies, predominantly of outpatients, and not
patients from a tertiary care setting. The majority of diagnostic switches were to BD type
II; as the annual rate of switch to bipolar II (2.14%) was higher than in previous studies
(0.5%-1.8%) (Akiskal et al., 1995; Coryell et al., 1995; Goldberg et al., 2001; Angst et
al., 2005) this study may have been more sensitive in its detection. The median time from
baseline to the first manic episode was a sixth from the time to hypomanic episode, and
about a third from age at onset. Previous reports have described switch rates to manic
episodes about 2 times faster than they were to hypomanic episodes (Coryell et al., 1995;
Goldberg et al., 2001; Angst et al., 2005). Type I BD patients have been reported in new
episodes to have more manic episodes than type II patients have hypomanic episodes
(Akiskal et al., 1995; Coryell et al., 1995; Goldberg et al., 2001; Angst et al., 2005).
The long time to diagnostic switch from age at onset of MDD, 7.7 years, was consistent
with earlier findings of 5 to 8 years (Goodwin and Jamison, 2007; Mantere et al., 2008b).
Overall, the results suggest that among outpatients presenting with MDE, a switch to BD
type II disorder is more likely than a switch to BD type I. All of the patients with mania
were women, which is in accord with the known gender differences in bipolar disorder;
among men, manic episodes tend to emerge at an earlier stage and with clinically more
acute symptoms, and are also likely to be diagnosed with BD sooner, and thus individuals
with this condition have not entered the study cohort as unipolars (Akiskal et al., 1983;
Mantere et al., 2004; Goodwin and Jamison, 2007).
A diagnostic switch from unipolar MDD to BD was associated with many clinical features,
i.e., higher baseline severity of MDD, higher psychiatric comorbidity, psychotic symptoms,
and negative life events. Somewhat surprisingly, the number of previous MDEs was not
associated with the switch unlike in many previous studies. However, it is important to
determine which of the predictors were confounded by other factors, and which appeared as
independent predictors. In the multivariate Cox proportional hazards analyses, higher
severity of MDD, comorbid OCD, social phobia, and a higher number of cluster B personality
disorder symptoms were the most significant independent predictors. Regarding the severity
of MDD, the findings were consistent with the results from the Zürich Follow-up Study and
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CDS, in which severity of MDD especially predicted the switch to BD type I (Akiskal et
al., 1995; Angst et al., 2005). Severity of MDD correlates with the existence of psychotic
symptoms, which has, in several studies, predicted the switch to BD (Strober and Carlson,
1982a; Akiskal et al., 1983; Coryell et al., 1995; Goldberg et al., 2001).
Comorbid psychiatric disorders are very common in both MDD and BD. Despite this, whether
different comorbid disorders might differentially predict a switch to BD has been rarely
systematically investigated. According to this study, both Axis I and II disorders were of
importance. Patients with BD have according to investigations twice likely to have social
phobia as unipolar MDD patients (Goodwin and Jamison, 2007; Mantere et al., 2008a).
Lifetime social phobia has been associated with an earlier age at onset of bipolar
disorder OCD contrary to the results of the present study, to delay the onset of
bipolarity (Kessler et al., 1999b). As in Study I of this thesis, social phobia seems to
be significantly associated with MDE recurrences, which may be related to the switch to BD
being frequently associated with a higher number of previous MDEs (Pini et al., 2006). A
previous study on temporal relationship between anxiety disorders and (hypo)mania in
bipolar patients, found social phobia and OCD to chronologically precede hypomanic
episodes (Angst et al., 1978; Angst, 1985; Winokur and Wesner, 1987; Winokur et al.,
1993). Nevertheless, it seems that none of these earlier studies have found social phobia
or OCD to also predict the diagnostic switch to BD among patients with MDD.
In the analyses of the present study, personality disorders were treated as dimensional
variables based on the number of different cluster or individual personality disorder
symptoms, as this is also in agreemenr with the current view on personality disorders. A
higher number of cluster B personality disorder symptoms was found to significantly
predict the diagnostic switch. Within cluster B, the number of antisocial personality
symptoms was the strongest predictor in multivariate analyses, while the number of
borderline narcissistic, and histrionic personality disorder symptoms predicted the switch
in only univariate analyses. In CDS, Akiskal et al. (Akiskal et al., 1995) investigated
predictors for a switch to BD type II and reported temperamental and mood instabilities
with minor antisocial acts and social anxiety to be significant. Benazzi (Benazzi, 2006)
revealed cyclothymic and borderline personality temperaments to be more common in patients
with BD type II than in patients with unipolar MDD, finding especially affect instability
to be associated with type II. None of these studies have found an association between
these features and BD type I. In the present study, the switch to both types of BD was
associated with a higher number of cluster B symptoms, but, taking into account the small
number of type I patients, these results must be interpreted with caution.
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8.6 Family history and outcome of MDD (Study IV)
Family history (FH) of some psychiatric disorder (mood disorder, alcoholism, or psychotic
disorder) was very common, as three-fourths (75%) of patients reported psychiatric
disorders in their first-degree relatives. Comparison of prevalence to other studies is
difficult because of different methods of assessing information on FH. A positive FH was
associated with several, clinically significant features of poor outcome, e.g. more
recurrent episodes, higher severity of depression and anxiety, more neuroticism, more
suicide attempts, and more comorbid, especially anxiety, and cluster C personality
disorders. Patients with these traits compared to those without a positive FH spent on
average nearly half (47%) more time in MDEs over five years.
Patients with a FH of alcoholism compared to those without had a two-fold prevalence of
alcohol dependence during the follow-up. This may reflect a specific familial effect and
is similar to the findings in the previous literature (Benazzi, 2006). Moreover, these
patients suffered significantly more from dysthymia, and had more cluster B personality
disorder symptoms, and of these especially borderline, and antisocial disorder symptoms.
The relationship of alcoholism and cluster B personality disorders corresponds also to the
factor model of externalizing disorders with possible shared genetic factors (Krueger and
Markon, 2006). Nevertheless, the predisposition of depressed patients to comorbid alcohol
dependence is likely to be influenced not only by a FH of alcoholism alone, but also by
other factors, including a FH of mood disorder. Accordingly, when a FH of mood disorder
was adjusted in the model for FH of mood disorder, alcohol dependence during follow-up
remained associated with familial alcoholism, but only as a non-significant trend.
Patients with a FH of (non-affective) psychotic disorders spent a significantly shorter
time in full remission during follow-up, and conversely they spent significantly more time
in symptomatic states of MDD and partial remission. Contrary to what has beeb
hypothesized, psychotic symptoms, or Cluster A disorders or symptoms were not more
prevalent among these patients. Therefore, no evidence for a specific predictive value
with regard to psychotic features was found; however, the number of MDD patients with
positive FH of non-affective psychosis was small.
Three-fifths of the patients (60.7%) had a FH of mood disorders. Previous studies
investigating first-degree relatives, have reported prevalences of 37.2-55.6% (Prescott
et al., 2000; Klein et al., 2001; Kendler et al., 2003b), of which STAR*D reported a
prevalence closest to the present study (55.6%), possibly due to a similar method of
investigating FH and a similar study cohort comprising clinical outpatients with high
comorbidity. One of the central findings was the significant association of FH of mood
disorder with higher neuroticism. This is compatible with the findings from a major
8  Discussion
106 THL - Research 44/2010Long-term Outcome of
DSM-IV Major Depressive Disorder
in Psychiatric Care
population based twin study, which reported neuroticism to reflect a liability to
depressive illness, and this relationship being due to common genetic factors (Klein et
al., 2001; Verhagen et al., 2008; Husain et al., 2009). There is a lack of clinical
studies which have previously investigated this association. In the present study, there
were gender differences as neuroticism and FH were significantly associated mainly with
women, while the study of Kendler et al. detected no significant interactions with gender
(Kendler et al., 2006b). Analogously, lower extroversion was associated with a FH of mood
disorders significantly only among female patients. Higher neuroticism was associated with
a larger number of cluster C personality disorders, which Study I predicted to result in a
poor outcome with more recurrences and a longer time spent in MDE.
Patients with a FH of mood disorders were also older, suffered from more severe
depression, and had attempted suicide during their lifetimes more often as a trend
compared to those without such a FH. A potential explanation for the association with
older age may be a larger number of first degree relatives and a larger interest and
knowledge of the matter. Severity of depression has also in previous reports been
associated with FH (Kendler et al., 2006b). In the present study, age at onset was not
significantly associated with FH, although, earlier age at onset has been one index of
familial liability to MDD. However, it has also been questioned as many previous studies
have not been controlled for age, the association has been nonlinear, and age at onset has
often been reported only with moderate reliability (Lieb et al., 2002; Janzing et al.,
2009).
In addition, the definition of age at onset has varied, and been often reported in studies
with adolescents. Nevertheless, it is possible that the somewhat earlier age at onset
among drop-outs may have slightly affected these findings. An overlap between mood
disorder and alcoholism FHs was common as two-thirds of patients with familial mood
disorder had also alcoholism among their first-degree relatives. However, when a FH of
alcoholism was adjusted in the model, the results remained the same indicating the
specificity of the findings. Overall, a FH of mood disorder was associated with clinically
higher severity of depression, which likely also increases the risk of a worse outcome.
Neuroticism may mediate the familial predisposition, at least among females.
Over a tenth (12.0%) of the patients followed-up and with information on FH, switched to
bipolar disorder (BD). Over four fifths (81.8%) of these patients had a FH of mental
disorder, while the prevalence of familial mood, alcohol use, and psychotic disorders was
largely similar to patients remaining unipolar. The heritability, clinical picture and
patterns of comorbidity have been reported to differ between unipolar and bipolar patients
(Kendler et al., 2005). It is probable that especially unrecognized or latent bipolar
disorder type II patients are included in clinical MDD cohorts, and may potentially bias
the findings of family studies. In this study, these patients somewhat affected the
findings concerning FH of mood disorders, while the association with neuroticism became
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only a trend when patients with BD were omitted from the analyses. However, this likely
results from a diminished statistical power due to smaller number of patients, rather than
higher neuroticism among bipolar patients. A recent report did not find significant
differences in neurotic features among patients with MDD, and BD type I and II (Sullivan
et al., 2000; Kieseppä et al., 2004; Sokero et al., 2005; Mantere et al., 2006; Valtonen
et al., 2008). The association with familial alcoholism and number of cluster B disorders
among probands also lost its significance after omitting patients with BD from the
analyses. This fact is likely to be associated with the findings in Study II, where a
significant relationship between diagnostic switch and cluster B personality disorders was
found.
Overall, positive FHs of the types of mental disorders investigated seem to be associated
with significantly more negative outcome of depression, and increased risk of suicidal
behaviour. However, despite the clinical significance of these findings, the specificity
of effects of different FHs appears limited, with an exception being alcoholism among male
patients.
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9  Conclusions and future implications
9.1 Conclusions
In conclusion, the long-term outcome of major depressive disorder (MDD) appears to be more
variable when its outcome is investigated among modern, community-treated, secondary-care
outpatients than among inpatients. MDD is also highly recurrent in these settings, but the
recurrent episodes seem shorter, and the outcome is unlikely to be uniformly chronic.
Higher severity of MDD predicted significantly the number of recurrences and time spent
ill. Besides known predictors, such as episode duration and preceding dysthymic disorder,
comorbid cluster C personality disorders and social phobia predicted a worse outcome.
The incidence rate of suicide attempts varied robustly depending on the level of
depression, being highest during MDEs. Although a history of previous attempts and poor
social support also indicated risk, time spent depressed was the central factor
determining overall long-term risk.
The overall switch rate from unipolar MDD to bipolar disorder (BD) (mostly to type II) was
to some extent higher than in previous studies. The switch to BD type I usually occurred
early, whereas the switch to type II took place more gradually over time. Besides
previously known predictors, a higher severity of MDD, comorbid social phobia, OCD, and
cluster B features predicted the diagnostic switch.
The followed-up patients typically suffered from comorbid disorders known to be heritable.
The majority of them were also likely to have positive family histories (FHs) not
exclusively of mood, but also of other mental disorders. Having a positive FH of severe
mental disorders was likely to be clinically associated with a significantly more adverse
outcome. More specifically, a FH of mood disorder correlated with probands level of
neuroticism among females, and that of alcoholism with male alcoholism.
9.2 Clinical implications
The findings that baseline severity of MDD predicts probability of recurrence, shorter
time to first recurrence, and number of recurrences not only confirm the results of our
18-month follow-up (Melartin et al., 2004b) over the long term, but also have implications
for generalizations about risk of recurrence and potentially also for indications for
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maintenance treatment. The severity of depression should influence clinical
decision-making regarding the need for maintenance therapy, particularly among patients
who are having their first or second MDE, when maintenance therapy is not usually
recommended. The use of observer and self-report scales measuring the severity of
depression should be used in routine clinical practice. Besides recurrences, an incomplete
recovery of MDD (partial remission) is a substantial problem; achieving full remission
should be the goal of treatment. Evaluation of recovery should concern several levels;
syndromatic, symptomatic, and functional recovery.
It is likely that greater diagnostic precision, and better recognition of comorbid
disorders would improve depression outcome. More complete and accurate diagnostic practice
could serve as a better predictor of course and outcome, and impact on patients’
satisfaction with treatment, their alliance with treating professionals, selection of
medication, and recommendation for psychotherapy. In the present studies, comorbid anxiety
disorders (especially social phobia) predicted a higher risk of recurrence, shorter time
to recurrence, higher number of recurrences, and the risk of diagnostic switch to bipolar
disorder. Moreover, comorbid personality disorders were of importance, cluster C
personality disorders prolonging the time to recovery from MDD. Thus, comorbid disorders
should be taken into account in planning the treatment of individual patients.
Suicide attempts among patients with MDD are strongly associated with the presence and
severity of depressive symptoms. The finding that the incidence rate of suicide attempts
is considerably elevated during high risk episodes of MDE is of fundamental importance
regarding the prevention of suicidal acts. Reducing the time at risk by effective
treatments is likely crucial for reducing future suicide attempts in the long-term.
Besides this, special attention should be targeted to younger patients with a history of
suicidal behaviour, living alone, and lacking social support.
Recognition of bipolar disorder is a major challenge even for psychiatrists and should be
improved. Especially diagnosing bipolar disorder type II is problematic and should be
improved. The evaluation of diagnosis and treatment of bipolar disorder should be done in
psychiatric care. Greater diagnostic precision concerning the type of mood disorder (MDD,
BD I, or BD II) is essential for improving the quality of treatment, and thus, the outcome
and quality of life of the patients. In addition to observing cross-sectional presentation
of illness, clinicians should consider a longitudinal course when making a diagnosis and
planning treatment. Besides previously known predictors (family history of mood disorders,
early age at onset, high number of MDEs), a clinician should take into account a higher
risk of diagnostic switch among patients with severe depressive episodes and comorbid
anxiety and cluster B personality features as the change in diagnosis has practical
clinical consequences for treatment and prognosis.
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A clinician often routinely inquires after the family history of mental disorders, but the
practical consequences of this information are not always clear. According to the present
findings, a family history of a mental disorder is likely to be clinically associated with
significantly more adverse outcome; with an elevated risk of attempted suicide, a more
chronic course, and comorbid personality disorders. Especially male patients with a family
history of alcoholism are at higher risk of developing alcohol dependence themselves.
9.3 Implications for future research
Future research should take into account MDD as a heterogeneous, and comorbid disorder.
Because of the varying course of MDD, follow-up studies should use life-chart methodology
in order to improve the longitudinal assessment and to investigate the effects of
variations in risk and time at risk. There also is future need for prospective studies to
investigate the wide range of risk factors of outcome and use of multivariate statistics,
which are needed to differentiate independent risk factors from confounding associations.
Further clinical studies with especially psychiatric outpatients should be carried out as
the predictors for outcome may be different among outpatient samples than among the
severely ill inpatients previously investigated. Studies on comorbid MDD using both the
dimensional and categorical models, and investigating factors from several potentially
relevant domains should be carried out. Such studies would help us to better understand
the nature of the mechanisms underlying comorbidity, and to discover the potential
neurobiological and structural variations in MDD in relation to patterns of comorbidity.
Further prospective longitudinal studies are needed to search for any logical pattern in
the symptom progression, and its relation to the comorbidity of MDD. Future studies based
on daily prospective mood ratings could investigate if the predictors for outcome are
identical during the whole phase of illness. Future studies on family history of MDD
patients should take into account both their variable phenotypes as well as variable
family histories. In addition, the possibility of latent or future bipolar disorder should
be acknowledged when investigating the family history of MDD patients.
Randomised controlled trials on both drug and psychosocial treatments should be carried
out among ordinary, highly comorbid depressive patients, especially beyond the acute phase
in order to reduce the risk of recurrences, and time they are ill. Structured treatment
stategies which take into account the heterogeneous clinical picture of MDD should be
further developed. Information is needed to help to develop better and more effective
treatments and treatment facilities, as well as to improve co-operation between various
treatment settings. More research is also needed to investigate specific psychotherapies.
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